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In drawing of chemical structures, stereochemistry is not implied but
a thickened or dotted line denotes a substituent located respectively
above or below the plane of the paper.
ABSTRACT OF THESIS
Platelets are circulating quiescent cells which play an
important role in haemostasia; following blood vessel injury,
platelets adhere to the damaged vessel, aggregate and form a
haemostatic plug which diminishes or arrests the haemorrhage. In
addition the platelet has been shown to have an important part in the
pathogenesis of thromboembolic disorders. Upon activation platelets
release arachidonic acid from membrane phospholipids, conversion of
which results in the production of prostaglandins and thromboxanes.
The prostaglandin endoperoxides and thromboxane A2 are potent
platelet aggregating agents and mediators of the platelet release
reaction. This thesis is primarily concerned with platelet function
and several aspects have been studied.
(i) An investigation into the modes of action of arachidonic acid
in rat platelets was carried out, since controversy exists as to the
precise mediators of aggregation in this species. Over a range of
arachidonic acid concentrations three types of response were evoked
in washed rat platelet suspensions; a thromboxane-dependent
irreversible aggregation at low concentrations; a suppression of
aggregation associated with subsequent inhibition of other
aggregating agents at intermediate concentrations; and an apparent
irreversible aggregation associated with platelet lysis at high
concentrations. The mechanisms underlying each of these responses
were investigated.
(ii) A second aspect concerned the pharmacological characterization
of the thromboxane-sensitive systems mediating aggregation of human,
rat and rabbit platelets. The relative potencies of a range of
thromboxane agonists were similar in the 3 species, yet when
antagonists were studied the rabbit platelet thromboxane-receptor was
consistently less sensitive to their blocking action.
(iii) The final section is concerned with platelet disfunction in two
pathological conditions, diabetes and hypothyroidism. In the former
condition an increase in platelet activity has been shown to be
intimately related to enhanced thromboxane A2 activity. This may
simply reflect an increase in thromboxane A2 production from
endogenous arachidonic acid, although improved receptor coupling or
an increase in the number of receptors may contribute.
In one study, platelet sensitivity to collagen and the stable
thromboxane mimetic, 11,9epoxymethano PGH2 was compared between
control subjects and diabetics. An increased sensitivity to the
thromboxane mimetic was observed in the group of diabetics with
proliferative retinopathy and in contrast to the findings in the
literature there was no apparent difference in sensitivity to
collagen. In another study platelet sensitivity to the aggregating
agents ADP and 11,9epoxymethano PGH2 was measured in a group of
poorly controlled diabetics who underwent short-term improvement of
glycaemic control. At the end of the six month period, there was no
detectable change in their sensitivity to aggregating agents ADP and
11,9emPGH2 yet a marked increase in responsiveness to the inhibitory
prostaglandin, Iloprost was observed.
Hypothyroidism like diabetes is associated with microvascular
complications. A study was carried out on a group of hypothyroid
patients, whose platelet sensitivity was measured at the beginning
and the end of a six month period of hormone replacement. Platelet
sensitivity was increased to a slight extent following hormone
replacement therapy but a marked fall in cyclic AMP levels from
plasma was found. This could suggest that improvement of the




1.1 Major metabolites of arachidonic aoid 3A
1.2 Schematic representation of platelet pathways 10A
1.3 Enzymatic pathways triggering arachidonic release 15A
from platelet membrane phospholipids.
1.4 Interaction of pathways involved in arachidonic acid 17a
release from phospholipids.
2.1 Concentration, volume and final concentration of 31
TXBp standards used in TXB2 standard curve.
2.2 Methodology used for TXB2 standard curve and sample 32
assay.
2.3 Standard curve of TXB2 33A
2.4 Standard curve for cyclic AMP. 40A
2.5 Typical quench curves for tritium using chloroform 43A
as quenching agent.
2.6 Synthesis of prostaglandin H2. 47A
3.1 Arachidonic acid induced responses in citrated PRP. 60A
3.2 Effect of blockers on AA-induced shape change in rat 60B
PRP.
3-3 Shape change induced by thromboxane mimetics and 61A
effect of various blockers.
3.4 Log dose response curves for shape changed induced by 61B
11,9-emPGH2 and EP171.
3.5 Aggregation and release induced by AA over wide conc. 62A
range in washed rat platelets.
3.6 Thromboxane B2 production in washed rat platelets in 62B
response to AA.
3.7 Inhibition of ADP aggregation induced by AA (10pM). 63B
3.8 Effect of ngda on arachidonic acid induced inhibition. 64a

























Effect of high concentrations of 5,8,11,14,ETYA on AA 65B
induced inhibition.
Effect of BW755C on inhibition induced by AA. 66A
Time course of onset of AA induced inhibition. 66C
Cyclic AMP levels in response to AA in washed 67A
platelet suspensions.
Effect of linoleic acid on thrombin induced 68a
aggregation.
Structures of fatty acid derivatives. 68C
Effect of fatty acid derivatives on AA induced 69A
responses in citrated rat PRP.
Effect of fatty acid 5,8,11-ETA on AA induced 69B
responses.
11,9-emPGH2 induced responses in washed rat and human 97A
platelet suspensions.
Thromboxane mimetics-structures. 97B
Log concentration aggregation curves for EP171 and 98D
11,9-emPGH2 in washed human platelets.
Log concentration aggregation curve for STA2 in washed 98E
human platelets.
Effect of STA2 on PAF and ADP induced aggregation in 99A
human/rabbit and rat washed platelets respectively.
Effect of AH6809 and SQ22536 on STA2 induced 99B
inhibition.
Effect of STA2 and 11,9~emPGH2 on cyclic AMP levels. 100A
Structures of partial agonists. 1 00B
Log concentration response curves for partial agonists.100C
Effect of PTA2 on PAF induced aggregation in washed 102A
human platelets.
Effect of SQ22536 on PTA2 induced inhibition. 103A
Structures of thromboxane receptor antagonists. 103B
Effect of EP169 and Iloprost cyclic AMP levels. 103C
Fig. No. Page
4.1^ Aggregation curves in the presence of high 104A
concentrations of EP092 and EP169 in washed human, rat
and rabbit platelets.
4.15 High concentrations of AH23848 on 11,9-emPGH2 105A
aggregation in human and rabbit washed platelets.
4.16 Cummulative dose response curves for 11,9-emPGH2 in 106B
rabbit aorta and guinea-pig trachea preparations.
4.17 Binding of [3h]-9,11-emPGH2 to human platelet 107A
membranes
4.18 Displacement of [3h]-9,11-emPGH2 by cold 11,9~emPGH2. 107B
4.19 Agonist EC50 values in smooth muscle and platelet 113A
preparations.
5.1 11,9-emPGH2 and collagen induced aggregation responses 142A
in PRP from control subjects and the effect of
blockers.
5.2 Basal levels and elevations in cyclic AMP in control 146A
and diabetic retinopathy groups.
5.3 TXB2 production in diabetics undergoing glycaemic 146B
control.
6.1 EC50 values for ADP and 11,9-emPGH2 induced 160B
aggregation before and after thyroxine replacement
therapy.
6.2 Cyclic AMP levels measured in plasma of trypothyroid 161A
patients undergoing thyroid treatment.




2.1 Protein protein concentration (mg/ml-^) in PRP
and washed platelet suspensions. 28
2.2 Cross-reactivity of rabbit TXB2 antibody. 35
2.3 Cyclic AMP assay protocol. 38A
2.1 Displacement of 3h cyclic AMP over the range
of standard curve protocol. 40
2.5 Quench curve protocol. 42A
2.6 Quench curve constants. 43B
3.1 Affinity constants for EP092 against 11,9-epoxy- 61C
methanoPGH2 and EP171 in rat PRP.
3.2 Inhibitory effect of arachidonate (100yM) on other 63A
aggregating agents.
3.3 Effects of lipoxygenase inhibitors on inhibition 66B
induced by arachidonate (100yM).
3.4 Summary of effects of linoleic acid and oleic acid 72B
in washed rat platelets.
4.1 Concentrations of thromboxane mimetics eliciting 98a
threshold aggregation in washed platelet
suspensions.
4.2 EC50 values for platelet aggregation induced by 98B
thromboxane agonists.
4.3 Equipotent molar ratios of thromboxane mimetics 98C
in washed platelet suspensions.
4.4 Threshold aggregation concentrations for the 101A
partial agonists, EP167 and EP204.
4.5 IC50 values for EP167, EP204 and PTA2 on 101B
11,9-emPGH2 induced aggregation.
4.6 PA10 values for thromboxane antagonists against 105B
11j9-emPGH2 in washed platelet suspensions.
4.7 PA-j0 values for ON011120 and EP092 against STA2 106A
and PGH2 in washed platelet suspensions.
Table No. Page
4.8 PA10 values for AH23848, 0N011120 and BM13177 on 106C
guinea-pig trachea and rabbit aorta isolated
preparations.
4.9 A comparison of EC50 values of STA2 induced 114A
aggregation of human and rabbit platelets in PRP
and washed platelet suspensions.
5.1 Clinical details of a control subjects and 141A
diabetics with retinopathy.
5.2 Aggregation EC5q'p and dose ratio values for 143A
collagen and 11,9-emPGH2 alone and in presence of
EP092 and Froben in control and diabetic groups.
5.3 Platelet release of 5HT in control and diabetic 144A
groups.
5.4 Clinical details of patients in diabetic study II. 145A
5.5 Platelet function tests from diabetic patients 145B
undergoing improvement of glycaemic control.
6.1 Clinical details and thyroid function tests of 160A
five hypothyroid patients.
CONTENTS PAGE NUMBER
Chapter 1: General Introduction 1
Chapter 2: Experimental Method?:
Preparation of platelet? 22
Meaourement of platelet aggregation 24
" " platelet releaae 25
" " platelet count 27
" " plaama-protein concentration? 28
Radioimmunoappay "
Cyclic AMP protein binding a??ay 37
Liquid pcintillation counting 42
I?olated pmooth mu?cle preparation? 43
Ligand binding methodology 45
Preparation of proptaglandin H2 47
Material? 49
Chapter 3: Arachidonic acid metaboliam in rat platelet?
Introduction 54
Experimental repult?:
citrated rat PRP 60
wa?hed platelet ?u?pen?ion? 62
TXB2 and cyclic AMP prodn. and 5HT relea?e 67
Linoleic and oleic acid "
Fatty acid derivative? 68
Dipcuppion:
citrated rat PRP 70
waehed platelet ?uppen?ionp 73
mode? of arachidonic acid action 77
Chapter 4: Characterieation of thromboxane receptor?
Introduction 89
Experimental reault?:
Effect of agonipts on platelet? 97
Partial agoni?m 100
Thromboxane receptor antagoniam 103
Ligand binding Ptudie? 107
Dipcuppion:
Thromboxane agonlpt activity 109
Structure-activity relationphip? 110
"STA2 activity in platelet? 114
Partial agonipm 116
Thromboxane receptor antagoniam 121

















Platelets are circulating anucleate cells playing a quiescent
role under normal physiological conditions. Upon injury to the
vessel wall circulating platelets adhere to the damaged vessel
forming an aggregate or heamostatic plug which diminishes or arrests
the haemorrhage. This interaction of platelets with the vessel wall
demonstrates one physiological function of the platelets, and much
clinical and experimental evidence has demonstrated that a deficiency
or defect in circulating platelets is often associated with
"spontaneous" haemorrhage from small vessels suggesting that
platelets are in some way essential for the functional integrity of
the blood vessels.
Platelets may play a pathological role in the formation of
intravascular aggregates since it has been shown that occlusive
thrombi in arteries damaged by atherosclerosis consist mainly of
platelets, (Davis and Thomas, 1981). A process of activation is an
essential prerequisite for adhesion and aggregation, inferred from
the non-reactivity of normal circulating platelets. Until recently
it was generally assumed that the process of aggregation depended
upon the adhesion of platelets to collagen. Collagen lies beneath
the endothelial cells that form the innermost layer of the vessel
wall and is exposed when the vessel is damaged. Adhering platelets
undergo aggregation and secrete the contents of intracellular
granules in a process called the release reaction. The secreted
materials include coagulation factors, vasoconstrictors and
aggregating agents and these substances promote the recruitment of
additional platelets to the aggregate.
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More recently it has been demonstrated under experimental
conditions that platelets still retain their ability to aggregate
when no collagen is present (Born & Kratzner, 1981)). It has been
suggested that in regions of abnormal blood flow, red blood cells may
release ADP which leads to the activation and aggregation of
platelets (Born & Wehmeier, 1979).
Furthermore, the presence of fibrin in the thrombus, indicates
that thrombin is present at the site of the damaged vessel and
thrombin too is a potent aggregating agent.
It is probable therefore that no single agent is responsible for
the initiation of platelet aggregation 'in vivo'. The initiation
and perhaps the growth of thrombi from platelet aggregates may be
influenced by products of the arachidonic acid (AA) pathway
(Fig.1.1). Thromboxane A2 (TXA2) a metabolite of AA, synthesized
within and released from the platelet, is a potent stimulator of
platelet aggregation and constrictor of blood vessels.
Prostacyclin, another AA metabolite is produced by endothelial cells
and has opposing actions to TXA2, whereby, it inhibits aggregation
and dilates blood vessels. A balance between PGI2 and TXA2 may
therefore prevent thrombus and haemostatic plug formation and in fact
it has been suggested that an imbalance in the PGI2-TXA2 system may
be related to certain pathological conditions; arterial thrombosis
(Lagarde and Dechavanne, 1977), diabetes (Harrison et al, 1978;
Johnson et al, 1978) and thrombocytopenic purpura (Remuzzi et al,
1980; Cocchetto et al, 1981). Prostacyclin synthetase, the enzyme
which converts prostaglandin endoperoxides (PGG2 and PGH2) to PGl2»
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Figure 1.1 The major metabolite? of arachidonic acid.
3a
is most highly concentrated in the intimal surface of the blood
vessel and progressively decreases towards the adventitial surface
(Moncada et al, 1977). Damaged endothelium may have a reduced
capacity for PGI2 production, thus allowing platelet deposition and
aggregation to occur more readily. A fall in PGI2 production at the
site of the damaged vessel may be a contributory factor to the
initiation of thrombus formation.
Before one can elucidate the mechanisms underlying platelet
activation, it is necessary to have an understanding of the roles of
the intracellular platelet ultra structures. Platelets contain
extremely labile microtubules, protein structures which are sensitive
to calcium ion fluxes, low temperature and pressure changes. A
marginal ring of microtubules has been identified in platelets of
most species studied so far and following platelet stimulation, the
ring of microtubules reduces in diameter, contracting towards the
centre of the cell, apparently concentrating the granular organelles
within a central cytoplasmic zone bounded by the microtubule bundle
(Nachmias et al, 1977). The microtubules in the activated platelet
are then seen in a newly polymerised configuration which cause local
activation of the contractile system giving rise to pseudopodia and
spikes which are observed in the course of shape change. It is
thought that the disassembly of the circumferential ring of
microtubules activates the contractile system which subsequently
gives rise to the pseudopods and spikes. The formation of these may
facilitate aggregation and secretion by increasing the opportunity of
cell-cell contact. The breakdown of the circumferential ring of
microtubules has been proposed to be due to local increases in
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calcium ions restricted to the submembraneous region (Le Breton et
al, 1976). (By employing low concentration of chlortetracycline as
a fluorescent probe for membrane calcium, a redistribution of calcium
away from membrane sites during shape change was demonstrated). It
was generally accepted that cytoplasmic calcium fluctuations played a
central role in the initiation of platelet activation and the shape
change response was found to be associated with elevations in
cytosolic free calcium, which have proved to be insufficient to
trigger aggregation or secretion. However, more recently, the shape
change response induced by a number of agents such as thrombin (low
concentrations), PAF-acether, ADP and adrenaline has been found to
occur without detectable changes in cytosolic free calcium levels
(indicated by quin-2) (Rink et al, 1982; Hallam et al, 1984A;
198MB).
Higher concentrations of the above agonists will subsequently
induce platelets to aggregate and primary aggregation follows
platelet shape change when platelets are stimulated with agents not
sufficiently potent enough to promote second phase aggregation.
Primary aggregation reflects the exposure of fibrinogen receptors on
the platelet surface and the interaction of fibrinogen subsequently
enhances cell-cell contact (Mustard et al, 1975). This response
requires a lower cytosolic calcium concentration than that necessary
to induce secondary wave aggregation and may in fact involve a
different pool of bound calcium ions (Charo et al, 1976; Le Breton
and Dinerstein, 1977). It has been suggested that extracellular
calcium ions are essential for the primary response since in the
presence of the chelating agent EGTA, primary aggregation is
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suppressed. Under most circumstances, primary aggregation
spontaneously reverses whereby platelets retain their discoid form
and this occurs if the stimulus is not sufficient to induce
endogenous thromboxane synthesis and the release reaction (Mustard et
al, 1975).
In the presence of physiological calcium concentrations, ADP
only induces a readily reversible platelet aggregatory response (no
formation of TXA2 or the release of granule contents). However, in
a medium with a low calcium ion concentrations such as citrated
plasma, high concentrations of ADP (1-2yM) induces two phases of
aggregation in human platelets. The second phase is associated with
activation of the arachidonate pathway and the release reaction
(Macfarlane et al, 1975; Mustard et al, 1975). This effect is
species specific since rabbit platelets never produce secondary wave
aggregation in response to ADP regardless of the medium (Joist et al,
1971; Macmillan, 1970). This observation would therefore explain
why 'in vivo' ADP only induces aggregation which is readily
reversible in most species and it should be emphasised that ADP
induction of the release reaction in some species is reaily only an
artefact of the 'in vitro' system. Human platelets prepared with
other anticoagulants such as hirudin and exposed to physiological
calcium concentrations only demonstrate primary aggregation waves
(Kinlough-Rathbone et al, 1983). These artefactual effects should
be taken into account when considering the mode of ADP induced
aggregation. Essentially the primary aggregation response results
from a direct effect of agonists at the platelet surface and it is a
process which is not affected by inhibitors of the cyclo-oxygenase
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pathway. Secondary aggregation occur? a? a consequence of the
release reaction and/or endogenous TXA2 synthesis. During the
release reaction the contents of platelet storage vesicles are
released from the platelet.
Platelet contains 3 types of storage vesicles; the dense
granules containing ADP, 5HT, ATP, calcium, antiplasmin and inorganic
phosphates; alpha granules containing fibrinogen, B-thromboglobulin
cell growth factor and platelet factor 4; and platelet lysozomes.
The movement of calcium across platelet membranes may be important in
the release process since calcium ionophores can induce such an
effect (Feinman and Detwiler, 1974) and calcium antagonists have been
found to inhibit release (Charo et al, 1976). The movement of
calcium into the cytoplasm may in fact exert an effect on the
platelet microtubules which move towards the centre of the cell in a
contractile wave during the release reaction (White, 1971). In
addition calcium-dependent activation of platelet actino-myosin is
thought to be involved (Haslam and Lynham, 1977; Daniel et al, 1977;
Bennet et al, 1977). Actino-myosin is a protein complex,
phosphorylation of which reaches a maximum before the completion of
secondary aggregation. Phosphorylation is followed by a slow
dephosphorylation. No increase in phosphorylation is observed when
aggregation without secretion occurs and it seems therefore that
phosphorylation is a prerequisite to the initiation of secretion
(Bennet et al, 1977). The protein-actir* complex has been
postulated to be involved in vesicular fusion of dense bodies with
the plasma-membrane, whereby an opening is formed through which the
contents are expelled (Daniel et al, 1981).
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The formation of endogenous TXA2, during secondary wave
aggregation occurs when arachidonate is released from membrane
phospholipids. The role of endogenous TXA2 in platelet aggregation
was discovered in the early seventies from the use of non-steroidal
anti-inflammatory drugs (NSAIDs) such as aspirin and indomethacin
(Ferreira et al, 1971; Smith and Willis, 1971; Vane 1971). These
drugs inhibit the prostaglandin synthetase (cyclo-oxygenase) enzyme
and were important factors in the elucidation of platelet aggregation
mechanisms.
Agents that can induce secondary wave aggregation include
thrombin, collagen, PAF and TXA2. They do so through one or both of
the following mechanisms; (A) by activation of the phospholipase
enzymes which cleave AA from membrane phospholipids. AA is then
converted to the prostaglandin endoperoxides (PGG2 and PGH2) and
TXA2. (These enzymes are inactivated by free radicals formed during
the reduction of PGG2 to PGH2 (Samuelsson et al, 1975; Smith and
Lands, 1972)) and/or (B) by directly triggering the release of ADP
and 5HT from platelet dense granules.
ADP, 5HT and TXA2 potentiate aggregation by either recruiting
other platelets or in the case of TXA2 trigger further release, and
it is these events which induce the second phase of aggregation. In
addition, ADP, 5HT and TXA2 may act synergistically with weak
aggregating agents such as ADP or adrenaline (Kinlough-Rathbone et
al, 1977; Packham et al, 1977A).
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Agents which promote secondary wave aggregation, whether they do
so via pathway (A) or (B) can be distinguished in the presence of
non-steroidal anti-inflammatory agents and/or ADP removing enzymes
(creatinine phosphate or creatinine phosphokinase, CP/CPK). Indeed
second phase aggregation induced by collagen (low concentrations) or
ADP is inhibited by aspirin and other NSAIDs, indicating that these
agents are dependent upon prostaglandin endoperoxide/TXA2 synthesis
to augment aggregation either by recruiting further platelets and/or
directly triggering the release reaction. In contrast, the
formation of irreversible secondary aggregates by agonists acting via
pathway (B) are not blocked by NSAIDs. Such agents include
thrombin, PAF and TXA2 which can act directly on the platelet
granules to trigger the release reaction (Kaplan et al, 1979). It
should be noted that aggregation induced by high concentrations of
collagen can overcome NSAID inhibition, possibly by promoting
secondary aggregation via a direct effect on the dense granules.
Although such a direct effect is apparent at high concentrations it
is not likely to be of any importance at low collagen concentrations
since NSAIDs completely abolish second phase aggregation in this
instance (Packham et al, 1977B).
A third pathway of aggregation has been postulated which is
independent of both TXA2 and ADP. In the presence of NSAIDs and
CP/CPK, thrombin induced aggregation is only partially inhibited,
indicating the involvement of another mechanism (Kinlough-Rathbone et
al, 1977; Packham, 1977).
It has been suggested that a phospholipid, 1-0-alkyl-2-acetyl-
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glyceryl-3-phosphorylcholine (platelet activating factor, PAF) may be
the mediator of this third pathway (Vargaftig et al, 1981). PAF
induced aggregation doe? not require ADP secretion or TXA2 synthesis
(Cazenave et al, 1979). Experiments were carried out whereby
radioactive acetate was incorporated into platelet membrane
phospholipids and the demonstration that radioactive acetate was
present in PAF as a consequence of calcium ionophore stimulation
would suggest that PAF may play a role as an intracellular mediator
of aggregation (Chap et al, 1981). Furthermore, platelets
desensitized to PAF lose their ability to respond to thrombin.
The mode of PAF-acether release from platelet membranes is not
fully understood. The calcium ionophore A23187 is the most active
releasing agent (Chignard et al, 1977b). Collagen and thrombin
release enough PAF to account for aggregation, whilst ADP, AA and PAF
are without any effect on PAF release (Vargaftig 1977b, Chignard et
al, 1980). Since all agents which induce PAF-acether formation also
trigger the activation of platelet phospholipase A2 (Bills et al,
1976) it has been proposed that this enzyme is implicated in PAF
acether formation by platelets (Cazenave et al, 1979). The finding
that inhibitors of platelet PLA2 activation, namely dibutyryl AMP
(Lapetina et al, 1977) and bromophenacylbromide (Vargaftig et al,
1980a) reduce or suppress PAF-acether formation in platelets
stimulated with the calcium ionophore supports the involvement of
PLA2 in PAF-acether release. A role for PAF in the third pathway of
aggregation has been schematically represented together with the AA
and ADP pathways by Vargaftig in Fig.1.2.
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c. txa2 adp paf
Collagen
Vargaftig et al, 1981
Schematic representation of three pathways of platelet
activation. Inhibition is observed at: (A) by
phospholipase inhibitors, (B) by cyclo-oxygenase
inhibitors and (C) by prostaglandin
endoperoxide/thromboxane A2 receptor antagonists.
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Evidence has been put forward, against such a role for PAF as
mediator of the third pathway of aggregation (Kloprogge et al, 1983)
based on the findings that NSAIDs, acetylsalicylic acid and CP/CPK
completely inhibited PAF induced aggregation and secretion. It is
possible that PAF-acether plays only a minor role, if any at all in
platelet activation induced via a third pathway. Indeed it has been
demonstrated that PAF-induced aggregation is accompanied by the
release reaction and TXA2 production. (Miller et al, 1982; Cargill
et al, 1983; Lapeti.oa et al, 1983).
In addition to the 3 mechanisms described above which require
the presence of agonists, platelets can also aggregate as a result of
close cell-cell contact, whereby activation of the AA pathway with
the subsequent formation of TXAp can trigger the release reaction,
which consequently promotes secondary aggregation. This type of
aggregation is blocked by NSAIDs and in this situation the release
reaction is secondary to close platelet contact and aggregation
(Massini and Zuscher, 1971).
A number of situations have been reported in which release and
secretion may occur without any aggregation being observed. For
example, thrombasthenic platelets change shape and release their
granule contents in response to thrombin but do not actually
aggregate (Caen et al, 1966; Zucker et al, 1966). Another example
is the observation that platelets can undergo the release reaction
when aggregation is not apparent in the presence of calcium
chelators. It would appear that although platelet contact
associated with aggregation can induce TXAg synthesis and hence
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trigger the release reaction, situations do exist whereby release and
secretion can occur independently of aggregation.
Irrespective of the precise mechanism underlying the platelet
response, whether it is shape change, primary or secondary wave
aggregation, activation of platelets is initiated by agonist
interaction at the surface membrane usually at discrete receptor
sites. Surface receptors have been identified for ADP (Nachman and
Ferris, 197^), thrombin (Detwiler and Feinman, 1973; Tollefsen and
Majerus, 1976), adrenaline (Byddeman and Johnsen, 1969), 5HT (Michal,
1 969) and certain prostaglandins and TXA2 (Le Breton et al, 1979;
Fitzpatrick et al, 1978; Nicolaou et al, 1979). 5HT and
adrenaline, in addition to their action at discrete receptor sites,
can be actively taken up into platelets, a phenomenon not associated
with aggregation.
Most of the compounds mentioned above induce only aggregation.
Metabolites of AA can either induce or inhibit platelet activation.
The prostaglandin endoperoxides, PGG/PGH2 and TXA2 fall into the
former category, acting at a TXA2/endoperoxide receptor. There is a
good deal of controversy as to the true biological activities of the
endoperoxides. For example, it has been reported that thromboxane
synthetase inhibitors virtually abolish AA aggregatory activity
(Fitzpatrick and Gorman, 1977; Blackwell et al, 1978) and that the
concentrations of endoperoxides detected in platelets following AA
induced aggregation are 100 times lower than would be required for
aggregation. In contrast, it has been demonstrated that the
addition of exogenous PGG2 to platelets 'in vitro' induces very rapid
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aggregation and release (Claesson and Malmsten, 1977). The fact
that exogenous PGH2 is degraded in PRP predominantly to PGD2 and PGE2
with less than 1? conversion to TXA2 (Smith et al, 1975) may possibly
explain why low levels of endoperoxides are detected in some studies
and why thromboxane synthetase inhibitors may block aggregation,
since the direct action of PGG2 or PGH2 may be masked by their rapid
transformation to PGD2 a potent inhibitor of aggregation (Oelz et al,
1977). Other workers have suggested that AA conversion to TXA2 is
not essential for aggregation (Needleman et al, 1976, 1977; Flower
and Cardinal, 1979) supporting the notion that endoperoxide
themselves are capable of inducing aggregation.
It is generally assumed that the endoperoxides and TXA2 act on a
common receptor; the greater potency of TXA2 predisposes one to
designate the receptor a "thromboxane receptor". From a chemical
viewpoint the majority of the TXA2 mimetics studied are in fact
endoperoxide-like in structure (Corey et al, 1976; Bundy, 1976).
Furthermore, receptor antagonists are capable of blocking the
aggregatory effects of both PGH2 and TXA2 suggesting that these
antagonists are acting on a common receptor.
In spite of these findings, it has also been postulated that
TXA2 activates platelets by acting as a physiological ionophore
transporting calcium directly from the dense tubular system of
platelets to the cytoplasm (Gerrard et al, 1977B, 1978B). However
more recently workers have disputed this role of TXA2, and their
argument against it was based upon studies using stable thromboxane
antagonists. In the presence of these antagonists, calcium release
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from intracellular stores in the intact platelet and from isolated
vesicular membranes was inhibited, supporting a receptor mediated
effect of thromboxane (Rybicki et al, 1983; Pollock et al, 1984).
Furthermore, Carey and colleagues (1985) when studying the calcium
sequestration nature of intracellular membranes, found that of the
three compounds, A23187, 11,9-emPGH2 and PGH2, only the calcium
ionophore A23187 had the ability to release sequestered calcium.
Platelets also contain receptor systems responsive to
prostaglandins E-| , 12 and D2. Occupation of these receptors leads
to an activation of adenylate cyclase with subsequent inhibition of
platelet function due to elevations in cyclic AMP. Two distinct
receptors for PGD2 and PGI2 have been identified (Mclntyre and
Gordon, 1977; Miller and Gorman, 1979) with PGE-) acting on PGI2
receptors.
Recently, PGE-) has been reported to inhibit platelet aggregation
independent of cyclic AMP involvement (Sinha and Colman, 1985). A
macromolecular plasma protein is thought to be involved which exerts
an inhibitory effect by altering a factor XA component. As yet, the
precise mechanism underlying this inhibition remains to be
elucidated.
Essentially, platelet responses are evoked by the interaction of
agonists at specific receptors and it is appreciated that such
responses are a sequelae of controlled intracellular reactions
mediated by second messengers.
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Phospholipase A2, a membrane bound enzyme is stimulated by many
agonists, and activation of this enzyme releases AA and possibly PAF
acether from membrane phospholipids which initiates intracellular
platelet mechanisms including Ca2+ fluxes and, cyclic AMP changes.
Another pathway for the release of AA from platelet
phospholipids independent of PLAp activation has also been described
(Lapetina and Cuatrecacas 1979, Bell and Majerus 1980, Mauco et al,
1978) and involves the activation of a phosphatidyl inositol
phosphodiesterase (phospholipase C, PLC), stimulation of which
results in the formation of diglycerides and polyphosphoinositides
from phosphoinositol. The presence of this enzyme in platelets was
first indicated from the presence of phosphatidic acid in platelets
without any evident AA release (Lapetina and Cuatrecasas 1979).
Phosphatidic acid is itself a potential trigger for aggregation. It
releases calcium from platelet membrane fractions and therefore acts
in many respects as a calcium ionophore (Gerrard et al, 1978). It
cannot however cross platelet membranes and so if added exogenously
to platelets, it does not possess the ability to trigger aggregation.
A schematic representation of these 2 pathways is illustrated in
Fig.1.3. Hydrolysis of phosphoinositides by PLC results in the
transient accumulation of 1,2-diacylglycerol within the platelet.
One of its function is to trigger the release of AA from membrane
phospholipids (Rittenhouse-Simmons, 1979) as well as to activate
protein-kinase C (Nishizuka, 1983). In addition diacylglycerides
have been shown to induce aggregation without an apparent elevation
in intracellular calcium above basal levels. Since endogenously
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Figure 1.3 Schematic representation of two enzymatic pathway?
triggering arachidonic acid release from membrane
phospholipids.
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not exert any appreciable aggregatory effect alone under
physiological conditions. However, responses of diacylglycerol
resembling those of natural agonists (ADP, thrombin, etc.) can be
evoked by the combined action of diacylglycerol and a modest
elevation in intracellular calcium, whereby independently they would
be inadequate to produce secretion and aggregation (Rink and Hallam,
1984). Another molecule generated from phosphoinositol is 1,4,5-
inositol-triphosphate (IP3) and it has been postulated to act as an
intracellular messenger triggering calcium fluxes within platelets.
Stimulation of platelets by thrombin (Lapetina and Cuatrecacas,
1979), collagen (Nishizuka 1983; Seiss, 1983a), PAF (Lapetina and
Siegel, 1983) and AA (Seiss et al, 1983b) is associated with rapid
changes in membrane inositol phospholipids through activation of both
PLC and PLA2. Stimulation of PLC has been reported to occur before
PLA2 (Lapetina and Seiss, 1983b). PLC products may act as second
messengers which act on the PLA2 enzyme (Lapetina, 1983b). In human
platelets stimulated with endoperoxide analogues (U44069 and U46619)
a rapid formation of 1 ,2-diacylglycrol and phosphatidic acid has been
reported (Pollock et al, 1984), a process which was found to be
insensitive to NSAIDs. Thrombin too was found to activate PLC with
the resultant formation of IP3 in the presence of aspirin
(Rittenhouse, 1985). On the other hand, the calcium ionophore did
not activate PLC in the presence of aspirin, apyrase or CP/CPK, and
it has been suggested that PLC is not actually activated by changes
in calcium ions but rather by the presence of agonists acting through
receptors (Rittenhouse, 1985). The calcium ionophore possibily
activates PLC enzymes indirectly by stimulating PLA2 (which is
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sensitive to calcium fluxes). The latter releases AA and it is the
prostaglandins and TXA2 which induce PLC to generate
polyphosphoinositides, and not the calcium levels which are elevated
by the ionophore. These pathways are illustrated in Fig.1 .-U.
Calcium therefore, is an important second messenger involved in
stimulus-induced platelets aggregation, secretion and generation of
potent arachidonate metabolites. On the other hand cyclic AMP
generated in platelets by stimulation of the adenylate cyclase
enzyme, acts to prevent nearly all manifestations of platelet
activation. Cyclic AMP may act in part by increasing intracellular
calcium sequestration within the platelet (Owen et al, 1980) with a
consequent effect on protein phosphorylation due to a restriction on
the amount of cytoplasmic calcium available to these enzymes
(Kawahara et al, 1980). Feinstein et al (1983) demonstrated that
cytoplasmic free calcium levels are regulated by cyclic AMP dependent
reactions in intact platelets. In their experiments they not only
demonstrate that elevations in cyclic AMP supress a rise in
cytoplasmic calcium induced by thrombin, but also that cyclic AMP can
lower cytosolic calcium levels following stimulation by an agonist.
The precise mechanisms underlying the action of cyclic AMP on
cytoplasmic calcium levels are not fully understood, but it has been
suggested that cyclic AMP may inhibit a crucial initial biochemical
reaction necessary for intracellular release of calcium or its influx
from the surrounding media (Feinstein et al, 1983). An involvement
of cyclic AMP on the stimulation of calcium ion transport and/or
calcium binding has also been suggested. Inhibitory prostaglandins
17
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Figure 1.1 Interaction of enzymatic pathways involved in
arachidonic acid release from platelet phosphilids.
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and Forskolin (Insel et al, 1982) can stimulate processes that
rapidly remove calcium from the cytoplasm induced by prior treatment
with thrombin. Furthermore the lowering of cytoplasmic calcium by
cyclic AMP stimulators closely corresponds both in the time course
and dose-response to their ability to reverse thrombin induced
aggregation, protein phosphorylation and cytoskeleton assembly
(Feinstein et al, 1983B). The involvement of a cyclic AMP dependent
protein-kinase on the stimulation of calcium ion reuptake and the
phosphorylation of proteins participating in the active pumping of
calcium ions from the cytoplasm to intracellular stores has been
postulated (Haslam et al, 1978; 1979; Kaser-Glanzmann et al, 1977).
Studies have also suggested that increases in cyclic AMP may depress
phospholipase C activity in intact platelets and this effect will be
of relevance to cAMP induced inhibition of cytosolic calcium
fluctuations if phosphoinositide breakdown is functionally related to
the mobilization of intracellular calcium (Rittenhouse, 1979). In
this situation cyclic AMP would be modulating the response of calcium
indirectly by exerting control at the level of the phospholipase C
enzyme and so presumably regulating the level of diacylglycerol
present in the system.
In addition to stimulating active sequestration of calcium, and
the inhibition of the phospholipase C enzyme, several groups have
reported that an elevation in cyclic AMP inhibits both arachidonate
liberation from phospholipids (Gerrard et al, 1977; Lapetina et al,
1977) and possibly the cyclo-oxygenase enzyme (Malmsten et al, 1976).
The ability of cyclic AMP therefore to lower cytosolic calcium,
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highlights an important role for cyclic AMP; as a modulator of (A)
the initiation of platelet activation by aggregating agents and (b)
in reversal of the activation process following stimulation.
It is apparent from this chapter that the platelet is a complex
entity whose functional integrity is important in the maintenance of
haemostasis. The platelet functions as a result of interactions of
many biochemical processes occurring at both the surface membrane and
the intra-cellular organelles. Only from pharmacological
manipulations of these events has many of the underlying mechanisms
been elucidated.
The work in this thesis has been concerned with only a few
aspects of platelet function and can be divided into 3 sections.
The first investigates the nature of AA induced aggregation in rat
platelets since much conflicting data exists in this area. AA was
found to evoke several responses in rat platelets and the aim was to
elucidate the underlying mechanisms involved in each of the modes of
action. The second section involves an investigation of the
prostaglandin endoperoxide/thromboxane system in platelets from 3
species; human, rat and rabbit. Much of the published data on
thromboxane-like action of platelets and smooth muscle appears to
suggest that the platelet receptor is different from the
corresponding smooth muscle receptor (Lefer et al, 1980), but whether
these receptor differences reflect heterogeneity between tissues or
perhaps between species is not clear. The overall aim of the work
carried out in this section was therefore to compare the
pharmacological characteristics of the thromboxane receptor of the
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human platelet with the rat and the rabbit platelet in terms of their
interaction with natural and synthetic prostanoids. The final
section in this thesis concerns the function of platelets in two
pathological conditions, namely diabetes mellitus and hypothyroidism.
Diabetes is a disease which is unfortunately often associated with
many other complications especially of the microvasculature.
Retinopathy is one such complication and the effect of platelet
disfunction as a possible cause of this condition was investigated by
comparing platelet sensitivity in non-retinopathic diabetics to those
with different degrees of retinopathy. In addition, platelet
function and sensitivity was studied in 'uncontrolled' diabetics
whose glycaemic control was improved over a six month period.
Finally, hypothyroidism, like diabetes, is associated with other
problems, including menorrhagia, increased incidence of
arteriosclerosis and easy bruising. The study in this section was
carried out on patients over a six month period who were undergoing
hormone replacement therapy and their platelet reactivity was






This chapter describe? the general procedures underlying the
methods utilized in this thesis and the materials used.
Preparation of Platelet Suspensions and Measurement of Platelet
Aggregation
Platelet preparation procedure
Blood was withdrawn from human subjects, rabbits and rats in the
studies carried out in this thesis.
Human blood was withdrawn from the antecubital vein of
volunteers, who had not previously taken any form of NSAIDs (for up
to 7 days) and added to acid-citrate dextrose (ACD) anticoagulant
(10mls/50mls blood) contained in plastic centrifuge tubes.
Rabbits were anaesthetized with Sagatal (30mg/kg body weight)
(pentobarbitone sodium B.P., May & Baker Ltd., U.K.) injected into
the marginal ear vein. Blood was withdrawn from both common carotid
arteries through heparinized cannulae (100u/ml) (heparin - Boots
Company Ltd., U.K.) and collected directly into plastic centrifuge
tubes containing ACD (10mls/50mls blood).
Rat blood was withdrawn via the abdominal aorta of etherized
rats, (diethylether, Rathburn Chemicals Ltd., U.K.) through
heparinized cannulae (100u/ml) into ACD (1ml/10mls blood).
The blood from either human donors, rats or rabbits once
22
collected was centrifuged at 200 x g for 20 minutes allowing the red
cells and other components to separate from the plasma. The upper
platelet-rich plasma layer was then carefully drawn off into another
plastic tube. At this stage the platelet-rich plasma layer was used
directly or treated further to afford a washed platelet suspension.
When platelet-rich plasma was used directly, it was left to stand at
room temperature for 20-30 mins. (in the case of the human or rabbit)
or 60 mins (in the case of rat plasma) allowing the platelets to
restabilize following the centrifugation procedures.
Washed platelet suspensions
The conditions for preparing washed platelets in these
experiments are not as rigorous as those used by other groups
(Mustard et al 1972; Vargas et al, 1982) where several washing
centrifugation steps are carried out. As a result, the washed
platelet suspensions are not totally free of plasma factors including
fibrinogen.
In order to prevent clumping of platelets during the second
centrifugation step, prostacyclin (PGI2) was added to the platelet-
rich plasma prior to centrifugation (final concentration 10ng/ml).
The platelet-rich plasma was then centrifuged at a minimum speed of
600 x g for a further 20 minutes allowing a platelet pellet to form.
The platelet poor plasma was then carefully poured off and the
platelet pellet was resuspended in calcium-free Krebs (3mls/ml PRP).
The washed platelet suspension was then left for 1 hour before use,
allowing time for the PGI2 to decay and the platelets to restabilize.
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During this 1 hour period and throughout the experiment, the platelet
suspension and the Krebs' solution were bubbled with 95$ 02/5$ C02-
This procedure prevents the pH of the platelets and the Krebs'
solution from increasing, which normally occurs with time if
platelets are not aeriated.
Platelet aggregation
Platelet aggregation was measured by the turbidometric method of
Born (1952). Each cuvette contained:- Vol. (ml)
platelet suspension (PRP or washed) 0.5
Krebs solution 0.3
Saline (0.9$) 0 - 0.2
Vehicle 0-0.1
Total volume 1 ml
All cuvettes and stirrer bars (teflon coated) were siliconized
with 2$ dichlorodimethylsilane in toluene and washed twice with
methanol before use. A Bryson aggregometer (H. Upchurch & Co.,
Ltd.) was used and the changes in light transmission of the platelet
suspension were recorded on a potentiometric recorder (Servoscribe
IS).
The cuvette, containing the platelet suspension was placed in
the aggregometer and incubated for 2 minutes at 37°C with constant
stirring (1100 rev/min). When studying the activity of antagonists
or inhibitors, these were added to the platelet suspension prior to
the 2 min incubation period. Agonists were then added and incubated
2iJ
for a further 2 mins.
Measurement of the platelet release reaction
Platelets are known to release the contents of their granular
storage vesicles when activated by aggregating agents. A method is
described below which allows a quantitative determination of the
amounts released from these granules and is based upon the principle
that platelets can actively take up and store 5HT and adrenaline into
their dense bodies.
Platelet rich plasma from blood was pre-incubated with
radiolabelled 5HT (5-hydroxy-(side chain)2-[14C]-tryptamine, specific
activity l43nCi/pg, final concentration of 1pg/ml-^) for 30 minutes
at 37°C. The [^C]-5HT is actively taken up by the platelet into
the dense granular bodies during this pre-incubation period.
Following the incubation period, platelet rich plasma was used
in aggregation studies as previously described. In order to
estimate [^C]-5HT release, at the end of the 4 minute period, 200pl
samples (X2) were withdrawn from the cuvette and added to 0.8ml ice-
cold ethylenediaminetetra-acetic acid (E.D.T.A. solution 0.4$ w/v in
0.9$ saline) in an Eppendorf tube. The quenched samples were
centrifuged immediately at 15000 x g (20°C for 30 seconds) in a bench
Eppendorf centrifuge. Subsamples (0.5ml) of the cell free
supernatant were then transferred into 10ml of scintillant (P.C.S.
and toluene 2:1).
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Radioactivity was counted in a Philip? PW4540 liquid
scintillation counter. Sample radioactivity was counted and
expressed as counts per minute and the amount of radioactivity
released per sample was calculated as follows;
Final concentration of [^C]-5HT 1yg/ml
Specific Activity of [^C]-5HT 143 nCi/yg
In 0.5ml PRP sample we have 71.5 nCi
Withdraw 200yl (1/5 total volume) 14.3 nCi
Withdraw further 500yl (1/2 of above vol.) 7.15 nCi
The amount of [^C]-5HT releasable was then converted from
disintegrations per minute (c.p.m.) to counts per minute (d.p.m.)
using the following formula;
0.00715yCi x 2.2 x 106 cpm = 15730 dpm
Correcting for counting losses, the maximal releasable C^C]-5HT
was calculated to be 11,450 dpm.
The amount of radioactivity released per sample was then
expressed as a percentage of the maximal releasable radioactivity.
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Estimation of platelet count
Reagents used: Solution A (100ml) 1g Sodium citrate
0.002g Mercuric chloride
0.2g Brilliant Cresyl Blue
Warmed to 45°C
Solution B (100ml) 20g Urea
Method
Estimation of the platelet number in a sample of plasma or
washed platelet suspension was determined by the Cresyl Blue Dye
method. Equal volumes of solutions A and B were mixed and filtered.
An aliquot (50yl) of platelet rich plasma or washed platelets was
added to 1ml of the dye mixture, and samples taken up by a glass
capillary and used to fill both chambers of a haemocytometer.
Sedimentation was allowed to proceed for 15 minutes in a petri-dish
containing moist filter paper. An aliquot (10yl) of the dye-
platelet mixture was placed in a counting chamber, marked with a
grid. The number of platelets in 5 squares of the grid were counted
and the mean value was multiplied by 1o\ giving an estimate of the
number of platelets per yl of PRP or washed platelet suspension.
Mean number of platelets (x10^) ml~^ of:
PRP Washed Platelet
Suspensions
Human 85 ± 8 89 ± 5
Rabbit 86 ± 12 115 ± 15
Rat 107 ± 15 141 ± 18
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Stock solutions of arachidonic acid (10mg/ml) were made up in ethanol
and stored at -20°C. For the aggregation studies an arachidonate
sodium salt (3mg/ml) was made up. A volume of 0.6ml of stock
arachidonic acid (in ethanol) was added to 20yl of NaOH (1M). The
ethanol was blown off under nitrogen and 0.9? NaCl (2ml) was added to
give a 3mg/ml arachidonate solution. Subsequent working dilutions
were made up in 0.9? NaCl.
Stock solutions of fatty acids were also made up in ethanol and
stored at -20°C. Working dilutions were made up following the same
procedure as for arachidonic acid.
All fatty acids were tested for the presence of impurities or
any degradation products by thin layer chromatography (T.L.C.).
Specific analysis of endoperoxide content was not carried out but the
presence of any contaminants was not apparent from the T.L.C.
analysis.
The aggregation solutions (ADP, collagen etc.) used in the
longitudinal studies were standardised as far as possible. Fresh
stock solutions (originally made up from the same batch) were used at
the beginning of each study period (0, 3 and 6 mths) and fresh
working dilutions were made up on the day of individual experiments.
Throughout this thesis the results are given as the mean of at
least 6 experiments and aggregation recordings were carried out in
duplicate.
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Estimation of plasma-protein concentration In washed platelet
suspensions
The residual plasma-protein concentration in washed platelet
suspensions was estimated by ultra-violet spectroscopy as follows:-
(i) A sample of the washed platelet suspension (2.5ml) (platelet-
free) was placed in a quartz cuvette and its U.V. extinction at
280nm recorded.
(ii) The P.R.P. was serially diluted until an extinction of similar
intensity to that of washed platelet suspension was obtained.
(iii)Assuming that one U.V. extinction is equivalent to 1mg ml-1 of
protein, one can estimate the protein concentration in PRP and
washed platelet suspensions (Table 2.1).
Table 2.1 Plasma Protein Concentration (mg ml~^) in PRP and washed
platelet suspensions, (± s.e. mean of 3 samples)
PRP Washed platelet suspension
Human 51.5 ± 2.65 1.50 ± 0.15
Rat 50.4 ±2.31 1 .26 ±0.13
Rabbit 40.71 ± 7.50 1.30 ± 0.06
Radioimmunoassay of Thromboxane Bp (TXB?)
The underlying principle of radioimmunoassay depends upon
competitive binding, where labelled and unlabelled antigen compete
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equally for antibody binding sites. A well designed antigen-
antibody equilibrium reaction is not affected by radionucleotide
labelling. The distribution of radioactive counts in the bound and
free states is proportional to the relative concentration of
unlabelled antigen. In general the purpose of a radioimmunoassay is
to determine the concentration of unlabelled antigen in a biological
sample.
A. Radioimmunoassay Procedures
A standard curve was set up whereby a series of tubes are
prepared, each containing exactly the same amount of tracer (labelled
antigen) and antibody reactants. Increasing known amounts of
unlabelled antigen (standards) are added to successive tubes. The
percentage of radioactivity (tracer) 8/80 to the antibody is
inversely proportional to the amount of unlabelled antigen present in
the tube.
The TXB2 antibody used in experiments throughout this thesis was
obtained commercially from The Pasteur Institute, France, in the
freeze-dried form, and before use was reconstituted in phosphate
buffer pH 7.5 (5.5 ml). Thromboxane B2 levels are believed to
reflect the levels of the active precursor thromboxane A2 present
from biosynthetic transformations of arachidonic acid.
Radiolabelled TXB2 (3h-TXB2) was obtained from Amersham PLC Ltd. UK
(specific activity 6.66 TBq/mMol). The 3h-tXB2 was stored in
methanol (20 yCi/ml) at -20°C and before use the methanol was
evaporated off at 45°C under a stream of nitrogen and resuspended in
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phosphate buffer (pH 7.5) to give a final concentration of 0.1
yCi/ml.
The following conditions were found suitable for TXB2
radioimmunoassay;
Standard/unknown sample in buffer 0.50ml
TXB2 antibody 0.05ml
Tracer - [3h] TXB2 0.05ml
Donkey - anti-rabbit serum (DARS) 0.05ml
Normal Rabbit serum (NRS) 0.05ml
Total volume 0.7 ml
In addition to the standards, a set of reference tubes were
prepared; counting standards containing only 3h-txB2 give a measure
of the total radio-active counts per tube. Zero standards - no
unlabelled antigen present, give an estimation of the maximum
possible binding of the tracer to the antibody. Non-specific
binding (NSB) tubes, containing excess unlabelled antigen, to
saturate the antibody binding sites give an indication of the degree
of binding of the tracer to other components of the assay, e.g. tube
walls, or other potential binding sites. NSB usually accounts for
10$ or less of the bound.
A series of standard solutions (5 pg ml-' to 1000 pg ml"') of
unlabelled TXB2 was made up in phosphate buffer (pH 7.5) diluent from
stock solution of TXB2 (1 yg ml"'') in methanol. TXB2 standards (0.5
ml) were added to the tubes in duplicate as detailed in Fig.2.1.
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Fig.2.1 Concentration, volume and the final concentration of
TXB2 standards used in setting up the TXB2 Standard
Curve










Counting standards (0.05 ml 3h TXB2 only), Zero standards (0.5 ml
diluent), and NSBs (0.5ml of 1 yg ml""'' TXB2) were set up in
quadruplicate.
Assay tubes containing the biological samples (with unknown
amount of antigen) were prepared (in duplicate) and set up in the
same manner as for the standards. It is essential that the
standards and samples are subjected to the same experimental
conditions. Fig.2.2 illustrates the procedural steps for standards,
reference and sample tubes.
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Fig.2.2 Methodology for TXB2 standard curve and sample assay
Biological Sample in EtAc
EtAc blown off at 145°C
under stream of nitrogen








Add 50 pi TXB2 antibody
Whirlimix and incubate
^ for 2hrs at room temp.
Add 50 pi DARS, 50 pi NRS
Whirlimix and incubate
for 16 hrs at 4°C
Centrifuge at 1300g for 30 mins at M°C
Counting standards i discard supernatant
^ Add 200 pi scintillant
whirlimixI




Separation of the bound tracer from the free is based upon the
double antibody separation technique in which the bound
antigen/antibody complex binds to donkey-anti-rabbit serum (DARS).
Normal rabbit serum (NRS) is added to the system during this
incubation period. The bound tracer/TXB2 antibody/DARS complex is
separated from the free tracer by centrifugation during which the
heavier precipitated fraction sediments to the tube bottom.
B. Counting and Data Analysis
The number of counts per vial were recorded using the Packard
4000 series scintillation counter. The standard curve is plotted as
% tracer bound (vertical axis) against concentration of TXB2
(horizontal axis) and a logistic curve formula matches a hyperbolic
curve model with the best fit curve statistics. The average
deviation between the computer curve and standard points is estimated
and if this deviation is more than 5%, the curve is not accepted.
If the gradient is less than 8%, then small changes in the amount of
TXB2 would produce changes in the % of the tracer bound, too small to
be accurately measured. In addition, if the curve is too steep the
working concentration range of the assay is decreased considerably.
In these situations, the curves are not generally accepted.
Fig.2.3 illustrates the standard curve drawn up from 6
individual assays (mean ± s.e. mean). The limit of sensitivity of
each assay was defined as the concentration of the unlabelled TXB2
which produces a 10$ decrease in the binding of the zero standards
and from Figure 2.3 the limit of sensitivity was approximately 25 pg
TXB2.
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Figure 2.3 Standard curve for TXB2 radioimmunoassay.
Results are mean ± s.e.m. of 6 consecutive assays.
vee
Intet—assay and Intra-assay coefficient of variation
The inter-assay and intra-assay coeffients of variation provide
an estimate of the accuracy within an experiment and the
reproducibility of individual experiments respectively.
The intra-assay coefficient of variation for the assay was
calculated using the following formula:
Standard Deviation of
Intra-assay coefficient of variance = £ assay duplicate x 100
mean
and for TXB2 in an assay was calculated to be 4.6?.
The inter-assay co-efficient of variation (from 5 experiments)
was determined for 80pg TXB2 from the following formula;
Standard Deviation of
Inter-assay coefficient of variance = £ standard from 5 expts. x 100
mean of standard
and for TXB2 assays, the inter-assay co-efficient of variance was
calculated to be 3.2%.
Both the intra and inter-assay coefficient of variance should




The cropp-react ivity of the TXB2 antibody with other
proptaglandine had been predetermined by the Paeteur Inptitute,
France (Table 2.2).
The percentage cropp-reactivity of the antibody ip determined by
eetimating the concentration of proptaglandin which produce? a 50$
inhibition of the binding of tracer and then applying the formula
below;
? Crop? reactivity =
Cone, of TXB? binding 50? tracer
Concentration of PG or metabolite binding 50? tracer x
Table 2.2 Cropp-reactivity of rabbit TXB2 antibody meapured at B/B0










In the radioimmunoassay of TXB2 from arachidonate aggregation
experiments (Chapter 3. Fig.3.6) any interference due to high
concentrations of arachidonic acid (100pM) was not accounted for.
It is possible that the high levels of TXB2 measured with 500pM or
more arachidonate could be due to some cross-reactivity of the
arachidonate itself with the TXB2 antibody. Pre-incubation of
arachidonate samples with a cyclo-oxygenase inhibitor would possibly
allow a quantitative estimation of the extent of interference in the
radioimmunoassay of TXB2.
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Extraction and Preparation of Biological Sample?
Thromboxane B2 was extracted from either platelet-rich plasma or
washed platelet suspensions, the method used is described below.
The PRP/washed platelet suspensions (1ml) were added to 10ml
siliconized glass test tubes. Following the addition of 200yl
collagen solution (2yg ml-"') the tube contents were mixed and
incubated at 37°C for 2 minutes. An aliquot of 2M HC1 (200pl) was
added at this stage to quench the reaction, the tubes whirlimixed and
10ml ethyl acetate was added. The tube contents were mixed
thoroughly and centrifuged on a bench centrifuge for 5 minutes. The
ethyl acetate layer was removed and stored at -20°C until assayed.
Basal TXBp were set up as above but omitting the addition of
collagen.
In aggregation experiments, the contents of the cuvette were
directly added to 10ml siliconized test tubes containing 200yl HC1
(2M) following aggregation, whirlimixed and 10mls ethyl acetate was
added. The samples were treated as described above.
Before assaying for TXB2, the ethyl acetate was evaporated under
a stream of air at 45°C and the dried down samples were taken up in a
known volume of ethyl acetate. Aliquots of the samples in ethyl
acetate were dispensed into radio-immunoassay tubes and the ethyl
acetate blown off at 45°C under a stream of air. A fixed volume of
assay diluent (0.5ml) (phosphate buffer pH 7.5) was added to these
tubes which were now ready to be assayed.
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Recovery of tritiated TXB? from blood plasma samples
A standard aliquot of 3h-txB2 in diluent was added to 1ml of PRP
in siliconized test tubes (in quadruplicate) and the extraction
procedure described above was carried out (omitting the addition of
collagen). A similar aliquot of 3h-txB2 in diluent was added
directly to scintillant (3.5 mis) (in quadruplicate). These tubes
give a reference of the total counts.
Following the extraction procedure the ethyl acetate taken off
was evaporated to dryness and the residue was redissolved in 2mls
ethyl acetate. The ethyl acetate was transferred to a scintillation
vial and evaporated to dryness under air at 45°C. Scintillant (3.5
ml) was added to these tubes. Radioactivity was counted and the
percentage recovery was calculated using the formula below;
% Recovery = mean disintegrations per min. (d.p.m.) per vial
mean d.p.m. of counting standards x ^
The percentage recovery (mean ± s.e. mean, n = 4) was calculated to
be 84.0 ± 3-2%. Since the method described for the extraction
procedure gave a high percentage recovery of TXB2, TXB2 levels
measured in radio-immunoassay experiments were not corrected for
procedural loss.
Cyclic AMP Protein-binding Assay
This assay is based upon competition between unlabelled cAMP and
a fixed quantity of 3h labelled compound for binding to a protein
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which hap a high specificity and affinity for cAMP (Gilmamn, 1970).
Separation of protein-bound cAMP from the unbound nucleotide is
achieved by adsorption of the free nucleotide onto charcoal, followed
by centrifugation step whereby the bound fraction remains in the
supernatant whilst the charcoal forms a pellet.
Following centrifugation, an aliquot of the supernatant is
removed for liquid scintillation counting; this gives an estimate of
the bound 3h cyclic AMP. The concentration of an unknown amount of
unlabelled cyclic AMP in a sample is then determined from a standard
curve.
The assay protocol is given in Table 2.3.
The assay buffer is 0.05 tris pH 7.5 containing 4 mM Na EDTA
(EOTA is a phosphodiesterase inhibitor and prevents the breakdown of
cAMP .(Eheu"wj w. V iq*o\).
3h-cAMP (8-3h adenosine 3'5'-cyclic phosphate ammonium salt was
obtained from Amersham Radiochemicals (Sp. Act. of 30 Ci/mmol)).
This was diluted 2000-fold in the assay buffer so that 50yl is
equivalent to 0.9 pmol cAMP (0.025 yCi). The adenosine 3'.5'-cyclic
phosphate standard was obtained as the free acid from Sigma.
The binding protein was diluted 10-fold with assay buffer
containing 0.1? bovine serum albumen (Sigma) which was reported to
promote cAMP binding by protein kinase. Tubes 1-3 determine the cpm
bound in the absence of the binding protein and the mean value is
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1/2/3 charcoal/blank 150 - - 50 -
4/5/6 0 pmol.cAMP 50 - - 50 100
7/8/9 0 .6 " - 50 - 50 100
10/11/12 1 .25 " - 50 - 50 100
13/14/15 2.5 " - 50 - 50 100
16/17/18 5.0 " - 50 - 50 100
19/20/21 10 " - 50 - 50 100
22/23/24 100 " - 50 - 50 100
50 100
25/26 (unknowns) - - 50 50 100
27 etc. t! - - 50 50 100
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subtracted from the cpm counted for the remaining tubes, giving the
true cpm bound to the binding protein. Tubes 4-24 determine the
binding over the range of the standard curve, i.e. 0-100 pmols cAMP.
Tubes 25 onwards are the sample tubes to be assayed; two 200 yl
aliquots are counted.
The tubes are whirlimixed and left on ice for two hours. At
least 15 minutes before the end of the incubation period, the
charcoal adsorbent was prepared by mixing 520 mg GSX charcoal and 400
mg bovine serum albumen with 20ml distilled water. This suspension
was stirred constantly on ice, and 100 yl of the charcoal adsorbent
was added to 16 tubes at a time. After whirlimixing they were
centrifuged for 2 minutes at 12000g in a refrigerated centrifuge. A
200yl sample was removed from each tube, added to 10ml scintillant
fluid (I) and counted on a Philips PW4540 liquid scintillation
analyser for 4 minutes. By carrying out the charcoal precipitation
step on only 16 tubes at a time, it ensures that the charcoal was
present for a maximum time of approx. 6 minutes. During this
period, the charcoal will bind free cAMP but with longer time
intervals the charcoal will strip and bind protein-bound cAMP.
This effect is minimised by carrying out this stage at 2-4°C and
so the charcoal is kept on ice throughout the experiment.
The displacement of 3h-cAMP over the range of the standard curve
is shown in Table 2.4
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Table 2.4 Displacement of 3h cAMP binding over the range of the
standard curve (0 - 100 pmol cAMP).
pmol cAMP CPM Bound Standard Error
0 4798 ± 303
0.60 3655 ± 320
1 .25 3111 ± 301
2.50 2312 ± 310
5.00 1267 ± 150
1 0.00 1754 ± 121
100.00 1099 ± 25
Fig.2.4 illustrates the cAMP standard curve over a concentration
range of 0-100 pmol (each observation is the mean ± s.e. mean of 4
experiments).
The inter-assay and intra-assay co-efficient of variation
The intei—assay co-efficient of variation for 5.0 pmol cAMP was
determined from the following formula;
Inter-assay co-efficient of
variation = Standard deviation
£ of ^ experiments
Mean x 100 = 11•
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Figure 2.H Standard curve for cyclic AMP assay.
Results are mean ± s.e.m. of M consecutive assays.
0-11000 CyclicAMP(pmol.log.scale)
The intra-assay co-efficient of variation was determined from 4
individual assays, using the following formula;
Intra-assay co-efficient of = £ Standard deviation of
variation triplicate
n x 1 00
where n = no. of assay triplicates, and for the cAMP assay was
calculated to be 3-75%.
Extraction Procedure for cAMP
(i) PRP or washed platelet suspension (1ml) was added to a 10ml
siliconized test tube and incubated for 30 sees at 37°C (basal camp
levels). In order to measure elevation in cAMP levels, Iloprost, a
stable prostacyclin mimetic was added to the PRP or washed platelet
suspension (final concentration 0.03yM) before incubation and
whirlimixed.
(ii) Samples (1ml) from aggregation experiments were added directly
to 10ml siliconized test tubes.
Following procedures I and II the reaction in the test tubes was
quenched by the addition of 2ml ethanol, the tubes were whirlimixed
and left to stand for 5 minutes at room temperature. After
centrifugation at maximum speed on a bench centrifuge, the
supernatant was decanted into small glass assay tubes. The
supernatants were evaporated to dryness at 55°C under stream of air
and the residue was dissolved in 0.5ml assay buffer and centrifuged
at 12000 xg for 30 minutes to remove insoluble material. Two 50yl
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sample? of the supernatant were assayed directly or if necessary the
supernatant diluted in buffer.
Liquid Scintillation Counting
Radioactivity in samples was counted by adding aliquot? to 10ml
scintillant and counting for 4 or 10 mins using either the Philips
PW4540 Liquid scintillation analyser or the Nuclear Chicago Liquid
scintillation counter. Sample radioactivity was expressed in counts
per minute (cpm) and these were converted to disintegrations per
minute (dpm) by correcting for the amount of quenching in the sample.
Unless it is certain that all biological samples are chemically
identical, except for the radioactive content, one cannot accurately
compare cpm obtained from one set of experiments to another. Thus
an appropriate means of standardisation can be carried out by
correcting for quenching where the efficiency of counting for each
sample is determined. Efficiency is defined as the ratio of the
observed cpm to the true dpm.
To determine the efficiency of counting, scintillation counter
machine constants are first of all determined by constructing a
quench curve using a calibrated tritiated standard, 3n-hexadecane, to
provide a known number of dpm. The cpm were determined at
different levels of quenching, using chloroform (CHCI3) as the
quenching agent (Table 2.5).
Throughout this thesis, both the Philips PW4540 and the Nuclear
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Table 2.5 Quench Curve Protocol
Vial No. Ml Chloroform DPM added Scintillant I or II
1/2/3 - - 1 0 ml?
4/5/6 - 42250 II
7/8/9 5 It II
10/11/12 10 It II
13/14/15 20 II II
16/17/18 50 II II
19/20/21 100 II II
22/23/24 200 II II
25/26/27 300 It II
28/29/30 400 II II
31/32/33 500 II It
34/35/36 600 II II
37/38/39 1000 II II
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Chicago Liquid Scintillation counters were used as well as two types
of scintillant (I and II - see materials). Machine constants for
both counters and the two scintillants were evaluated from the quench
curves (Fig.2.5) and listed in Table 2.6.
The quench curve is plotted by measuring effiency of counting,
CPM/DPM (y axis) against ratio (x-axis), either the sample channel's
ratio (S.C.R.) or external standard ratio (E.S.R.) can be used. The
quench curve is described by the equation;
Y = K0 + K-)X + K2X2 where K0, K1 and K2 are constants. Typical
quench curves and the values of K0, K-] and K2 are given in Fig. 2.5.
These constants are used to determine the efficiency of counting
in each sample so that DPM can be calculated accordingly.
Isolated Preparations
Rabbit Aorta
Thoracic aorta from male rabbits (2-3 kg) were removed
immediately after they had been killed. Any connective tissue was
carefully removed and spiral strips (3mm wide) were cut and suspended
in 8ml organ baths containing Krebs' solution at 37°C and gassed with
95% 02/5% CO2 (B.O.C.). Tension changes were recorded with a Grass
FT03 force displacement transducer linked to a Grass Polygraph. The
resting tension for the rabbit aorta was set at 2g and the recorder
full scale reflection at 4g.
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Figure 2.5 Typical quench curves for tritium using chloroform for
the quenching agent on a Phillips PN^^O counter using









Table 2.6 Quench curve constants determined for the two types of
scintillant used, in the Philips PW4540 and Nuclear
Chicago liquid scintillation counters.
Liquid Scintillation Counter
Scintillant Constants Philips PW4540 Nuclear Chicago
a. I (Ethoxyethanol/ Ko - 11.484 91.979
(PPO/tolue.ne) K1 107.832 - 95.287
k2 0.529 1 .125
b. II (PCS scintillant)
Ko - 7.913 83.918






Each preparation was allowed 2 hours to relax to a stable
resting tension during continual upward displacement of the bathing
fluid (one nominal bath clearance per minute).
Guinea-pig trachea
Trachea from female guinea-pigs (600-950g) were removed
immediately after the guinea-pigs had been killed. Spiral strips
were (3-^mm wide, 8-1Omm long) cut and suspended in 8ml organ baths
containing Krebs' solution. In addition the bathing fluid contained
atropine sulphate (2 x 10~^M) and indomethacin (10~^M). Tension
changes were recorded witha Grass FT03 force displacement transducer
linked to a Grass Polygraph as for the rabbit aorta. The resting
tension for the guinea-pig trachea was set at 0.5g and full scale
deflection at 2g. Again each preparation was allowed 2 hours to
reach a stable resting tension and during this time washed through
with Krebs' solution in a continuous upward displacement.
For both the rabbit aorta and the guinea-pig trachea, two series
of cummulative doses of the standard agonist, 11,9-epoxymethano PGH2
were added with an intervening wash period of 60 minutes.
When studying the antagonistic action of thromboxane receptor
blockers, the antagonist concerned was added directly to the bath and
left in the bathing solution for 30-60 minutes (the flow of Krebs'
solution was stopped during this period). The preparation was
challenged with another series of cummulative doses (suitably
increased) of 11 ,9-epoxymethano PGH2. Only one antagonist was
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studied in any one preparation.
At the end of each experiment, any changes in the sensitivity of
the preparations were estimated by calculating the difference in
responses of the control preparation at the beginning and end of the
experiment. This difference was expressed as a fraction of the
total initial response (correction factor). The agonist and
antagonist potencies determined in other preparations were corrected
for any changes in sensitivity by multiplying by this factor.
Ligand Binding Methodology
Both fresh human blood platelets and fresh platelet packs
(obtained from the Blood Transfusion Unit, Royal Infirmary of
Edinburgh) were used in the preliminary ligand binding studies
carried out in this thesis. Plcx"t<ale."t joa-Ctes l-ess "Unan 2.1+
old.
A. Preparation of platelet membranes
Human blood (200ml) was centrifuged at 200 x g for 20 minutes.
Prostacyclin (10 ng/ml final conc.) was added to the PRP which was
spun for a further 20 minutes at 600 x g. The platelet pellet was
resuspended in approximately 50ml of Tris buffer pH 7.4 (50 mM)-FVoc.X
Fresh platelet packs (x 2) were spun down at 200 x g for 20
minutes to remove any residual red cells present. The platelet
concentrate was diluted 1:1 with tris buffer pH 7.4 (50mM)-Proc.IT.Both
I and II were ultracentrifuged at 9000 x g for 15 minutes at 4°C and
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the pellet was resuspended in 5mM Tris Buffer. Thin suspension was
homogenized with a Polytron homogenizer for 2-3 minutes, breaking up
the cells. The lysed platelet suspension was centrifuged for a
further hour on an ultracentrifuge at 120,000 x g at 4°C. The
pellet was taken up in 16 mis of Tris Buffer (50 mM). If necessary,
the suspension was homogenized for a few minutes to break up the
pellet. The amount of protein present in the membrane suspension
was determined by the method of Lowry (1951). The membrane
suspension was adjusted with Tris Buffer (50mM) to give a final
protein concentration of 4-6 mg ml-"'.
B. Binding Assay Protcol
Tubes were set up in triplicate, each assay tube containing the
following:-
Tris Buffer pH 7.4 (50mM) 30yl
Mg.SOi} in 50mM Tris buffer (100mM) 1 Oyl
radioligand in 50mM Tris buffer (cont.5^ etoH) 1 Oyl
selected PG in 50mM Tris buffer (cont.5^ etoH) 10yl
or buffer control (also cont. 5$ etoH). 10yl
platelet membranes (protein content 0.16mg) 40yl
Final assay volume == 1OOyl
The tubes were set up as described above (omitting the
membranes) and kept on ice throughout. At 40 second intervals 40pl
of the membrane suspension was added to a tube which was whirlimixed,
then incubated for 10 minutes at 37°C. The contents of the tubes
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were filtered through Whatman GF/B glass filter discs, and washed a
further two times with 3.5ml of ice cold Tris buffer (50mM). The
filter papers were dried under a lamp for 1 hour and then placed in
10ml scintillant fluid I. The filters were counted for
radioactivity on a Philips PW^IO liquid scintillation counter.
page, w).
Preparation of Synthetic Prostaglandin Hp (PGH?)
PGF2a was converted into 96,118~dibromo-9,11-dideoxy PGF2a by
the method of Porter et al (1979). Treatment of the dibromo
derivative with 90? F^C^/Silver trifluoroacetate converted the
dibromo derivative to PGH2 which was purified by silicic acid
chromatography (10g Unisil, 100 - 200 Mesh, Clarkson Chemical Co.,
U.S.A.; gradient elution, 20? ethylacetate in hexane to pure
ethylacetate over 3 hr; - 20°C). Fig.2.6 illustrates this
conversion of PGF2a to PGH2.
Biological Assay of PGH?
PGH2 activity was measured using a washed platelet system, where
aggregation was the biological response.
A sample of the PGH2 in ethylacetate (at -20°C) was dried down
at 0°C on a rotary evaporatory and taken up in a volume of ice-cold
Krebs' solution, and kept on ice throughout the experiment. An
aliquot PGH2 (in Krebs' solution) was added to a cuvette containing
the washed platelet suspension, and incubated for 2 minutes at 37°C.











Figure 2.6 Synthesis of PGH2 from dibromo - PGF2a derivative and
the conversion of PGH2 to PGF2a by stannous chloride.
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activity of the PGH2 and log concentration response curves were
established to compare the activity of PGH2 to other thromboxane
mimetics.
A quantitative estimation of the mass of PGH2 used in these
experiments was made by reduction of approximately 1 yg of PGH2 (50yl
of PGH2 in the Krebs' solution) to PGF2a with fresh stannous chloride
(0.5 mis of 1Omg/ml solution) in aqueous ethanol. This mixture was
left for 30 minutes at room temperature, before adding 5m 1 H2O and
then extracted with 2 x 5ml volumes of ethylacetate. The
ethylacetate mixture was washed with 2m 1 H2O. These samples
(aqueous/ethylacetate) were frozen until ready for assay. Before
assaying for PGF2a the samples were thawed, the ethylacetate layer
carefully removed and made up to 10 mg (11 mis) with ethylacetate.
Aliquots of the PGF2a samples in ethylacetate were prepared for
radioimmunoassay.
The amounts of PGF2a measured were corrected for decay of the
PGH2 during experimental procedures (30? loss per 2 hr).
The separation of free and bound ligand by this filtration method
took about 1 minute. The conditions were not optimalised and it is
possible that the procedure could have been shortened if optimal
conditions were found.
Solution?
Acid citrate dextrose (ACD) - 120ml
3g D-glucose
2g Disodium Hydrogen Citrate
Kreb?' solution - 1 litre
BDH Chemicals Ltd. U.K.
2.1g Glucose
2.1g Sodium Dihydrogen Phosphate "
6.9g Sodium Chloride "
1.4ml Magnesium Sulphate (10?) "
1.6 ml Potassium Dihydrogen
orthophosphate (10?) "
2.5 ml Calcium Chloride (M) "
3.5 ml Potassium Chloride "
E.D.T.A. Solution - ethylenediaminetetra-acetic acid
0.4? weight/volume in 0.9? saline
Phosphate buffer pH 7.5 (.05M) - litre
6.9g diSodium hydrogen phosphate
(anhydrous)
11.2ml Sodium hydrogen phosphate
(: 2H20) (1M)
0.1g sodium azide
BDH Chemicals Ltd. U.K.
BDH Chemicals
Ltd. U.K.
BDH Chemicals Ltd. U.K.
1.Og Gelatin
Tris Buffer pH 7.4 (500mM) - 1 litre
6.057g of Tris taken to
pH 7.4 with concentrated HC1
Hopkin & Williams Ltd.
U.K.
BDH Chemicals Ltd. U.K.
May & Baker Ltd. U.K.
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Magnesium Sulphate in trip buffer (100mM) - 1 litre
24.6g Magnesium Sulphate in tris BDH Chemicals Ltd. U.K.
0.4g Bovine Serum Albumen BDH Chemicals Ltd. U.K.
Cyclic AMP assay buffer - 1 litre
0.6g Tris buffer (50mM)










P.C.S. Scintillant (2 parts)
Toluene (1 part)
BDH Chemicals Ltd. U.K.
Fisons U.K.
BDH Chemicals Ltd. U.K.
BDH Chemicals Ltd. U.K.






Glacial acetic acid (analar)
Hexane (analar)
Methanol (analar)








DARS (1:10 dilution in diluent)
NRS (1:40 dilution in diluent)
3h TXB2 (sp.act. 6.66 TBq mMol-^)
11|C-5HT (sp.act. 1.92 GBq mMol"1)
3H-Hexane (sp.act. 260 kBq)





J. Burroughs Ltd. U.K.






BDH Chemicals Ltd. U.K
tt
Pharmacia, Sweden





Prepared by Dr. N.L.
Poyser by method of











Most authentic PGs, thromboxanes, their metabolites and stable
analogues were gifts of Dr. J. Pike, Upjohn Co., Kalamazoo, U.S.A.
All EP compounds, 9,11 epoxymethano PGH2 (labelled by Amersham
U.K.) and PGHp were prepared by chemical synthesis in this department
by Dr. N.H. Wilson.
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CHAPTER 3
Arachidonic Acid Metabolism in Rat Platelets
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INTRODUCTION
Variations in the anatomy and physiology of platelets from
different species are well established (Dodds, 1978). Such
differences may manifest themselves in the mechanisms underlying the
arachidonic pathway since several studies have demonstrated species
variations in reactivity of platelets to arachidonic acid. Chignard
et al (1976) have shown that platelets from some dogs do not
aggregate to arachidonic acid even though they form TXB2. Meyers et
al (1979) have demonstrated that equine platelets rarely exhibit
biphasic aggregation responses and irreversible aggregation has not
been observed with arachidonic acid. In addition Meyers (1980) has
also shown lack of an aggregation response to araehidonic acid and
thrombin in platelets from mink, pig and cow. Human platelets on
the other hand have a well developed arachidonic acid pathway
producing significant amounts of the arachidonate metabolites,
malondialdehyde and thromboxane B2 (Meyers et al, 1980). With the
apparently significant role of arachidonic acid pathway in man and
its possible involvement in platelet related disorders, thrombosis
and thromboembolism, it is therefore important to have an
appreciation of the role of this pathway in the activation of
platelets from other species especially those used as animal models
in the evaluation of potential antithrombotic drug prior to their
implementation in man.
The arachidonic cascade comes into effect upon stimulation of
cell receptors with the subsequent release of arachidonic acid from
membrane phospholipids. The mobilization of arachidonic acid from
5^
membrane phospholipids is the rate limiting step in the further
metabolism of arachidonic acid to thromboxane and lipoxygenase
products (Carey et al, 1985). The above sequence of events can be
mediated in platelets by stimulation with certain substances;
thrombin, collagen, ADP and adrenaline. In the case of thrombin, it
has been established that AA is liberated from phosphatidylcholine in
the platelet membrane and then converted to endoperoxides and
thromboxanes (Bills et al, 1975). Collagen and ADP also induce
prostaglandin formation during aggregation (Smith et al, 1972). The
subsequent production of prostaglandin endoperoxides and thromboxane
A2 by these agents contributes to the second phase of aggregation and
the release reaction, demonstrated by experiments using non-steroidal
anti-inflammatory drugs (NSAID). O'Brien, (1968) using aspirin
showed that the irreversible aggregation was inhibited when platelets
were challenged with moderate amounts of thrombin and collagen, the
primary wave was unaffected. ADP, although a weaker stimulant than
thrombin or collagen also induced aggregation with the concomitant
liberation of arachidonic acid.
The contributory role of arachidonic products in mediating the
platelet response has been most thoroughly studied in the human
model, but one should bear in mind that the precise role of the
arachidonic cascade will undoubtedly vary from species to species.
Controversy does exist as to the involvement of the arachidonic
metabolites in mediating platelet aggregation in other species,
(Dutihl et al, 1978; Bult and Bonta, 1976). Several groups have
suggested the possible involvement of lipoxygenase products in the
platelet response (Dutihl et al, 1978, 1980; Buchanan et al, 1986).
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Overall, the arachidonic acid cascade, associated with platelet-
aggregation and in particular prostanoid formation has been well
documented (Samuelsson et al, 1978). The lipoxygenase pathway has
received much less attention especially with respect to the
biological effects of the lipoxygenase products.
The lipoxygenase and prostaglandin synthase complex represents
the 2 major pathways for the utilization of arachidonic acid in blood
platelets; oxygenation of arachidonic acid by the prostaglandin
synthetase complex yields prostaglandins and related compounds whilst
oxygenation of 12-lipoxygenase enzyme results in the production of
12-hydroperoxyeicosatetraenoic acid (12-HPETE) which is subsequently
reduced to the 12 hydroxy - derivative, 12-hydroxyeicosatetraenoic
acid (12-HETE) by a glutathione dependent peroxidase (Siegel et al,
1979). 12-HPETE has been shown to be an inhibitor of human
thromboxane synthetase enzyme (Hammarstrom et al, 1977) as well as
inhibiting the liberation of arachidonic acid from
phosphatidylinositol, the latter activity being shared by 15-HPETE
(Rittenhouse - Simmons 1980; Lagarde et al, 1981B). More recently
12-HPETE has also been reported to counteract the aggregatory
activity of PG endoperoxides/thromboxane A2 (PGH2/TXA2) and a
although significantly less potent, the reduced derivatives 12-HETE
and 15-HETE exhibit similar inhibitory effects (Aharony et al, 1982).
Although the precise nature of the biological effects of the
lipoxygenase products has yet to be clearly defined, one group have
suggested a role for lipoxygenase products in platelet aggregation
(Dutihl et al, 1980). Using rat blood, Dutihl and co-workers have
56
suggested that the products of the lipoxygenase pathway are essential
for irreversible blood platelet aggregation during collagen induced
aggregation. Using the dual cyclo-oxygenase/lipoxygenase inhibitor,
eicosatriynoic acid (E.T.Y.A.), they found that there was a complete
inhibition of collagen-induced aggregation. They also looked at
concomitant product formation in the presence of E.T.Y.A. and
demonstrated a decreased lipoxygenase activity, accompanied by an
apparent increase in cyclo-oxygenase activity. Based on these
results Dutihl suggested that for irreversible blood platelet
aggregation, the activity of the lipoxygenase enzyme is possibly as
essential as that of the cyclo-oxygenase. This suggestion was
further supported by the observation that if one of these enzyme
pathways is blocked, aggregation of rat blood platelets is always
inhibited.
Furthermore, studies have also shown species differences in the
contribution of arachidonic acid cascade in collagen-induced
aggregation of platelets 'in vivo' (Mallarkey and Smith, 1985).
Using the guinea-pig and rat model, Mallarkey and Smith demonstrated
that arachidonic acid metabolites (prostaglandin endoperoxides and
TXA2) play only a minor role in collagen induced intravascular
platelet aggregation in the rat (70% of the aggregation was
independent of activation of the arachidonic acid cascade). On the
other hand, conversion of arachidonic acid to PGH2 and TXA2 is of
importance in the guinea-pig with 40^ of the aggregation being
independent of arachidonate conversion. These results demonstrate
that species differences are observed 'in vivo' as well as 'in vitro'
studies.
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These differences highlight the need for elucidating the precise
mechanisms involved in platelet aggregation in different species,
since animal models are used in preclinical 'in vivo' and 'in vitro'
studies to investigate drugs for potential anti-thrombotic therapy.
Thus it is of prime importance to find such a model which bears a
close resemblance to the human model with respect to it platelet
mechanisms.
Since rats are frequently used in many platelet studies, this
chapter deals with the elucidation of the precise nature of the
arachidonic acid pathway and the role of its metabolites in platelet
aggregation in rat blood. Much conflicting data exists concerning
the nature of arachidonic acid induced aggregation in rat blood.
Nishizawa et al (1983) has suggested that irreversible aggregation
induced by arachidonic acid is not entirely dependent upon the
formation of prostaglandin endoperoxides and thromboxanes A2. Their
studies demonstrated that both PGH2 and the stable thromboxane
mimetic, 11 ,9-epoxymethano PGH2 failed to induce aggregation in
citrated or heparinized platelet-rich plasma despite the formation of
thromboxane 82- However, full scale irreversible aggregation was
demonstrated with arachidonic acid itself.
Work in our laboratory has also demonstrated a lack of
irreversible aggregation using 11,9,epoxymethano PGH2 and arachidonic
acid in rat citrated platelet rich plasma. With both agents shape
change did occur.
This study was aimed at clarifying the discrepancies observed in
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other studies concerning the role of the arachidonic acid cascade,
the contribution of prostaglandins and thromboxanes and the possible
involvement of lipoxygenase products in inducing platelet
aggregation.
The main aims of this chapter were as follows
i. to obtain a kinetic description of arachidonic acid activity in
platelet rich plasma and washed platelet suspensions.
ii. to establish whether arachidonic acid itself or its metabolites
induce shape change and the aggregatory response in platelets.
iii. and in light of the findings of (ii) to establish the relative
importance of the prostaglandin endoperoxide, thromboxanes and
the lipoxygenase pathway products in mediating the arachidonic
acid responses.
Many studies have shown that variations in dietary fatty acids
may alter the ratios of the fatty acid precursors incorporated into
platelet membranes whereby the amount of arachidonic acid available
is decreased. (Renaud et al, 1970). As a result the liberated
unesterified fatty acids may be substrate for the lipopxygenase
and/or the cycloxygenase routes. Consequently, the relative amounts
of the fatty acids 'in vivo' may play a role in the regulation of
arachidonic activity in platelets.
The final aim of this chapter was thus concerned with the
effects of various fatty acids on arachidonic acid induced responses.
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Citrated Rat Platelet Rich Plasma
The responses of rat platelets in citrated plasma to stimulation
with sodium arachidonate and two stable thromboxane mimetics,
11,9,epoxymethano prostaglandin H2 (11 ,9~emPGH2) and EP171 were
studied.
The response of the platelets to stimulation with sodium
arachidonate is shown in Fig.3-1. Shape change responses were
observed with low arachidonate concentrations (10-250yM)and only
when the arachidonate concentration was increased above 500yM was a
maximal aggregation response observed. The effects of several
blockers on these responses were investigated; Fig.3.2 illustrates
the effect of the thromboxane receptor antagonist, EP092 (3yM), the
cyclo-oxygenase inhibitor, Froben (10yM) and the thromboxane
synthetase inhibitor, Dazoxiben (312yM) on the shape change response
induced by AA (250yM). Both EP092 and Froben completely abolished
the arachidonate induced shape change. The thromboxane synthetase
inhibitor Dazoxiben on the other hand was found to only partially
inhibit the response.
Abolition of the platelet response can also brought about by
elevations in cyclic AMP levels through activation of platelet
prostacyclin (PGI2) receptors. The effects of both Iloprost, a
stable prostacyclin mimetic (0.06yM) and PGEi (1.5yM) on arachidonate
induced shape change were studied. Fig.3.2 illustrates the
Figure 3.1 Arachidonic acid induced responses in citrated rat PRP;






















Figure 3.2 Effect? of various blockers on arachidonic acid induced
shape change in citrated rat PRP; (A) AA control
(250yM) and in the presence of (B) EP092 (3yM), (C)
Froben (10yM), (D) Dazoxiben (312yM), (E) PGE-| (1.5yM)
and (F) Iloprost (0.06yM).
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inhibition observed with these prostaglandins.
The effects of two stable TX-mimetics 11,9emPGH2 and EP171 were
compared to those induced by arachidonate in rat platelet rich
plasma. 11,9-emPGH2 at concentrations up to 3yM produced only a
shape change and EP171, although somewhat more potent than 11,9—
emPGH2 demonstrated a similar response at concentrations of 2.5~50nM.
Increasing the concentrations of 11,9-emPGH2 or EP171 over 3yM and
50nM respectively did not produce an irreversible aggregatory
response (Fig.3.3A & D).
The effects of EP092 (6yM) Froben (10yM) and Dazoxiben (312pM)
on 11,9~emPGH2 and EP171 induced shape change were investigated.
EP092 completely abolished the shape change response, whilst
Flurbiprofen and Dazoxiben had little effect (Fig.3.3).
EP092 produced a parallel shift to the right of the shape change
log dose response curve obtained with 11,9-emPGH2 and EP171
(Fig.3-^). The apparent affinity constants for EP092 against EP171
and 11,9~emPGH2 were determined from these curves and are shown in
Table 3.1.
A comparison of the EP092 affinity constant for shape change in
human platelet rich plasma using 11,9-emPGH2 was made and is also
shown in Table 3.1.
The nature of the irreversible aggregation induced by high













e 3.3 Shape change response? induced by 11,9-emPGH2 and EP171
in citrated rat PRP; (A) 11,9-emPGH2 control (300pM)
and in the presence of (B) EP092 (6yM) and (C) Dazoxiben
(312yM), (D) EP171 control (10nM) in the presence of
(E) EP092 (6yM).
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Figure 3.^ Log dose response curves for shape change induced by
EP171 and 11,9-emPGH2 alone and in the presence of EP092
(6yM) in citrated rat PRP.
110100100 Logconcentration(pM)
Table 3-1 The Affinity Constants for EP092 determined from
11,9emPGH2 and EP171 induced shape change responses in
rat citrated platelet rich plasma
Kg value
11,9emPGH2 3-OM x 106 (9.9 x 106)
EP171 6.48 x 106
Value in parenthesis obtained for EP092 against 11,9emPGH2 in human
PRP (Jones et al, 1985).
G1C
incubation with EP092 (15pM), Froben (10pM) and Iloprost (0.06yM) did
not exert any significant inhibitory effect on this apparent
irreversible aggregation(not shou>n).
Washed Rat Platelet Suspensions
Rat platelets suspended in plasma-free buffer aggregate
irreversibly in response to micromolar concentrations of sodium
arachidonate. The optimal concentration for this irreversible
response being 10pM. On increasing the concentration of
arachidonate to 100pM, the aggregatory response was supressed.
However, at concentration of arachidonate over 30yM, what appeared to
be an irreversible response was evident. Thus over a range of
concentrations a bell-shaped response curve was produced with
arachidonate (Fig.3-5). The mechanisms underlying each response
were investigated and the results are reported below.
Irreversible Aggregation obtained with low AA concentrations
Arachidonate over a range of concentrations (1-30 yM) produces
aggregation waves, a maximal response observed at 10yM (Fig.3.5A).
The release of labelled 5HT (^C-5HT) was associated with these
aggregatory waves. EP092 (3yM), Froben (10pM) and Iloprost (0.06pM)
all inhibited the aggregation induced by low micromolar
concentrations of arachidonate.
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Figure 3.5 Aggregation (continuous line) and [1^C]-5HT release
(broken line) response of washed rat platelets to
araehidonic acid.
Values displayed are means ± s.e.m. of 4 experiments.
°Aggregation *-•ReIa
Log.ConcentrationAA(jjM)
Figure 3.6 Thromboxane B2 production in response to increasing
concentrations of arachidonic acid in washed rat
platelets.


















Suppression of aggregation intermediate arachidonate concentrations
(IQOyM)
Over a very narrow range of AA concentrations (75-1OOyM) no
aggregation response was observed (Fig.3.5B). It was noted that the
responses of other aggregating agents in the presence of 100yM AA
were also inhibited; ADP , 11 ,9-epoxymethano-PGH2» Thrombin,
collagen and low concentration of AA (Table 3-2). Thrombin at high
concentration (1 unit ml-'') could overcome this block.
The precise nature of this effect was investigated to see
whether metabolites of either the cyclo-oxygenase or the lipoxygenase
pathways or even arachidonate itself were mediating this inhibitory
response.
Fig.3.7 illustrates the inhibitory effect of 100yiM arachidonate
on ADP induced aggregation. In the presence of froben (10yiM) the
inhibition of ADP (10-^m) induced aggregation was not overcome
(Fig.3.7C). Froben alone did not have any effect on the ADP
aggregating wave (Fig.3.7D). A similar inhibition by AA OOOyM) was
observed when 11,9~epoxymethanoPGH2 (700nM) was used as the
aggregatory agent.
In order to investigate the possible role of lipoxygenase
products as mediators of this inhibitory effect, the effects of
several lipoxygenase inhibitors were studied.
No specific inhibitor for this enzyme is known as yet, and those
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Table 3.2 Effect of 100pM AA on the action of other aggregating
agent?
AA (1OOpM) was incubated for 2 min before the addition
of the following agents
AGENT CONCENTRATION % INHIBITION
ADP 1 pM 98%
10 pM 78%
Collagen 2 pg/ml 100%
1 pg/ml 96%
Thrombin 0.1 q/mi 100%
1 11/ml 24%
11,9-epoxymethano PGH2 1.5 pM 100%
3 pM 100%




Figure 3.7 The inhibitory effect of pre-incubation with arachidonic
acid (100ym) on ADP (10~5m) induced aggregation in
washed rat platelet? and the effect of Froben (10pM) on
this inhibition; (A) AA control (100yiM), (B) AA (100yM)
and ADP (10~5m), (c) Froben (10pM), AA (tooym) and ADP
(10"5m) and (D) Froben (10yM) and ADP (10~5m).
Both AA and Froben were pre-incubated for 2 minutes
prior to the addition of ADP.
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studied in this chapter, were also inhibitors of the cyclo-oxygenase
enzyme. Since it would appear that products of the cyclo-xygenase
pathway are not mediators of the inhibition, dual inhibition of the
lipoxygenase and cyclo-oxygenase enzymes should still demonstrate
whether lipoxygenase products are mediators.
Rat washed platelet suspensions were pre-incubated with the
lipoxygenase enzyme inhibitors, and their effect on the AA (100yM)
inhibition was studied;
Nordihydroguaiaretic Acid (NDGA)
NDGA (33yM) inhibited the thromboxane/endoperoxide dependent
irreversible aggregation attained with low aa concentrations (10yM)
0 not shown). There did not appear to be any reversal of the
inhibitory activity of AA (100yM) on ADP (10~5m) induced aggregation
(Fig.3.8A-D) when platelets were pre-incubated with NDGA (33~l65yM).
The irreversible aggregation observed with AA at concentrations over
300yM appeared to be slightly inhibited in the presence of high NDGA
concentrations 065yM) (Fig.3.8E and F).
Concentrations of NDGA over l80yM tended to directly affect the
platelets causing them to change shape and induce small reversible
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Figure 3.8 The effect of pre-incubation with NDGA on arachidonic
acid induced response? in washed rat platelets;
(A) NDGA (33uM) and AA (100pM), (B) AA ClOOpM) and ADP
(10~5m), (c) NDGA (33pM) and AA (100pM) and ADP (10"5m),
(D) NDGA (165uM), AA (10yM) and ADP (10~5m), (E) AA
(500yM) and (F) NDGA 065pM) and AA (500pM).
NDGA and AA were pre-incubated simultaneously for 2
minutes prior to the. addition of ADP (experimental
traces run from right to left).
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8,11 ,1M-eicosatrienoic acid (E.T.A.)
E.T.A. (100pM) like NDGA inhibited the irreversible aggregation
induced by low AA concentrations. This same concentration (100yM)
did not have any effect on the inhibition of ADP (10~5m) induced
aggregation by AA (100yM). Furthermore, this concentration of
E.T.A. did not have any effect on the irreversible wave attained with
high arachidonate concentrations (300yM).
5,8,11.11! Eicosatetraynoic Acid (E.T.Y.A.)
E.T.Y.A. at concentrations between 3~5yM inhibited the
irreversible aggregation induced by low AA concentrations. E.T.Y.A.
(1OyM) did not appear to reverse the inhibitory effect of 100yM AA on
11,9-emPGH2 (750nM) and ADP (10~5m) induced aggregations. However,
pre-incubation with E.T.Y.A. alone (10yM) was found to inhibit both
ADP and 11,9-emPGH2 induced aggregation responses (Fig.3-9).
Higher E.T.Y.A. concentrations (15~30yM), were found to reverse
the suppressed aggregation obtained with 100yM AA. However, pre¬
incubation with E.T.Y.A. in the presence of EP092 (3yM) and froben
(1OyM) did not appear to inhibit this irreversible wave (Fig.3.10).
BW755C
BW755C like all 3 other inhibitors, blocked irreversible
aggregation induced by low arachidonate concentrations.
Concentrations of BW755C (M0-300yM) did not reverse the AA induced
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Figure 3-9 The effect of pre-incubation with 5,8,11,14-ETYA on the
inhibition by arachidonic acid of 11,9-emPGH2 and ADP
induced aggregation; (A) ETYA (10pM), AA (100ym) and
11,9-emPGH2 (280ym), (b) ETYA (10ym) and 11,9-emPGH2
(280ym), (c) ETYA (10pm), AA (100ym) and ADP (10~5m) and
(d) ETYA (1opm) and ADP (10"5m).








Figure 3.10 The effect of higher concentrations of 5,8,11,1H-ETYA on
the inhibition induced by arachidonic acid; (A) ETYA
(15yM) and AA (100yM), (B) ETYA (20yM) and AA (100yM),
(C) EP092 (3yM), ETYA (15pM) and AA (100yM) and (D)
Froben (10yM), ETYA (15yM) and AA (100yM).
EP092 and Froben were added simultaneously with ETYA two







inhibition of ADP (10~5) or 11,9-emPGH2 (750nM). It was noted
however that although aggregation induced by ADP (10"^m) was
unaffected by BW755C (lOOyM) the aggregation wave induced by
11,9emPGH2 was completely abolished (Fig.3-11).
Table 3.3 summarizes the effects of the lipoxygenase inhibitors,
reported above.
Time course of onset of inhibitory effect of AA (IQOyM)
A time course of the inhibitory effect of 100ym AA was studied
to determine how soon following the addition of AA, the onset of the
inhibition was apparent. Fig.3.12 illustrates this time course and
within 10 seconds the inhibitory action has already come into effect,
shown by the percentage inhibition of ADP (10~5m) induced
aggregation. Within 40 seconds as much as 80% of the ADP response
is inhibited and complete inhibition is attained within 120 seconds.
The response of adp (10~5m) 15 minutes after the addition of
1OOyM AA was tested and the inhibitory effect was still fully evident
after this time.
Maximal aggregation observed with high arachidonate concentrations
(>300uM)
When arachidonate concentrations were increased over 300yM, a
maximal aggregation response was observed, similar in appearance to
an irreversible secondary wave aggregation response. The nature of
66
•t drug addition
Figure 3.11 The effect of BW755C on the inhibitory effect of
arachidonic acid; (A) BW755C (100yM), AA (100yM) and
ADP (10~5M), (B) BW755C (100yM), AA (100yM) and 11,9-
emPGh2 (750nM), (C) BW755C (10yM) and ADP (10~5m) and
(D) BW755C (1OyM) and 11,9-emPGH2 (750nM).
BW755C and AAiwere added simultaneously 2 minutes prior
to the addition of the aggregating agents. Experimental
traces run from left to right.
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Figure 3.12 The time course of onset of arachidonic acid induced
inhibition of ADP (10"5m) aggregation. Arachidonic
acid was added to the washed platelet suspension before
the addition of ADP at the times indicated above.
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this effect was investigated; Frobe.n (10yM), EP092 (10yM) and
Iloprost (0.06yM) had no inhibitory effect on this maximal response.
Thromboxane B? production, cyclic AMP production and 5HT-release in
washed rat platelets measured over a range of arachidonic acid
concentrations
TXB2 production was measured in washed rat platelets suspensions
over a range of arachidonate concentrations. Fig.3.6 illustrates a
dose dependent increase in TXB2 production, reaching a plateau at
about 10OyM arachidonate. On increasing concentrations of
arachidonate over 100yM, TXB2 production was maintained.
Cyclic AMP production was found to increase above basal levels
from 50yM arachidonate concentrations upwards, and high levels were
maintained over 300yM (Fig.3.13).
Simultaneous measurement of aggregation and C^C]-5HT release
was recorded in response to AA over a range of concentrations (1-
1OOOyM). The concentration response curves for aggregation and
release 5HT are shown in Fig.3.6. Maximal release is apparent at
both peaks (10yM and 300yM) in the AA concentration-response curves.
The effect of llnoleic acid and oleic acid effects on washed platelet
Linoleic acid at low concentrations (10yM) appeared to have no
effect on washed platelet suspensions. However, in the presence of
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Figure 3.13 The effect? of arachidonic acid on platelet cyclic AMP
level?. The data ehowe the concentration dependent
effect? of arachidonic acid on platelet aggregation and
on cyclic AMP level?. (Cylic AMP level? were measured
from pample? following aggregation experiments).





















higher linoleic acid concentration? (100yM) aggregation wave? induced
by adp OCT^m), 11,9-emPGH2 (0.15~2.86yM) and Thrombin (0.1u/ml) were
completely inhibited. Higher concentration? of Thrombin (1u/ml)
could overcome thi? block. Increa?ing the concentration of linoleic
acid over 500yM demonatrated that linoleic acid itself could induce
irreversible wave? (Fig.3-11) and these were associated with the
release of 1l|C-5HT.
Oleic acid over a range of concentrations (10-100yM) did not
cause the platelets to aggregate but did inhibit the aggregation
response to ADP (10~^-10~^M). The working concentration range of
oleic acid was limited since it was difficult to get oleic acid into
solution over 100yM.
These effects of both linoleic acid and oleic acid are
summarised in Table 3-1.
Effect of fatty acid derivatives on AA Induced responses in rat
citrated PRP
Five, -polyunsaturated fatty acids were studied in citrated rat
PRP, (structures are shown in Fig.3.15); 3,5,8,11,11 eicosapentanoic
acid (20:5 W3); 5,8,11,11 eicosatetraynoic acid (20:1 YW6); 5,8,11-
eicosatrienoic acid (20:3 W9); (docosatetraenoic acid C22:1 W6) and
docosahexaenoic acid (C22:6).
The C22:6 (200~300yM) fatty acid caused the platelets to undergo






Figure 3.1^ The effect of linoleic acid on thrombin induced
aggregation; (A) linoleic acid (10vjM) and thrombin
(0.1U/ml), (B) linoleic acid (10yM) and thrombin (1U/ml)
and (C) linoleic acid (500pM).
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Figure 3.15 Structures of fatty acid derivatives used in this study.
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apparent (Fig.3.l6A). C22:H W6, (400pM) did not have any apparent
effect on the platelets themselves, but partially inhibited the shape
change response induced by AA over 5~50yM concentration range. In
the presence of C22:iIW6 at concentrations of AA over 50yM, the
concentration response curve was shifted to the left (Fig.3-16B).
C22:5W6, (500yM) did not have any direct effect on the platelets
themselves, but completely inhibited the shape change response
induced by AA (5-100yM) and shifted the irreversible wave induced by
AA slightly to the left (Fig.3.16c). C20-MYW6 (500yM) also
completely abolished the shape change response induced by AA (5-
100yM) and shifted the AA induced irreversible wave further to the
left (Fig.3-16D). 20:3W6 was found to exert mixed effects on the AA
induced responses. Low concentrations of 20:3W6 (100yM) had very
little effect on the platelet shape change response, although a
significant inhibition of the irreversible was apparent (Fig.3.17A).
Higher 20:3W6 concentrations (500yM) completely inhibited the AA-
induced shape change response, and significantly inhibited the
irreversible wave (Fig.3.17B). 20:3W6 (1mM) also completely
abolished the shape change response but only a small inhibition of
the irreversible wave was apparent (Fig.3.17C).
69
Figure 3-16 The effects of fatty acid derivatives on arachidonic
acid responses in citrated rat PRP. Log dose response
curves illustrate the AA control curve, (A) C22 : 6
curve and AA curves in the presence of (B) C22 : Mw6
(MOOuM), (C) C20 : 5w3 (500yM) and (D) C20 : MYw6
(500yM).
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Figure 3-17 The effect of 5,8,11-ETA on arachidonic acid induced
response? in citrated rat PRP. Log dose reponse curves
are illustrated for the AA control and in the presence






It was hoped that studies described in this chapter would help
to elucidate the precise mechanisms involved in arachidonate induced
activation of rat platelets and possibly clarify the conflicting
results reported by other groups. The responses to arachidonate
were compared in two platelet systems; citrated rat platelet rich
plasma (PRP) and suspensions of washed rat platelets. The results
are discussed below.
Citrated Rat Platelet Rich Plasma
Arachidonate added exogenously to rat PRP revealed two types of
response dependent upon the arachidonate concentration. Over a
range of concentrations, 10-250pM, arachidonate induced ony a shape
change response. This effect was fully inhibited by froben, a
cyclo-oxygenase inhibitor, EP092, a thromboxane receptor antagonist
and only partially inhibited by Dazoxiben, a thromboxane synthetase
inhibitor (Fig.3.2). These results would suggest that products of
the cyclo-oxygenase pathway are mediators of the shape change
response and that the partial inhibition observed in the presence of
Dazoxiben can be accounted for by the endoperoxides which can also
induce the shape change response. Complete abolition of shape
change by the specific thromboxane receptor antagonist would indicate
an action at a discrete receptor site.
A comparison of the actions of two stable thromboxane mimetics
was made in rat PRP. 11 ,9-Epoxymethano PGH2 and EP171 exhibit a
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similar profile of activity to arachidonate in rat PRP with only
shape change responses being observed. Increasing the
concentrations of each mimetic (up to 3yM for 11,9-emPGH2 and 50nM
for EP171) did not even produce even a primary wave. EP092,
completely abolished the shape change response induced by these
mimetics. Froben and Dazoxiben were without any effect. These
observations provide a good indication that the effects of these
agonists and those of arachidonate are receptor mediated.
Prostaglandin E-| and Iloprost (stable Prostacyclin mimetic)
stimulate prostacyclin receptors to induce an elevation of cyclic AMP
and in this instance were found to inhibit shape change induced by
arachidonate as well as the two thromboxane mimetics, indicating that
the mechanisms underlying the shape change response whether mediated
by arachidonate or the thromboxane mimetics are both susceptible to
inhibition by elevations in cyclic AMP.
The affinity constants (Kg) for EP092 against 11,9-emPGH2 and
EP171 were determined (Table 3-1). These values are in good
agreement with the Kg value for EP092 against 11,9-emPGH2 induced
shape change in human PRP, suggesting that the mechanism underlying
the shape change response in rat PRP is similar to those in human
PRP.
A somewhat different effect was observed in PRP when the
arachidonate concentration was increased (300-1OOOyM). What
appeared to be an irreversible aggregation wave associated with the
release of 5HT was observed (Fig.3.1C-D). This response was
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unaffected by both Froben and EP092 demonstrating that arachidonate
conversion to prostaglandins and thromboxane is not a prerequisite
for this effect. In addition increasing concentrations of the
thromboxane mimetics did not elicit an irreversible wave adding
support to the above suggestion that the response is not mediated by
endoperoxides or thromboxane A2. Arachidonate itself or products of
the lipoxygenase pathway may be the mediators of this response and
these possibilities will be discussed later.
The lack of a thromboxane dependent aggregation wave
demonstrated in PRP may be due to binding of arachidonate and the
thromboxane mimetics to plasma proteins. Albumen has indeed been
shown to inhibit arachidonate induced aggregation, and it is possible
that it would also inhibit thromboxane mimetic induced aggregation.
The addition of increasing concentrations of albumen to a washed
platelet system prior to the addition of either thromboxane mimetic
or arachidonate would demonstrate whether albumen has an inhibitory
effect on mimetic or arachidonate induced aggregation in this system.
However, full irreversible aggregation can be induced with
thromboxane mimetics in human and rabbit PRP. Since all three
species have comparable plasma-protein levels (Chapter 2 - plasma-
protein estimation) this would suggest that plasma-protein effects
cannot fully explain the lack of aggregation in rat PRP.
Alternatively in PRP preparations the presence of citrate may
sequester the calcium in the medium, reducing the extracellular
calcium concentrations. In heparinized PRP, the plasma calcium ion
concentration is of normal physiological levels (Lages and Weiss,
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1981). Similar studies to the ones described here, using heparin as
the anti-coagulant would possibly demonstrate whether the presence of
citrate in the system was preventing aggregation from occurring.
Washed Rat Platelet Suspensions
When aggregation and the release of 5HT are the biological end
points, washed rat platelets exposed to a range of arachidonate
concentrations display a bell shaped dose response curve. Peaks of
maximal aggregation and release of 5HT occur at approximately 10yM
and above 500yM arachidonate (Fig.3.5A & C). Over a small range of
arachidonate concentrations (75-1OOpM) no apparent aggregation was
observed (Fig.3.5B). The nature of the three responses were
investigated and discussed below.
Low Arachidonate Concentrations (1-50pM)
When washed rat platelet suspensions were stimulated with low
arachidonate concentrations, irreversible aggregation waves were
observed. The demonstration that EP092 and Froben, completely
inhibit these responses provides good evidence to support the notion
that rat platelets utilize arachidonate to produce sufficient
prostaglandin endoperoxide/thromboxane A2 to evoke irreversible
aggregation mediated through a thromboxane/endoperoxide receptor
interaction. Dazoxiben only partially inhibited the irreversible
wave indicating that the endoperoxides themselves can induce
aggregation. The small inhibition of aggregation which was observed
may be explained by the redirected metabolism of prostaglandin H2 to
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prostandin E2 which has been found to have anti-platelet activity
(Bruno et al, 1974). Whether sufficiently high amounts of PGE2 are
produced would need to be investigated. Alternatively, PGH2 may
exert a weaker effect at the thromboxane receptor.
Recently a study by Cerletti and co-workers (1986) demonstrated
that the endoperoxide induced aggregation induced response in human
PRP was reduced in comparison to that of a thromboxane A2 and only in
the presence of ADP was the extent of endoperoxide induced
aggregation similar to that of TXA2. Whether such an ADP
requirement for full endoperoxide induced aggregation occurs in
washed rat platelets remains to be investigated. It is possible
that the partial inhibition of aggregation evident in the presence of
Dazoxiben could be due to a decreased activity of the endoperoxides
arising from the absence of ADP in the washed platelet media.
Intermediate Arachidonate Concentrations (75-1OOpM)
Exposure of washed rat platelets to intermediate arachidonate
concentrations (100yM) resulted in a suppression of the aggregatory
response which was associated with inhibition of subsequent
reactivity to other aggregating agents. The possibility that other
prostaglandins metabolised from arachidonate could be causing this
effect was investigated since it is known that high concentrations of
PGE2 can exert an anti-aggregatory action on human platelet
suspensions (Bruno et al, 1974). It is possibile that PGE2 produced
from arachidonate in rat platelets could be exerting a similar
effect.
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Pre-incubation of washed rat platelets with Froben should
prevent any conversion of arachidonate to its metabolites, including
PGE2 and the subsequent inhibition mediated in the presence of
arachidonate would be absent if PGE2 or other prostaglandins were
mediators of the inhibitory effect. However, this was not found to
be the case when platelets were pre-incubated with Froben, suggesting
cyclo-oxygenase products have no role as inhibitors of the
aggregatory response in this instance.
The possibility that either products of the lipoxygenase pathway
or arachidonate itself could be exerting this inhibitory effect was
examined. Two products of the lipoxygenase pathway 12-hydro-
peroxyeicosatetraenoic acid (12-HPETE) and its derivative 12-
hydroxyeicosatetraenoic acid (12-HETE) have been reported to have an
inhibitory effect on platelets, due to suppression of prostaglandin
H2 induced aggregation (Croset and Lagarde, 1983). Their role as
possible inhibitors in washed rat platelet suspensions was
considered.
None of the four lipoxygenase inhibitors studied were totally
specific for the lipoxygenase enzyme. Cyclo-oxygenase activity was
inhibited to varying extents demonstrated by the suppression of
thromboxane/endoperoxide dependent aggregation induced by low
arachidonate concentrations (Table 3.3). However, if the inhibition
was mediated by a lipoxygenase pathway product, pre-incubation with a
lipoxygenase/cyclo-oxygenase inhibitor should in fact show a reversal
of the inhibitory effect of other agents or in fact a reversal of the
suppressed aggregation. However, any subsequent response may in
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fact be masked if the cyclooxygenase enzyme was also inhibited. It
is apparent from Table 3-3 that none of the lipoxygenase inhibitors
diminished the inhibition exerted on other aggregating agents.
5,8,11,14-ETYA however at concentrations over 150pM appeared to
reverse the suppressed aggregatory response (Fig.3.10) and what
looked like an irreversible wave was attained within two minutes.
The aggregatory waves observed were not inhibited in the presence of
EP092 or Froben, indicating that the response is not mediated by
either endoperoxides or thromboxane A2.
The onset of inhibition was measured as a function of time
(Fig.3.12). The inhibitory effect is apparent within 10 seconds.
Whether this inhibition is mediated by products of an enzymatic
conversion or by another mechanism would need to be investigated
since the lag period sufficient to allow activation of enzymes and
conversion to inhibitory products is not known and it could be
possible that 10 seconds is long enough for this to occur. The
inhibitory effect was still evident 15 minutes after exposure to
arachidonate, indicating that the mediator of the inhibition was
either of a very stable nature or was irreversibly altering the
functional integrity of the platelet.
The data so far presented supports the notion that it is the
arachidonate itself which is exerting the inhibition but the precise
mechanism underlying this anti-aggregatory action has yet to be
elucidated.
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Mode? of arachldonate action
The specificity of the arachidonate-induced inhibition was
considered. The results show that ADP, collagen, Thrombin and 11,9-
epoxymethanoPGH2 are all inhibited by prior treatment of washed rat
platelets with 100pM arachidonate, indicating that the mediator of
these effects does not discriminate between various aggregating
agents.
It is possible that the inhibition is mediated at the membrane
level of the platelet, whereby it could be interacting with the
plasma-membrane impairing membrane-linked functions. Collagen and
Thrombin are known to accelerate a variety of membrane functions.
Collagen stimulates the release of arachidonate from membrane
phospholipids and it is the endogenous production of endoperoxides
and TXA2 which induce aggregation (Hamberg et al, 1975). Since
collagen induced aggregation is inhibited by arachidonate, post-
receptor inhibition at one or more sites in the arachidonate pathway
is possible. Thrombin induced aggregation on the other hand cannot
be accounted for soley by the arachidonate cascade; Lapetina et al
(1978) have shown that cyclo-oxygenase and lipoxygenase inhibitors do
not inhibit Thrombin induced aggregation yet block the metabolism of
arachidonate release from membrane phospholipids. Indeed, Thrombin
induced aggregation (low concentrations) was inhibited by
intermediate concentration of arachidonate, and since thrombin
induced aggregation is thought not to involve the arachidonate
pathway, this corroborates the suggestion that the inhibitor acts at
a site(s) not involved in the arachidonate cascade.
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In these studies, high concentrations of Thrombin (1U/ml) could
overcome the inhibition by arachidonate. The precise mechanism
underlying aggregation at high Thrombin concentrations is not fully
understood but it has been suggested that at high concentrations
Thrombin may be acting in a similar manner to calcium ionophores,
whereby the membrane permeability is increased. Calcium ionophore
induced activation is more difficult to inhibit (Coene et al, 1986).
In addition, 11,9-emPGH2 responses were also inhibited. Since
11,9~emPGH2 activation of platelets is possibly mediated through
mobilization of intracellular calcium stores (Brace et al, 1985),
occurring independently of arachidonate release from membrane
phospholipids, this would support the postulation that the inhibition
is mediated at a site other than those at the level of the
arachidonate pathway.
It is possible that arachidonate inhibits platelet responses by
immobilizing intracellular calcium fluxes. In the studies described
here, both the shape change and aggregation responses induced by
different agents were inhibited. A recent report (Simpson et al,
1986) has shown that intracellular calcium levels are not elevated in
11,9~emPGH2 induced shape change. Based on these results it would
seem unlikely that arachidonate is in fact immobilizing calcium
stores since shape change responses induced by 11,9~emPGH2 and other
agents were inhibited by arachidonate. In contract to these
findings Brace and co-workers (1985) have reported that arachidonic
induced shape change is mediated by increases in intracellular
calcium.
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The effect of other fatty acid derivatives, linoleic acid and
oleic acid were also studied to determine whether these too exhibited
similar properties to those of arachidonate.
Linoleic acid is an 18-carbon atom fatty acid with a methylene-
interupted double bond system at the 9 and 12 positions. This fatty
acid can be converted by various enzyme systems to Jf-linoleic acid,
dihomo- % -linoleic acid and arachidonate and so can produce
prostaglandins of the 1, 2 and 3 series (Crawford, 1983).
Linoleic, was also found to exert inhibitory effect on other
aggregating agents at concentrations in the micromolar range OOOyM).
What appears to be an irreversible aggregation was exhibited at
higher concentrations, the nature of which will be discussed later.
Vallee et al (1980) have shown that Thrombin induced aggregation
was inhibited when platelets were incubated with linoleic acid.
They attributed this effect to a disruption of prostaglandin and TXA2
biosynthesis due to an alteration in the phospholipid composition
which reduced phospholipase activity. Silver et al (1973) have also
demonstrated that linoleic acid inhibited platelet aggregation.
However they interpreted this effect to a direct action of linoleic
acid on the phospholipase A2 enzyme. Pace-Asciak & Wolfe (1968)
have suggested that the inhibition of aggregation induced by linoleic
acid is mediated through irreversible inactivation of the cyclo-
oxygenase enzyme. However, inhibition of the cyclo-oxygenase or
phospholipase enzymes by linoleic acid cannot explain its anti¬
platelet activity in these studies because it is known that primary
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aggregation induced by ADP and 11,9-emPGH2 occur independently of
endogenous arachidonate metabolism (Mills and McFarlane, 1976).
Oleic acid which was also studied is also an 18-carbon atom
fatty acid derivative, but with only a single bond at the C-9
position. Mono-saturated fatty acids are not substrates for the
oxidising enxymes of the cyclo-oxygenase or lipoxygenase pathway. In
these studies low concentrations of oleic acid were found to block
ADP induced aggregation (lO-11 - 10~®m) to a considerable extent.
However, at higher oleic acid concentrations, ADP (10~^M) could
overcome the block. From these results, it would appear that the
inhibition observed with intermediate concentrations of arachidonic
acid is not restricted to this fatty acid molecule since linoleic and
even oleic acid exhibit similar properties. The question whether
all 3 fatty acid derivatives are acting through a common mechanism
remains to be elucidated. The demonstration that increasing
concentrations of ADP can overcome the oleic acid induced block could
illustrate some structure activity specificity in mediating this
inhibition, whereby oleic acid is only exerting a weak effect.
From the data presented here, one could postulate that
arachidonate and other fatty acid derivates are mediating their
effects through perturbation of the membrane. In support of this
theory, Maclntyre et al (198^) have demonstrated that cis-unsaturated
fatty acid (but not trans isomers) exhibit anti-platelet activity and
they attributed these effects to a perturbation of the platelet
membranes in specific lipid domains.
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Furthermore, studies by Kanaho et al (1983) have shown that
certain amphipilic drugs (those having both polar and non-polar
structures in the same molecule) of non-related compounds can exert
inhibitory effects on arachidonate, collagen and Thrombin induced
stimulation of rabbit platelets. They have suggested that such
compounds could become incorporated into the lipid bilayer of the
platelets whereby bringing about a change in the membrane morphology.
Such a membrane perturbation could indirectly affect the
microfilaments and as a result prevent pseudopod formation.
Microfilaments have been reported to play an important role in the
formation of pseudo pods, a prerequisite for the induction of
platelet aggregation with some aggregating agents (Pribluda & Rotman,
1982).
High Arachidonate concentrations associated with an irreversible wave
and release of 5HT
The irreversible aggregation waves induced with high
arachidonate acid concentrations (> 300yM) were not affected by prior
treatment with Froben, EP092 or Iloprost, indicative that this effect
is not due to a thromboxane/endoperoxide dependent component, even
although [)^C]-5HT release was associated with these irrversible
waves. The lipoxygenase enzyme inhibitors, NDGA and ETYA did not
have any effect on these waves. This would exclude the possibility
that lipoxygenase products were responsible. In addition, high
concentrations of linoleic acid (100yM) also appeared to elicit
irreversible waves, which too were associated with [^C]-5HT release.
In citrated platelet rich plasma, only shape change was induced at
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low arachidonate concentrations but over 300yM irreversible waves
were also apparent which were not blocked by Froben or EP092.
These irreversible waves could possibly be explained by a
phenomenon known as platelet lysis. Fatty acid molecules may exert
non-specific physical effects at the membrane level, causing the
platelets and their cellular granules to lyse, resulting in the
release of intracellular constituents inducing 5HT. This phenomenon
has been reported by Ts'ao and Holly (1979) who demonstrated that
high concentrations of arachidonate in artificial media cause
platelet membranes to undergo structural changes resulting in lysis.
Their observations were supported by electron micrographs
illustrating platelet membrane remnants devoid of cellular
components. Lysis may also explain the mixed effects observed with
the fatty acids studied in platelet rich plasma.
The following fatty acids C22 : 4w6, C20 : 5w3 and C20 : MW6
(Fig.3.16) at higher concentrations of arachidonate shift the log
dose response curve to the left, such that the irreversible wave is
evident at a lower arachidonate concentrations. If lysis is the
underlying cause of the irreversible wave, an increase in the overall
effective free fatty acid concentration due to the presence of these
fatty acids in the platelet suspension could cause the lysis
phenomenon. An other alternative explanation could be that the
fatty acids are preferentially bound to plasma-proteins possibly
albumen, resulting in more unbound arachidonate in the media, thus
increasing the availability of arachidonate at the platelet membrane.
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The other fatty acid studied C22 : 6 induced small primary waves
in the absence of arachidonate suggesting that it alone was acting
directly on the platelet membrane causing platelet changes. All
with the exception of C22 : 4w6 completely inhibited the shape change
response induced by low arachidonate concentrations. These fatty
acids could be inhibiting the conversion of arachidonate to its
metabolites by inhibition of the cyclo-oxygenase enzymes. Indeed
C20 : 5W3 and C20 : MYW6 have been reported to have this activity
(Morita et al, 1983A; Ahern & Downing, 1970).
A different profile of activity in rat PRP was observed with the
fatty acid derivative C20 : 3w6 (8,11 ,14—ETA). It only inhibited
the shape change at concentrations above 500pM, but in contrast to
the other fatty acids studied, higher concentrations of this molecule
did not enhance the non-specific irreversible wave but in fact
inhibited it to varying degrees (Fig.3.21). It could be postulated
that this fatty acid, instead of raising the overall effective free
fatty acid concentration, is actually interacting with the
arachidonic acid molecule itself, whereby decreasing the amount of
free arachidonate available at the platelet membrane.
Alternatively C20 : 3w6 may be converted into prostaglandins of the
'1' series (Crawford, 1983). The presence therefore of this fatty
acid in PRP may not in fact increase the overall effective
concentration of free fatty acid but rather fatty acid metabolites
may themselves compete with arachidonate for platelet membrane sites.
The evaluation of arachidonates mode of action in rat platelets
in this chapter would suggest that the response mediated is very much
83
dependent upon the concentration of arachidonic acid available to the
platelet and other factors in the system such as plasma - proteins
and citrate.
At low concentrations, arachidontc acid is taken up by the
platelet and the conversion of arachidonate acid to its metabolites,
the endoperoxides and TXA2 if an essential prerequisite for the
induction of shape change and irreversible aggregation. It has been
demonstrated that the endoperoxide analogue 11,9-emPGH2 mobilizes
intracellular calcium ions in the process of (Brace et al, 1985) and
since endoperoxides/TXA2 production is essential to arachidonate
induced responses, this would suggest that both arachidonate acid and
mimetics are mediating their effects via a common mechanism, which is
likely to involve the mobilization of intracellular calcium.
The finding that arachidonate acid can turn off platelets at
intermediate concentrations (75-1OOpM) whereby they are subsequently
refractory to other aggregating agents raises the question as to the
physiological status of the inhibited platelets; are they
physiologically intact during this period ? In fact, the platelets
were found to actively synthesise both cyclic AMP and TXB2 during the
inhibitory period indicating that the platelets are metabolically
intact. In addition the platelets were still capable of undergoing
aggregation in response to high thrombin concentrations.
Two possible mechanisms were considered by which arachidonate
could 'turn off' platelet function; (i) via the formation of
inhibitor products or (ii) through the inhibition of critical
enzymes. The results presented here would indicate that products of
arachidonate metabolism are not responsible for this inhibition and
the antiplatelet activity induced by arachidonate is not due to
inhibition of some critical enzymes, but rather that the arachidonate
molecule itself is mediating a non-specific effect (also demonstrated
by other fatty acids) at the membrane level. The effect may
possibly be due to a perturbation of the platelet membrane which
renders the platelets refractory to other aggregating agents as
discussed earlier. It was noted however, that cyclic AMP levels
were increased approximately two-fold over this concentration range
of arachidonate acid which exhibited the inhibitory effect. This
magnitude of rise in cyclic AMP levels could be adequate to account
for the inhibition of platelet function. If this were the
explanation, the precise mechanism by which the arachidonate acid was
raising cyclic AMP remains to be elucidated. Could the rise in
cyclic AMP reflect an effect of arachidonate acid itself on the
adenylate cyclase or phosphodiesterase enzyme or could a perturbation
of the platelet membrane by arachidonate exert an effect on these
enzymes ? These questions remain to be answered.
At concentrations of arachidonate over 500pM the apparent
irreversible aggregation associated with release of 5HT, TXB2 and
cyclic AMP production has been postulated to be due to a non-specific
(thrombxane-independent) physical effect of arachidonate on the
platelet membrane. The fact that TXB2 and cyclic AMP production
occurs at these arachidonate levels indicates that the enzymes
systems responsible for their production are intact even though the
functional integrity of the platelet as a whole is affected. It is
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possible that on increasing arachidonate above a critical threshold
concentration, plasma-proteins may become saturated whereby more free
fatty acid is available in the surrounding medium. The elevated
levels of fatty acids may give rise to the physical effects,
including membrane perturbation and activation of platelet enzymes.
When using plasma-free suspensions, the complications of plasma-
protein binding are removed and the direct effect of the fatty acid
on platelets becomes apparent. The data presented here illustrates
how thromboxane/endoperoxide components of arachidonate induced
responses may be overlooked in a plasma-protein system and therefore
lead to misinterpretated conclusions which may well explain some of
the discrepancies seen in other studies concerning the nature of
arachidonate mediated effects in rat platelets.
The physiological significance of the inhibition induced by
arachidonate whereby it turns off platelet function remains to be
established. Linder and Goodman, (1982) has proposed that local
concentrations of endogenously released arachidonate attained during
platelet stimulation may turn off aggregation when arachidonate
concentrations reach a critical level. Thus arachidonate may play a
role in regulation of platelet function.
When considering the activation of platelets 'in vivo' the
amounts of endoperoxides and thromboxanes produced from arachidonate
may well be controlled by the relative levels of free arachidonate as
well as other related fatty acids (Bang et al, 1972). In addition
albumen itself may be an important controlling factor in haemostasis
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since it has been demonstrated that this plasma-protein itself can
inhibit platelet aggregation induced by arachidonate, ADP and
collagen (Dratewka-Kos et al, 1985). The inhibitory capacity of
albumen in circulating blood may vary considerably depending on
factors such as the availability of albumen binding sites and the
competition for such sites with fatty acids and other substances.
Bills et al (1976) have shown that prostaglandin formation from
arachidonate is greater in washed human platelets than in platelet
rich plasma suspensions, suggesting that exogenously added
arachidonate becomes more available to platelet synthesizing enzymes
in plasma-free systems when albumen is absent. This adds further
support to the notion that albumen in circulating blood may play an
important role in regulating prostaglandin production as well as
regulating platelet activation.
Thus the precise mode of arachidonate action may be very
different when a comparison is made between 'in vitro' and 'in vivo'
situations. Factors such as plasma-proteins (including albumen),
the anticoagulant (whether heparin or citrate) and other competing
substances (for example other fatty acids) should be considered.
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CHAPTER H
Characterisation of thromboxane receptors
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INTRODUCTION
Many compounds exert their biological actions by interacting
with specific receptors situated on the plasma membrane of the cell.
The more recent isolation and characterisation of receptors has
opened the way to a better understanding of the molecular basis of
drug actions and the concept has proved to have important practical
consequences in the development of drugs for therapeutic use.
A general theory of drug action was first proposed by Clarke who
suggested that stimulant drugs occupied specific receptors eliciting
a response which depended on the number of these receptors occupied
(Clarke 1926, 1929).
This approach was later modified by Gaddum (1937) to consider
the action of antagonists which he supposed acted by binding to a
receptor without eliciting a response.
In determining the concentration-response relationship for a
particular drug, it is usual to express the concentration in
logarithmic terms. For agonists these relationships often take the
form of a sigmoid curve. A parallel shift to the right of the log
dose response curve for an agonist is observed in the presence of an
antagonist and this effect was explained by competition between the
agonist and antagonist, whereby the agonists competes with the
antagonist for the receptor sites.
However, it was demonstrated from experimental evidence that
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even when 90-99$ of the receptors were being occupied by the
antagonist, a maximum response could still be elicited if sufficient
agonist was added.
This observation led to the concept of spare receptors, and the
suggestion that an agonist need only occupy a small fraction of these
receptors to produce a maximal response (Stephenson, 1956) and only
in the presence of increasing concentrations of an antagonist will
these receptors be occupied. It should be emphasised that these
'spare receptors' are qualitatively similar to non-spare receptors
and all are equally available to the agonist.
In competitive antagonism, when an agonist and antagonist are
presented simultaneously in solution they are thought to compete for
receptors to the exclusion of the others, such that the response is
determined by the concentration of the 2 drugs and their relative
affinity constants.
In addition to competitive antagonists, 3 other types exist;
non-competitive, chemical and physiological antagonists. A non¬
competitive antagonist acts in an irreversible or nearly irreversible
manner and the affinity of such antagonists is so high that the
receptor is unavailable for binding by the agonist. Some non¬
competitive antagonists in fact produce irreversible effects by
forming covalent bonds at the receptor site. Chemical antagonism
does not actually involve the receptor but in fact another drug which
binds to the agonist, inactivating it and consequently preventing the
agonist from activating the receptor. The third type of antagonism
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is physiological or functional antagonism which involves the action
of a drug on another receptor site to the one the agonist binds to,
and activation of this other receptor leads to a response which
opposes the action of the agonist. An example of this is observed
with PGI2 and TXA2 receptor agonists, whereby elevations in cyclic
AMP opposes the action of thromboxanes. In general, this latter
type of antagonism produces effects which are less specific than
those of a specific receptor antagonist.
In drug receptor studies, the relationship between receptor
activation and response is based upon the assumption that an agonist
must occupy the same number of receptors in the presence or absence
of an antagonist to produce a given response, and this assumption has
led to the use of the dose ratio (the ratio of the concentration of
agonist in the presence and absence of an antagonist to produce a
given response) to estimate the affinity constant (Kg value) of an
antagonist for a particular receptor. The affinity constant may be
derived from Schild's equation; DR-1 = BKg where DR = dose ratio, B
concentration of antagonist, and Kg = affinity constant
(Arunlakshana and Schild, 1959).
Determination of the Kg value is one approach used in the
classification of drugs according to the receptors on which they act.
If a particular antagonist has the same Kg value when measured
against different agonists on a given tissue,it is indicative that
the agonists are acting on common receptors although not conclusive
evidence. Furthermore, comparison of receptors in different tissues
which are activated by the same agonist can be made by comparing the
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Kg value? of a common antagonist. Thus Kg values are generally used
as a measure of the affinity of antagonists. On the other hand,
equipotent molar ratios (EPMR) can be used as a measure of the
effectiveness of different agonists at a given receptor, and this
approach allows the relative activities of agonists to be compared on
one or more systems. The dose-response relationships for agonists
will depend on the density of receptors; low efficacy will tend to
result in low potency on sparsely populated systems. Efficacy is
the term used to describe the effectiveness of a drug-receptor
complex to elicit a response (Stephenson, 1956). Full agonists have
an efficacy ranging from zero to an upper limit of one, whilst
antagonists have zero efficacy.
The EPMR values are therefore used to compare relative potencies
of agonists at a given receptor site and can be used in conjunction
with Kg values of antagonists in the classification of receptors.
In addition to full agonists which produce a maximal response when
occupying only a small percentage of receptors, some compounds
(partial agonists), are incapable of producing this maximum even at
high concentrations. It is suggested that the efficacy of these
compounds is so low that insufficient biological stimulus is
generated to ensure a maximum response. At high concentrations, the
partial agonist occupies the majority of the receptor pool and hence
it opposes the action of a full agonist.
The studies in this chapter make use of the basic concepts of
drug-receptor interactions to characterize receptors, and such
studies have proved to be a difficult task for the following reasons:
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(i) Many pharmacological preparations contain more than one receptor
type often giving rise to opposing actions and one prostaglandin may
produce both excitatory and inhibitory responses in the same
preparation.
(ii) Prostaglandins may trigger the release of other substances which
can interfere with the response. These substances may be prostanoid
or non-prostanoid in nature.
(iii)Prostaglandins may be metabolised by tissues to varying extents,
or if they are highly unstable they may decay spontaneously in
neutral aqueous solutions.
It is important therefore, when carrying out differentiation studies
to ensure that only one response is being observed and that
metabolism and sequestration are limited.
In this chapter, our main concern deals with the thromboxane-
sensitive system with the aim of characterizing the thromboxane
receptor. Much controversy exists as to whether thromboxane
receptor subtypes exist either between tissues or between species.
Earlier reports have suggested that there is a dissociation of
thromboxane activity on the vasculature from that on the platelets
(Lefer et al, 1980), as well as species differences in the
thromboxane receptor on platelets and the vasculature (Maclntyre &
Anderson, 1982; Lefer et al, 1983; Mais et al, 1985A and B).
There are limitations when comparing data from different systems
in one species as well as between species which should be considered
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when critically evaluating data:
(i) When studying isolated tissue preparations, the accessibility of
the receptor to agonists and antagonists should be considered since
the unionised forms of many antagonists are highly lipophilic and as
a result of the distribution between the aqueous and lipid phase in
the region of the receptors, the organ bath concentration may not
actually represent the true concentration adjacent to the receptor.
If the lipid compartment has a high capacity, then a stable situation
may arise when the aqueous phase concentration near the receptor is
much lower than the bathing fluid concentration.
(ii) Of equal importance is the accessibility of receptors to
agonists and antagonists in platelet systems. In platelet rich
plasma, the binding of lipophilic agonists and antagonists to plasma-
proteins may be a factor which could effectively decrease the free
drug concentration, whereby the apparent potency of the drug would be
decreased.
(iii)The time that a tissue is exposed to a drug is important since a
sufficient period is necessary to allow equilibrium occupancy of the
receptor to be attained. This is especially important when studying
isolated tissues since many analogues have a slow onset of action
whereby they can take up to one hour to reach equilbrium. On the
other hand, the platelet system represents a dynamic situation
whereby the drug interacts almost instanteously with the receptor,
with a rapid onset of equilibrium occupancy.
(iv) Tissue preparations may spend different lengths of time outside
the body before an experiment and this factor should be considered
since it could possibly affect the sensitivity of the tissue to
drugs. Although the time factor may affect the actual potencies of
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certain drugs it should not affect the rank order of potency of such
compounds.
(v) Finally, the use of non-selective agonists and antagonists could
lead to misinterpretation of results, due to their possible actions
on other receptor types. In order to make an accurate comparison of
one receptor type, it is essential that truly specific agonists or
antagonists are used.
Bearing in mind these considerations when comparing data, the
following studies involve an evaluation of the thromboxane receptor
with regards to its possible heterogeneous nature.
The high instability of both PGH2 and TXA2 presents special
difficulties in the characterisation of their receptors. One of the
first thromboxane mimetics to be synthesized was the endoperoxide
analogue 11,9-epoxymethano PGH2 (Yankee et al, 1976) and because of
its selectivity, stability and similar profile of activity to TXA2
(Malmsten, 1976; Coleman et al, 1981) it is generally used as the
standard agonist.
Much work has been carried out in our department on thromboxane-
sensitive systems and much progress has been made in this are due to
the recent development of highly potent analogues mimicking the
action of the parent compound and high affinity competitive
antagonists.
In 1975, the discovery that the 16-p-fluorophenoxy PGF2a
analogue, ICI79939 had full thromboxane-like agonist activity
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prompted the substitution of this aromatic unit into two stable
0
prostaglandin endoperlijxde analogues, 9,11 -ethenoPGH2 and 9,11-
ethanoPGH2» The resulting analogues EP011 and EP031 showed high
agonist activity on some smooth muscle tissues which was difficult to
reverse on removal of the agents from the bathing fluid (Jones et al,
1979). Later studies in which the 16-p-fluoro-phenoxy moiety was
introduced into a prostanoid which already exhibited high TX-like
agonist activity has given rise to a compound EP171, of outstanding
agonist activity (Jones et al, 1985B). More radical chemical
alterations of the w-chain of 9,11-etheno and 9.11-ethano PGH2 has
resulted in thromboxane receptor blockade. Two examples are the
semicarbazone analogue EP045 and the thiosemicarbazone analogue EP092
(Armstrong et al, 1985). Other groups have also synthesized TX
receptor antagonists and three compounds which were available to use
were ON011120 (Katsura et al, 1983), BM13177 (Patscheke & Stegmeier,
1984) and AH23848 (Brittain et al, 1985).
The work in this chapter makes use of the wide range of agonists
and antagonists available to compare the thromboxane receptor on the
platelet from different species, namely man, rabbit and rat.
Studies were carried out using plasma-free platelet suspensions to
limit the complications which may arise from plasma-protein binding
due to the highly lipophilic nature of thromboxane analogues.
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RESULTS
Effects of Agonists on human, rabbit and rat platelets
The stable thromboxane mimetic, 11 ,9-epoxymethano PGH2 (11,9-
emPGH2) was used as the standard agonist to induce aggregation in
platelets throughout this study. 11,9~emPGH2 has been shown
previously to exhibit a similar profile of activity to the naturally
occurring compound, thromboxane A2 (TXA2) (Coleman et al, 1981), with
little agonist activity on PGD, PGE, PGF and PGI receptors.
Washed platelet suspensions from human, rabbit and rat blood
were prepared. In both human and rabbit washed platelet suspensions
distinct secondary aggregation waves to 11,9-emPGH2 were not usually
observed and more often the primary and secondary waves were
kinetically indistinguishable (Fig,4.1A). However, quite often when
using rat platelets, a slow onset primary wave aggregation was
apparent which merged into a secondary wave of aggregation giving
rise to a biphasic pattern (Fig,4.1B). Irreversible aggregation was
always apparent at concentrations of 11,9-emPGH2 over 0.25yM.
Log concentration response curves were established and the
concentrations of 11,9-emPGH2 required to produce a 50% response (the
EC50 value) in platelets from these species were determined. Six
other agonists were studied; 9,11-Azo PGH2, 9a11a-oxa-1Oahomo PGH2,
EP171, EP109, STA2 and PGH2. (EP171, EP109 and PGH2 were synthesised
in our laboratories). Their structures are illustrated in Fig.4.2.
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Figure 4.1 11,9-EpoxymethanoPGH2 induced responses in (A) washed
human and (B) washed rat platelets.
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Figure 4.2 Structure? of the thromboxane mimetic? used in this
study.
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concentration-response curves were parallel to that of the standard
agonist. The threshold concentrations for aggregation (TAC) induced
by each of the agonists were determined and are shown in Table 4.1.
The concentration of each agonist to produce a 50% maximal response
was determined and the EC50 values are shown in Table 4.2. The
equipotent molar ratios of determined from these EC50 values and are
shown in Table 4.3 (EPMR of 11,9em PGH2 =1).
It is evident from these values that EP171 is somewhat more
potent than any of the other agonists in all three species, in fact
EP171 is the most active thromboxane agonist reported to date.
Despite its high potency, the profile of activity of EP171 is similar
to that of 11,9-emPGH2 in platelets from different species (Fig.4.3).
It is also evident from these EPMR values that PGH2, the only natural
prostaglandin used in this study, is 1.5 to 2.0 times less potent
than 11,9-emPGH2 in human and rat platelets and equipotent in rabbit
platelets. The decreased potency may be due to the redirected
metabolism of PGH2 to other prostaglandins, especially PGD2 which
exhibits anti-platelet activity in some species or possibly due to
some decay. However, the log concentration response curves of PGH2
were found to be parallel to those of the other agonists, indicating
that the profile of pharmacological activity of the synthetic
analogues closely resembles the profile of the natural compound,
PGH2. Although, these agonists exhibited parallel log dose response
curves, STA2 at high concentrations in human platelets only was found
to exert effects different from the other agonists. What appeared
to be a reduction in the maximal aggregation response was evident
(Fig.4.4). The nature of this effect was investigated.
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Table 4.1 Concentration? of Thromboxane Mimetic? Eliciting
Thre?hold Aggregation in Wa?hed Platelet Suspension?
(nM)
Species Human Rat Rabbit
Mimetic n = 5 n = 4 n = 4
ep171 1 .45 + O o 2.07 + 0.05 2.02 + 0.56
sta2 11 .2 + 2.2 12.9 + 4.5 5.83 + 4.5
9,11-azoPGH2 16.6 + 4.5 44.8 + 6.7 11.2 + 4.5
9a11a-oxoHomoPGH2 33.6 + 5.6 78.5 + 10.1 22.5 ± 1 .6
11,9emPGH2 36.1 ± 4.6 78.3 + 8.1 48.5 + 5.2
pgh2 67.2 + 16.8 123 ± 22 44.8 + 16.8
ep109 92.5 + 6.5 106 + 5 101 + 7
(All values are the mean ± s.e. mean)
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Table 4.2 ^50 Values (nM) f>or platelet aggregation induced by
Thromboxane Agonists
Species Human Rat Rabbit
Tx Mimetic n=5 n = 4 n = 4
EP1 71 2. 60 ± 1.10 3.75 + 0.10 3.60 + 0.20
sta2 20. 0 + 4.0 23.1 ± 8.1 1 0.4 + 1 .0
9,11-azoPGH2 30. 0 + 9.1 80.0 + 11.5 20.3 + 4.0
9a11a-oxoHomoPGH2 60. 1 + 11.2 1 40.0 + 20.0 40.2 + 3.2
11,9emPGH2 60. 0 + 4.0 150.0 + 20.0 60.0 ± 20.0
pgh2 120. 0 + 30.0 220.0 ± O•O■=T 80.0 ± 30.0
EP109 165. 0 ± 13.0 190.0 ± O•O 180.0 ± 15.0
(All values are the mean ± s.e. mean)
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Table 4.3 EPMR values of Thromboxane Mimetics in Washed Platelet
Suspensions (EPMR 11,9_emPGH2 = 1)




EP171 0.041 0.034 0.045
sta2 0.31 0.17 0.13
9,11-azoPGH2 0.47 0.57 0.24
9a11a-oxoHomoPGH2 0.93 1 .00 0.47
11,9emPGH2 1 .00 1 .00 oo•r—
pgh2 1 .86 1 .57 1.33




Figure 4.3 Typical log concentration aggregation curves for EP171
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Figure 4.4 Log concentration response curve for STA2 induced
aggregation in washed human platelets.
Each result is the mean and standard error of 4
observations.
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PAF induced aggregation (110nM) was studied in human and rabbit
platelets in the presence of increasing concentrations of STAp.
Similar experiments were carried out on rat platelets using ADP, as
the aggregating agent. The thromboxane receptor antagonist, EP092
was present in all experiments to eliminate any thromboxane agonist¬
like action. PAF-induced aggregation of human platelets was also
tested in the presence of high 11,9-emPGH2 concentrations. The
results are shown in Fig.4.5. STA2 markedly inhibited the response
to PAF on human platelets, but had little inhibitory effect on rabbit
platelets. 11,9-emPGH2 did not inhibit PAF action on human
platelets. The ADP response in rat platelets was unaltered in the
presence of STA2 (results not shown).
The possibility that STA2 was acting on PGD2 receptors in human
platelets thereby elevating cyclic AMP was considered. Using the
PGD2 receptor antagonist AH6809 (Kerry & Lumley, 1985) platelet
responses to PAF were observed in the presence of STA2 and EP092.
A marked inhibition of the control PAF response (110nM) by STA2
(0.27yM) is illustrated in Fig.4.6(A & B). Pre-incubation with
AH6809 (7.5yM) did not reduce the inhibitory effect of STA2
(Fig.^.6C).
In addition, the effect of the adenylate cyclase inhibitor,
SQ22536 on STA2 inhibition of the PAF response was studied. Pre¬










Figure 4.5 Percentage inhibition of PAF (110nM) induced aggregation
by STA2 in (A) human washed platelets, (B) rabbit washed
platelets and (C) the effect of 11,9-epoxymethanoPGH2 on
PAF induced aggregation in human washed platelets (all











Figure 4.6 The effect of the PGD2 receptor antagonist AH6809 and
the adenylate cyclase inhibitor SQ22536 on STA2 induced
inhibition of PAF aggregation in washed human platelets.
(A) PAF control (110nM)f (B) STA2 (0.3yM) and PAF
(11Onm), (C) AH6809 (7.5yM), STA2 (0.3yM) and PAF
(11OnM) and (D) SQ22536 (250yM), STA2 (0.3yM) and PAF
(110nm). (All experiments were carried out in the
presence of EP092 (0.7yM). EP092, AH6809 and SQ22536
(added simultaneously) were pre-incubated for 2 minutes
prior to addition of STA2. PAF was added 2 minutes
after the addition of STA2).
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Carboxylic-thromboxane Ap (CTA2) i? structurally very similar to
STA2 and it has previously been shown to produce a primary
aggregation wave in washed human platelets but which was rapidly
reversed within the 2 minute incubation period. Since CTA2 has been
found to raise cyclic AMP levels, the reversal of primary aggregation
could be brought about by the cyclic AMP (Armstrong et al, 1985).
It is possible that STAp which is structurally very similar, may also
have the ability to elevate cyclic AMP. This possibility was
assessed by incubating washed platelet suspensions (in calcium free
Krebs' solution) with increasing concentrations of STA2. A similar
procedure was carried out using 11,9~emPGH2 in order to make a
comparison with an agonist having no apparent inhibitory effect.
Samples were prepared for cyclic AMP binding assay (described in
methods chapter). The results are shown in Fig.4.7. An apparent
dose dependent increase in cyclic AMP levels is observed.
Partial agonism
The effects of three prostanoids, PTA2, EP167 and EP204, each
known to have partial agonist activity on smooth muscle preparations,
were examined on washed platelets from the three species.
Structures are shown in Fig.4.8. Shape change and small primary
aggregation waves were observed with EP167 and EP204. The log
concentration response curves for these analogues were shallower than
that of 11,9~emPGH2 and full aggregation was never attained in
platelet suspensions from any of the 3 species. Typical log
concentration-response curves for EP204 and EP167 on human platelets











Figure ^.7 Elevations in cyclic AMP induced by STA2 and 11,9-
epoxymethanoPGHp in washed human platelets. (Expressed
as multiples above basal. Basal cyclic AMP = 1.70


















Figure ^.8 Structures of partial agonists used in this study.
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gure ^.9 Log concentration response curves for 11,9-
epoxymethanoPGH2. EP167 and EP201) in washed human
platelets.
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EP204 in rat and rabbit platelet suspensions. On the other hand,
only a small shape change response was observed with PTA2 in platelet
suspensions from human, rat and rabbit, and primary aggregation waves
were never observed.
EP171 and EP204
EP167 and EP204 are both structurally similar with respect to
the w chain; containing a substituted imino group at the 13 carbon
position but with different ring structures. The threshold
concentrations of each of these partial agonists required to produce
primary aggregation waves are shown in Table 4.4. The ability of
these partial agonists to inhibit full aggregation induced by
11,9emPGH2 was assessed; from 5 experiments, the mean concentration
of each partial agonist which inhibited the maximal response by 50$
(IC50) was determined. These IC50 values are shown in Table 4.5.
In addition experiments were carried out in which platelet
suspensions from the 3 species were pre-incubated with either EP167
(1 yM) or EP204 (1 pM) before the addition of PAF (110nm in human
platelets and 10nM in rabbit platelets) or ADP (1yM in rat platelets)
to see whether there was any effect on their aggregatory responses.
EP167 and EP204 did not antagonise the aggregatory action of PAF or
ADP and in fact a slight potentiation of their responses were
observed.
PTA;
PTA2 (pinane-thromboxane A2) has a pinane ring structure with
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Table Threshold Aggregation Concentrations (T.A.C.) (yM) for
the Partial Agonists EP167 and EP204
Species
Partial
Agonists Human Rat Rabbit
EP167 0.85 1.50 0.55
EP204 1.00 2.85 0.75
(Values are means of 3 experiments)
101A




Agonists Human Rat Rabbit
EP167 0.6H ± 0.08 0.55 ± 0.07 0.95 ± 0.03
EP204 0.9M ± 0.06 1.11 ± 0.10 0.98 ± 0.06
PTA2 0.10 ± 0.09 1.25 ± 0.05 11.10 ± 0.05
(Mean ± s.e. mean of 3 experiments)
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both natural a and w chain? and structurally is similar to TXA2
(Fig.4.8). In washed platelets from human, rat and rabbit, only
very small shape change responses were observed. These effects were
inhibited by EP092, indicating that PTA2 does have some degree of
thromboxane-like activity as well as the ability to inhibit
aggregation induced by 11,9-emPGH2- The IC50 values for PTA2
against 11,9-emPGH2 are also shown in Table 4.5.
It should also be noted that PTA2 has been demonstrated to exert
dual actions on human platelets (Armstrong et al, 1985) but the
precise mechanisms underlying the actions of PTA2 remain obscure.
It has been suggested however that in addition to its thromboxane
agonist-like action, PTA2 in fact exerts an inhibitory effect
possibly through the elevation of cyclic AMP and this increase could
be mediated through activation of PGD2 or PGI2 receptors. Indeed,
PTA2 did reduce the aggregation response induced by PAF in human
platelets (Fig.4.10).
The possibility that PTA2 was exerting similar inhibitory
effects in rat and rabbit platelet suspensions was investigated; PAF
and ADP induced aggregation in rabbit and rat platelets respectively
were tested in the presence of PTA2. (Froben (10yM) was present in
each of these experiments, preventing any endogenous production of
thromboxane). Essentially the profile of activity of PAF and ADP in
rabbit and rat platelets was unaltered in the presence of PTA2.
The effect of the adenylate cyclase inhibitor on PTA2 induced
inhibition of 11,9-emPGH2 aggregation (0.3yM) was tested in washed
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Figure 4.10 Effect of PTA2 on PAF induced aggregation in washed
human platelets. (A) PAF control curve (110nm), (B)
Froben (10yM) and PAF (110nm), (C) Froben (10yM), PTA2
(2.5yM) and PAF (110nm) and (D) Froben (10pM), PTA2
(12.5yM) and PAF (110nm). (Froben and PTA2 were added












human platelets. The IC50 concentration of PTAp (2.5yM) was tested
and in the presence of SQ22536 (250yM) and no reduction in the
inhibition of the 11,9-emPGH2 response was observed (Fig.4.11).
Thromboxane receptor antagonism
Six specific thromboxane receptor antagonists were studied for
their ability to inhibit aggregation induced by 11,9-em PGH2. The
structures of these are illustrated in Fig.4.12. In all cases log
dose-responses curves to 11,9~emPGH2 were shifted to the right in a
parallel manner. Of the six antagonists EP092 (Armstrong et al,
1985), AH23848 (Brittain et al, 1985), 0N011120 (Katsura et al, 1983)
and BM13,177 (Patscheke & Stegmeier, 1984) have been reported to
exhibit only specific thromboxane antagonist effects, micromolar
concentrations having no effect on cyclic AMP levels. Both EP115
and EP169 (synthesised in our laboratories) were investigated for any
PGI2 or D2 like activity in platelets from all 3 species. Platelet
suspensions were pre-incubated with the antagonists to see whether
there was any inhibitory effect on PAF (in human (110nM) and rabbit
(10nM) platelets) and ADP (10~^M in rat platelets) induced
aggregation, possibly due to elevations in cyclic AMP. Froben
(1 0 yM), a cyclo-oxygenase inhibitor was present so as to prevent any
endogenous thromboxane synthesis. Neither antagonist appeared to
exert an inhibitory effect on the aggregatory responses induced by
both PAF and ADP. Cyclic AMP levels in PRP from human platelets
following the exposure to EP169 were also measured and it is apparent
from Fig.4.13 that there is not a significant increase in cyclic AMP







Figure 4.11 The effect of SQ22536 (250yM) on PTA2 (2.5yM) induced
inhibition of 11,9~epoxymethanoPGH2 aggregation (0.3yM)




0 - v COOH /Ns c O O H
(JX N-NH^NH-<0 CiX;jN-NH^NH-<^>
ch3 S CH;j s
EP092 EP169
COOH v
_ l/=W/COOHV \ n V
'--s-Q)
OH OH
ONO 1 1120 PTA2 Zll 1 5(S)
:ooh

















1.10 2.25 22.5 0.03
i ■ '
EP 1 69 (|iM) tloprost (|iM)
Figure JJ.13 The effect of EP169 and Iloprost on cyclic AMP levels in
PRP from human blood.
(Values are expressed as the mean ± s.e.m. of 3
experiments (6 samples)).
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The aim at this point in the study was to construct Schild plots
for each of the antagonists in the 3 species. However, this proved
to be practically unfeasible for 2 reasons;
(i) only a limited amount of data can be obtained from one
suspension of platelets and so a large number of experiments would be
necessary to provide enough data to construct a Schild plot for each
of the six antagonists in the three species.
(ii) the nature of aggregatory waves in the presence of the two
higher affinity antagonists (EP169 and EP092) in both human and rat
platelets differed markedly from that of the control (Fig.4.14). In
the presence of both of these antagonists, at a concentration
producing a dose ratio of 20 or more, the onset of primary
aggregation was slowed relative to that of the control, however
irreversible aggregation was still attained within the 2 minutes.
This initial slow wave was however not observed in rabbit platelets.
As a result of this when constructing Schild plots the slope
tend to deviate from unity at higher concentrations of antagonists.
It is possible that these high affinity antagonists (EP169 and EP092)
may dissociate more slowly from the receptor, delaying equilibrium
occupancy by the agonist, therefore allowing disaggregation to become
more effective (Jones et al, 1981!). Thus, a compromise was
necessary in order to make a comparative analysis of the 6
antagonists. A concentration of each was found which shifted the
log dose response curve to the right by 1 log unit, in effect giving
a dose ratio of 10, from which pA-|Q values could be determined.
(The pA-jo value is the negative logarithm of the molar concentration
of the antagonist). The pAio values for each of the 6 antagonists
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Figure *1.1 ^ The effect of EP092 and EP169 on 11,9-epoxymethanoPGH2
induced aggregation in wa?hed human platelet?. (Both
EP092 and EP169 were pre-incubated for 2 minute? prior
to addition of 11,9~epoxymethanoPGH2).
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studied are listed in Table 4.
In these studies, the nature of the block produced by AH23848
differed from the block by other antagonists at concentrations
producing a dose ratio of greater than 10. This was only apparent
with human and rat platelets and was not observed with rabbit
platelets. At concentrations between 0.1-0.4yM in human platelet
suspensions and 0.02-0.10yM in rat platelet suspensions, an
unsurmountable block was apparent (Fig.4.15). The nature of this
effect was investigated by measuring the effect of AH23848 on PAF and
ADP induced aggregation in the presence of Froben (10yM). AH23848
(0.1yM) did not appear to have any effect on the primary response
produced by PAF (110nM) or ADP (1yM) in human and rat platelets
respectively.
A large difference in the pA-jg values of EP092 and ON011120 is
observed with rabbit platelet but not with human and rat platelets
(Table 4.6). The possibility that ON011120, which has a pinane-ring
structure (similar to PTA2) could have agonist-like activity for the
PGI2/PGD2 system in human or rat platelets whereby it would exhibit
enhanced blocking potency was investigated. PAF induced aggregation
in the presence on 0N011120 and Froben was compared to aggregation
induced by PAF and Froben alone in both human and rabbit platelet
suspensions. No inhibition of the PAF response was observed in
either species.
In these experiments the six antagonists were all compared
against the standard agonist 11,9-emPGH2. In addition a comparison
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Figure ^. 1 5 The effect of high concentrations of AH23848 on 11,9-
epoxymethanoPGH2 log dose reponse curves in washed human
and rabbit platelets. Control 11,9-epoxymethanoPGH2
curve in the presence of AH238A8 (1.21yM) in rabbit
platelet suspensions and AH23848 (0.1OyM) in human
platelet suspensions.
Logconcentration(jjM)
Table 4.6 Apparent pA-jq values for thromboxane antagonism of
11,9-emPGH2 induced aggregation of washed platelets
suspensions from man, rat and rabbit
PA10
Antagonist Human Rat Rabbit
n = 5 n = 4 n = 4
EP169 7.15 7.35 6.28
(7.05-7.30) (7.30-7.41) (6.24-6.32)
AH23848 6.81 6.96 5.26
(6.72-6.91) (6.71-7.26) (5.60-5.71)
EP092 6.77 6.84 5.75
(6.35-6.99) (6.69-7.03) (5.71-5.89)
0N011120 6.53 6.42 4.99
(6.45-6.61) (6.39-6.85) (4.97-5.00)
PTA<Z>ZII 1 5(S) 6.28 5.89 4.74
(6.21-6.39) (5.81-5.99) (4.70-4.82)
EP115 6.02 6.04 5.19
(5.98-6.07) (6.00-6.09) (5.11-5.29)
BM13177 5.25 5.15 4.91
(5.19-5.31) (5.12-5.15) (4.87-4.95)
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of the blocking potency of 0N011120 and EP092 against two other
agonists, STA2 and PGH2 was made to see whether a similar profile of
activity was observed in the three species. As before log dose
response, control curves for both agonists were shifted to the right
by each of the antagonists and the dose ratio values were converted
to pA-jo values which are shown in Table 4.7.
Effects of TX antagonists on smooth muscle
In addition to the platelet studies, the effects of thromboxane
antagonists on 2 smooth muscle preparations were studied, the guinea-
pig trachea and rabbit aorta. From these preliminary studies it was
hoped to make a comparison of the thromboxane receptors on smooth
muscle tissue to those on platelets.
These preparations in terms of thromboxane-like action are
relatively 'slow' preparations, whereby the onset of action of the
agonist or antagonist is relatively slow (30-60 minutes) and so the
only practical method of obtaining complete concentration-response
relationships is by cummulative addition of suitable doses to the
system.
Cummulative dose responses for 11,9-emPGH2 induced contraction
of the rabbit aorta and guinea-pig trachea are illustrated in
Fig.4.16. In the presence of the antagonists (AH23848, ON011120 and
BM13177), the concentration of agonist was suitably increased and
from the shift in the log dose response curve the dose ratios and
hence the pA-jo values were determined (Table 4.8).
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Table 4.7 PA10 value? (+ range?) for 0N011120 and EP092 again?t





Human EP092 6.77 7.85 6.61
(6.35-6.99) (7.82-7.86) (6.59-6.76)
ON011120 6.40 6.51 6.18
(6.23-6.52) (6.49-6.52) (5.96-6.48)
Rat EP092 6.84 6.86 6.58
(6.69-7.03) (6.69-7.05) (6.44-6.80)
ON011120 6.35 6.88 6.14
(6.25-6.65) (6.77-6.97) (5.93-6.36)
Rabbit EP092 5.75 6.04 6.02
(5.71-5.89) (5.84-6.21) (5.98-6.12)
ON011120 5.01 5.01 4.42
(4.93-5.14) (4.92-5.15) (4.22-4.73)
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Figure 4.16 Typical cumulative dope response curves for 11,9—
epoxymethanoPGH2 induced contractions in (A) rabbit







Table 4.8 PA-|o values determined for AH23848, 0N011120 and
BM13177 on guinea-pig trachea and rabbit aorta isolated
preparations. (11,9-emPGH2 was used as the standard
agonist)
Tissue
Guinea-pig trachea Rabbit aorta
Antagonist
(n) (n)
AH23848 7.20 1 5.68 1
0N011120 6.38 3 4.86 4
(6.16±6.53) (4.67±4.99)




Preliminary ligand binding studies were carried out on human
platelet membranes using the tritiated, 9,11-epoxymethano-pgh2
ligand. This radioligand was found to exhibit similar biological
activity to that of the unlabelled compound on washed human
platelets. Separation of bound from free ligand was achieved by
rapid filtration of the membranes through microfibre filters.
Washed platelet membranes were incubated with increasing
concentrations of [3h]-9,11-emPGH2 (4-400nM) in the presence of a
fixed concentration of cold 11,9-emPGH2 0 4yM) for 10 minutes at
37°C. The specific binding of [3h]-9,11-emPGH2 over this range was
determined by subtracting the non-displaceable binding from the total
binding (Fig.4.17). It is evident from these curves that on
increasing the concentration of [3h]-9,11-emPGH2 (> 50nM), there is
no further increase in displaceable binding (perhaps even a decrease)
indicative of a saturable system. It also appears that there is
considerable non-displaceable binding which ranges from 50-90$ at low
( [3h]-9,11-emPGH2 concentrations and as much as 80-97$ at high
concentrations. A large degree of non-displaceable binding reduces
the accuracy of the assay.
Despite high non-displaceable binding, attempts were made to
carry out displacement studies. Fixed concentrations of [3h]-9,11-
emPGH2 (50, 70nM) were incubated simultaneously with the displacing
agent, cold, 9,11-emPGH2 (0-14yM) for 10 minutes at 37°C. The
displacement curves are illustrated in Figure 4.18. Unfortunately,
the percentage of displaceable binding was low; 25$ at 50nM and 30$
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Figure 4.17 Binding of [3h]—9,11-epoxymethanoPGH2 to human platelet
membrane? over a concentration range (0-400nM).
Displaceable binding ha? been estimated as the portion
of total binding displaceable by excess cold 11,9-
epoxymethanoPGH2 0 4pM).
Each result is the mean ± s.e.m. of 3 observations.
 
Figure 4.18 Displacement of [3h]=9,11 -epoxymethanoPGH2 (50nM and
70nM) by 11,9-epoxymethanoPGH2.
Concentrationf11,9-epoxymethanoPGH2(pM)
at 70nM. Although a small displacement is evident (1-^yM), the
error is large, which makes it difficult to determine the exact
concentration range of free ligand which displaces the radioligand.
No improvement of the displacement curve was achieved by increasing
or decreasing the incubation period, or by increasing the ligand
concentration. The underlying cause of the large degree of error is
not clear. It may be due to either the low affinity (high
dissociation rate) of the ligand or perhaps its high lipophilicity.
Whatever the cause, it proved to be unsuitable ligand for extensive




Due to the labile nature of the naturally occurring agents, PGH2
and TXA2, agonist ranking measurements are generally carried out
using stable synthetic mimetics. The 11,9-epoxymethano analogue of
PGH2 shows a similar profile of activity similar to that of TXA2
(Coleman et al, 1981) and it was used in these studies as the
standard agonist against which the activity of other mimetics were
assessed. Seven agonists were tested on the platelet suspensions
from the 3 species. It is evident from tables 4.1 and 4.2 that
there are not any marked interspecies differences in both the
threshold aggregation concentration values and the EC50 values.
The apparently higher values observed with rat platelets may be
due to the nature of the aggregation wave. The onset of primary
aggregation is relatively slow compared to those observed with human
and rabbit platelets, but irreversible aggregation is attained within
the 2 minute incubation period. As a result, the primary and
secondary waves are kinetically distinct giving rise to a biphasic
response. It is possible that in rat platelets, this effects is due
to a less efficient triggering of the release reaction, and in effect
a higher concentration of agonist in necessary to induce release and
hence irreversible aggregation.
Table 4.3 lists the EPMR values for the seven agonists studied
and it is apparent from this data that the rank order of potency of
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the seven agonist? is similar in the 3 species. EP171 is the most
potent of all the agonists studied and as much as 23 times more
potent that the standard agonist 11,9-emPGH2. In fact EP171 is the
most potent thromboxane mimetic reported to date (Jones et al, 1985).
In platelets from all 3 species, a similar profile of activity of
EP171 was observed, and it is evident from Fig.^.3 that the log
concentration response curves are parallel in nature, the EP171 curve
lying further to the left.
Structure - activity relationships
On analysis of the structure of these agonists, it is evident
from Fig.3.2 that all have natural a chains and the 15-(S)-hydroxyl
group, despite other modifications to their structures. 11,9-emPGH2
is nominally endoperoxide-like with a modified ring structure - the
peroxide oxygen attached to C-9 has been replaced by a methylene
group. The 9,11-azo compound is also an endoperoxide analogue which
also shows high TX-like activity being about twice as potent as 11,9—
emPGH2. The 9a, 11a-oxa-1Oa-homo analogue may be considered a ring
hybrid of PGH2 and TXA2 (Sprague et al, 1983). It has high potency
being equiactive with 11,9~emPGH2 on human and rat platelets and
slightly more active on rabbit platelets.
The very high activity of EP171 can be correlated with the large
increase in potency seen when the 16-p-fluorophenoxy substitution is
made on rather weak thromboxane-mimetics (e.g. PGF2a -> ICI79939)
(Jones and Marr, 1977). However, it was by no means certain that
the substitution of this aromatic unit would produce a marked rise in
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activity when the parent was already a potent Tx mimetic.
In EP109 the 16-p-fluorophenoxy aubatituent haa been combined
with a pinane ring ayatem. On amooth muacle preparationa it behavea
aa a potent partial agoniat (relative maximum reaponaea ranging from
10-30%). On plateleta it behavea aa a full agoniat. Thia
difference may not be of any great aignificance aince the exact
nature of partial agoniat log concentration-reaponae curvea may be
dependent on both the receptor denaity in the ayatem and on the
'gain' of the poat-receptor eventa.
Other agoniata which have ring atructure related to TXA2 include
STA2 and CTA2 • STA2 waa in fact uaed in thia atudy and haa proved
to be a potent agoniat, three to nine timea more potent than 11,9-
emPGH2 in waahed platelet ayatema. It might be thought that
aubatitution of aulphur for oxygen at the 9.11 poaition haa
maintained thromboxane-like activity. However, the aituation ia not
aa aimple aa thia. The ayntheaia of the 9,11-oxy-11a carba analogue
of TXA2 haa been reported in the literature (Sprague et al, 1985) and
it ia reported to have virtually no Tx-like activity, nor doea it
block TX-receptora. Thia aituation warranta further inveatigation
in view of opinion expreaaed by N.H. Wilaon (peraonal communication)
that the forcing conditiona required for the cloaure of the
membered ring may have reaulted in a rearrangement reaction occurring
to give an iaomeric product. Thia view ia given aome credance by
the obaervation that the all-carbon ring veraion of TXA2 named CTA2
ia a potent TX-mimetic (Lefer et al, 1980). On human platelet
auapenaion CTA2 doea not produce irreveraible aggregation. One
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reason for this is its proposed ability to raise cyclic AMP levels
(this area will be dealt with later).
The natural endoperoxide prostanoid, PGH2, appears to be less
effective as a TX-agonist (1.3 ~ 2.0 times less potent than 11,9-
emPGH2) whilst the other agonists which are nominally endoperoxide
analogues, 11 ,9-epoxymethano, 9,11-azo and 9a, 11a-10-oxa-homo PGH2
were all found to be more potent than PGH2 itself.
It is probable that the increased potency of the synthetic
analogues is due to the fact that modifications to the endoperoxide
ring structures introduces chemical stability and therefore decreases
the extent to which the molecule will be metabolised. In addition,
there may be redirected metabolism of PGH2 to other prostaglandins
which in effect would decrease the amount of PGH2 available at the
thromboxane receptor.
The overall picture arising from these structure activity
relationships illustrates that modifcations of the ring structure and
the w chain alters the potency of an agonist and without doubt the
incorporation of a 16-p-fluorophenoxy group has the most marked
effect on potency. Furthermore, it is evident that the presence of
the 15—C hydroxyl group is essential for full thromboxane like
activity, removal of which gives rise to inhibitory actions. For
example, the 15-deoxy-9,11-azoPGH2 compound has been found to have
potent inhibitory action of arachidonic acid and endoperoxide induced
aggregation (Gorman et al, 1981).
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The data presented here so far illustrates a wide range of
structural analogues with varying degrees of aggregatory activity,
but despite the difference in relative potencies it should be
emphasised that there does not appear to be any marked interspecies
differences in their thromboxane-like activities.
A previous study has reported similar data in that the rank
order of potency of a range of agonists was similar when compared in
both human and rabbit platelet rich plasma (Maclntyre & Anderson,
1982). Based on their results and the data above on the relative
agonist potencies it would appear that there is no convincing
evidence that thromboxane receptor subtypes exist or in fact that
distinct prostaglandin endoperoxide and thromboxane receptors exist.
In addition, from a consideration of other published work concerning
other thromboxane-sensitive system, including vascular smooth muscle
and guinea-pig trachea, there also does not appear to be any marked
differences in thromboxane sensitivity with respect to
thromboxane/endoperoxide agonists (Jones et al, 1982; Armstrong et
al, 1985). Fig.4.19 illustrates the range of EC50 values for
thromboxane activity in several tissue and platelet systems. A
consideration of this data, in conjunction with other studies (Jones
et al, 1982; Armstrong et al, 1985) based on relative agonist
potencies supports the notion that there are no subtypes of the
thromboxane receptor. A consideration of thromboxane receptor
sensitivity with respect to antagonists will be discussed later.
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Figure 4.19 Sensitivities of 8 thromboxane-sensitive and 1 PGF-
sensitive preparation (dog iris) to selective
prostanoids. On smooth muscle preparations the symbols
indicate EC50 values for contraction whereas on washed
platelet suspensions, they represent concentrations
producing threshold aggregation waves.
* denotes the presence of 5pM AH6809.
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STA? activity in platelets
From the data presented here, STA2 appears to be a potent
agonist on platelets from human, rat and rabbit and consistently more
active than 11,9-emPGH2 (3~8 times more potent). These results are
in conflict with some recently published data (Narumiya et al, 1986)
where the potency of STAp was found to be much less (8 fold) in
rabbit PRP than when compared to human PRP. A comparison of their
EC50 values (1.75 and 8.17yM in human and rabbit PRP respectively)
with those presented here in washed platelet systems (0.02 and 0.01yM
in human and rabbit washed platelets), demonstrate STA2 to be about
100 fold and 800 fold less potent in PRP from human and rabbit
respectively. Although one would expect a decrease in potency of
the agonist due to plasma-protein binding, an 800 fold difference is
perhaps rather excessive to be explained merely by this.
A comparison of STA2 activity in PRP and washed platelets was
made employing similar experimental conditions (Table 4.9). This
data shows only a 10 fold reduction in potency of STA2 when PRP of
rabbit and human blood is used. This magnitude of decreased potency
in PRP is what might be expected from plasma-protein binding.
Furthermore, the EC50 values in human and rabbit washed platelet
suspensions were not markedly different in this study.
It would appear therefore that the discrepancies in Narumiya's
results on STA2 activity in rabbit platelets cannot be explained
solely by increased plasma-protein binding and as yet the precise
reasons remain obscure. Although a full steep dose response curve
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Table 4.9 ^50 values (nM) of STA2 induced aggregation in human
and rabbit platelets using PRP and washed platelet
suspensions




for STA2 was obtained at lower STA2 concentrations (0.01 - 0.10yM) in
all 3 species, a reduction in the maximal response was obtained at
STA2 concentrations over 0.25yM in human platelets. Possible
explanations for this effect were sought. Neither the prostaglandin
D2 antagonist, AH6809 nor the adenylate cyclase inhibitor, SQ22536
was found to reverse the inhibition evoked by STA2. This would
suggest that the inhibition is not due to an interaction with a PGD2
receptor or that elevations in cyclic AMP are solely responsible.
However, since SQ22536 does not fully inhibit the adenylate cyclase
enzyme, perhaps the degree of inhibition by SQ22536 may not be
sufficient to lower cyclic AMP below its threshold inhibitory level.
It is well known that only very small increases in cyclic AMP levels
are enough to exert full inhibition on platelet activity (Tateson et
al, 1977; Harris et al, 1979). The use of a more potent adenylate
cyclase inhibitor, a stimulator of phosphodiesterase or ideally a
PGI2 receptor antagonist would perhaps elucidate the mechanism
underlying this inhibition. The demonstration that AH6809 did not
have any effect on the inhibition would rule out the possibility of a
PGD2 receptor activation of cyclic AMP since this compound is a PGD2
receptor antagonist and its action is much more direct than enzyme
inhibitor. The possibility of STA2 overcoming the receptor block by
AH6809 is improbable since STA 2 likely to exhibit only a weak
action at the PGD2 receptor reflected by the fact that even at high
concentrations, STA2 never induces full inhibition of PAF aggregation
response.
Despite the lack of effect of SQ22536 on the inhibition by PAF,
there did appear to be an elevation in cyclic AMP levels above the
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basal (by about 1.5-1.8 fold) and although these levels were not high
it is possible that they are sufficient to exert the inhibitory
effect that was observed. The inhibition appears to be induced only
by STA2 since high concentrations of 11,9-emPGH2 neither inhibit PAF
induced aggregation (Fig.*1.5) nor raise cyclic AMP much above basal
levels (Fig.4.7).
CTA2 which is structurally similar to STA2 has also been found
to raise cyclic AMP levels by as much as 4-fold. The onset of the
inhibitory effect follows that of the thromboxane-like effect and
consequently reversal of the rapidly developing primary wave is seen.
Abolition of the cyclic AMP elevating action of CTA2 may result in
irreversible aggregation (i.e. CTA2 may truly be a full agonist on
the thromboxane system). In fact, CTA2 was studied in the presence
of SQ22536 (250|iM), but there did not appear to be any reversal of
effect. Again the possibility that SQ22536 was not sufficiently
inhibiting the adenylate cyclase enzyme to prevent total production
of cyclic AMP could possibly be an explanation for this lack of any
effect. However, one cannot exclude the possibility that STA2 and
perhaps also CTA2 may exert an inhibitory effect through mechanisms
other than those involving elevations in cyclic AMP.
Partial agonist activity
Three structural analogues all demonstrating partial activity
were studied on platelets from man, rat and rabbit.
116
EP167 and EP204
EPl67and EP204 are structurally similar in that they possess
identical a and w chains and a bicyclic ring structure. Although
full aggregation is never attained with either of these agonist,
small primary aggregation waves were obtained as shown in Fig.4.9.
Although these partial agonists act on the thromboxane/endoperoxide
receptor to induce weak agonist activity it is probable that they do
not exhibit high enough efficacy to induce a full response hence the
reason why increasing the partial agonist concentration never results
in full aggregation. The TAC (Table 4.4) for these 2 partial
agonists show that there is not a great difference in the activity
when compared in the 3 species. Rabbit platelets appear to be
slightly more sensitive to their TX like action. The scatter of
values is quite large, whether it is due to the variable presence of
a secondary factor or due to small numbers is not known. Increasing
the numbers of experiments would show whether or not the slight
increased sensitivity of rabbit platelets is a genuine species
difference.
EP167 is marginally more potent that EP204 and this increased
activity is consistently observed in the 3 species. This increased
activity may be attributed to the presence of an etheno group in the
ring, since this is the only difference in their 2 structures. When
comparing their ability to inhibit 11,9-emPGH2 induced aggregation,
EP167 is again marginally more potent (Table 4.6). It is possible
that EP167 has a higher affinity than EP204 for the
thromboxane/endoperoxide receptor hence the increased inhibitory
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effect of EP167. Although in this instance, EP167 is marginally
more potent with respect to its agonist activity as well as its
ability to inhibit 11,9~emPGH2 aggregation, this need not always be
the case when comparing activities of 2 partial agonists since one
may have a higher efficacy to produce agonist like action but have
lower affinity for the receptor and so therefore will have a weaker
inhibitory effect. These two parameters are independent of each
other and one way of determining the affinity of these partial
agonists would be to carry out ligand binding studies where efficacy
is no longer important.
In line with the data from the full agonists, the platelets from
the 3 species are equisensitive to these partial agonists,
reinforcing the notion that thromboxane receptor heterogeneity is not
apparent when looking at agonist like effects.
PTA?
The pinane thromboxane analogue, PTA2 has been found to
consistently exhibit partial agonist activity on smooth muscle and
human platelet systems (Armstrong et al, 1985). In addition, it has
been found to inhibit aggregation induced by non-thromboxane agonists
including PAF and ADP. This additional activity may be due to
functional antagonism of PTA2 at either PGD2 or PGI2 receptors and
may in fact explain the large differences observed in the inhibitory
potency of PTA2 on 11,9~emPGH2 induced aggregation observed in human
rat and rabbit platelets (Table ^.5).
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PTA2 produced shape change responses, but primary aggregation
waves were never observed. These small changes were in fact
inhibited by EP092 which would indicate that they are due to a
thromboxane agonist like action.
The precise mechanisms underlying the dual action exhibited by
PTAp on human platelets is not clear, but Armstrong et al (1985) have
found that PTA2 has the ability to elevate cyclic levels above basal
and although the increases are small, they may in fact be sufficient
to exert an inhibitory effect on platelet aggregation.
Table 4.5 illustrates the wide range in the IC50 values for PTA2
in the 3 species, and it is evident that human platelets are much
more sensitve to the blocking action of PTA2; about 10 fold and 100
fold greater than in rat and rabbit respectively.
The nature of this inhibitory action was investigated in the 3
species by studying the effect of PTA2 on PAF induced wave
aggregation in human and rabbit platelets and ADP induced aggregation
in rat platelets. It is apparent from Fig.4.10 that PTA2 has a
significant inhibitory activity on PAF aggregation in human
platelets. Negligible inhibition was observed on rat and rabbit
platelets. This is compatible with the demonstration that PTA2 also
has the most potent inhibitory effect on 11,9-emPGH2 induced
aggregation in human platelets. In principle partial agonists
inhibit full agonist action by occupying the same receptor, but
evidence here points to the fact that PTA2 exhibits additional
inhibitory effects. If indeed this inhibitory effect was mediated
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by elevation? in cyclic AMP through activation of the PGD2 or PGIp
receptor then it i? possible that the adenylate cyclase inhibitor
(SQ22356) would reduce this inhibition through suppression of the
enzyme activity. An experiment whereby human platelets were pre-
incubated with SQ22356 (250yM) before the addition of PTA2 was
carried out and as illustrated in Fig.4.11, the presence of SQ22356
did not reduce the inhibition by PTA2 on 11,9-emPGH2 induced
aggregation. This at first would suggest that cyclic AMP ha? either
no or only a minor role in the PTA2 induced inhibition. In spite of
these findings it should be considered (as discussed previously) that
this SQ22536 compound does not fully inhibit the adenylate cyclase
enzyme and so although there may be a reduced amount of cyclic AMP
produced, the reduced level of cyclic AMP may still be sufficent to
inhibit the response as only small elevations above basal levels are
necessary for responses to be inhibited.
With regard to the wide range of IC50 values of PTA2 obtained
from human, rat and rabbit platelets, it may be of relevance here
that there is also a wide range of inhibitory activities by the
prostacyclin mimetic, Iloprost in the same 3 species. In fact the
rank order of potency of Iloprost is such that human platelets are
the most sensitive and the rat and rabbit least sensitive to its
inhibitory action (Armstrong et al, 1986). It is possible that the
differences in the IC50 values of PTA2 in these 3 species, may be
accounted for by differences in the sensitivity of the PGI2 or PGD2
receptors.
Of the 3 compounds exhibiting partial agonist activity, EP167
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and EP204 show no inhibition of aggregation induced by non-
thromboxane agonists, with only PTA2 demonstrating the ability to
block PAF induced aggregation in human platelets. It is possible
therefore on this basis to distinguish between compounds with true
partial agonism at the thromboxane/endoperoxide receptor and those
with other actions as well as partial agonist activity. PTA2 falls
into the latter category. Since PTA2, structurally resembles the
parent compound, TXA2 with natural a and w chains, the very weak
agonist action of PTAp must undoubtedly arise from substitution of
the oxane ring system with carbon atoms, and the addition of the 2
bulky methyl groups at the C-10 position.
Other compounds with similar ring structures include EP109.
This compound is a full agonist, whose activity must undoubtedly be
attributed to the presence of the 16-p-fluorophenoxy group.
ON011120, EP115 and pta < > zil also possess pinane ring structures
and these compounds are in fact specific thromboxane/endoperoxide
receptor antagonists. Their lack of agonist activity must be due to
the loss of the 15-(S) hydroxyl group as well as further
modifications to the w chain.
Comparison of the actions of thromboxane receptor antagonists
The basic aim of the following studies was to evaluate
thromboxane antagonist activity on platelets from human, rat and
rabbit blood. The antagonists shown in Fig.4.12 were studied in
washed platelet preparations from these 3 species. All have been
reported to have selective thromboxane/endoperoxide antagonist
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activity with minimal actions on other prostanoid systems.
A comparison of their antagonist activity in the 3 species was
made and Table 4.6 summarizes the results of these antagonists in
these 3 species.
Several important findings emerge from these results:
(i) Firstly, all 7 antagonists exert significant antiplatelet
effects, extending over a wide range of pA-jo values (4.91 - 7.15),
corresponding to almost 100-fold difference in molar concentrations.
Despite their wide range of activity the rank order of potency for
the antagonists is similar in the 3 species; human, rat and rabbit.
(ii) Secondly, all of the antagonists with the exception of BM13177
are more potent as blocking agents on human and rat platelets, than
on rabbit platelets. The pA-jg values determined for the rabbit
platelet thromboxane/endoperoxide receptor are 1 order of magnitude
lower than those determined from either human or at platelets.
BM13177 is equiactive on platelets from all 3 species.
(iii)Thirdly, ON011120 is significantly less potent on the rabbit
platelet (by 1.5 orders of magnitude) in comparison to the other
antagonists which are only about 1 order of magnitude lower than on
human or rat platelets.
The possibility that 0N011120 was exerting some additional
inhibitory action on human and rat platelets resulting in a higher
blocking effect was considered. Essentially, 0N011120 has a pinane-
ring system, similar to that of PTA2 and since this compound has been
found to exhibit inhibitory activity possibly due to elevations in
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cyclic AMP, the effect of 0N011120 on PAF and ADP-induced aggregation
in human and rat platelets respectively was investigated. However,
ON011120 did not exert an inhibitory effect on these agonists. The
apparent difference in the antagonist potency of 0N011120 between
human/rat and rabbit, is possibly due to a genuine specific effect of
ON011120 at the thromboxane/endoperoxide receptor.
The AH23848 compound although it appears to behave as a
competitive thromboxane antagonist at concentrations shifting the log
dose response curve by 1 log unit, at concentrations in excess of
these (10-400nM in human platelets and 50-1OOnM in rat platelets),
the curves appear to be no longer surmountable indicating that
competitive antagonism no longer exists (Fig.4.15). This effect was
not apparent when using AH238il8 in rabbit platelets even although
much greater concentrations of the compound were needed to produce a
block. The primary aggregation waves of PAF and ADP in human and
rat platelets respectively were not inhibited in the presence of
AH238M8. This would suggest that AH238i)8 is unlikely to be
elevating cyclic AMP at these concentrations. A possible
explanation for this unsurmountable effect is that AHZSS1^ could
itself be acting in an irreversible manner at high concentrations
whereby it may be forming covalent bonds at the receptor site. In
order to show this, one could incubate a platelet suspension with
high concentrations of this antagonist and then finding a suitable
method of washing the platelets to remove the antagonists. If the
antagonists were binding in a reversible manner the platelets should
retain their ability to aggregate.
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Another explanation for this effect could arise from the fact
that this compound is not very stable, the presence of the hydroxyl
group may cause it to readily dehydrate and it is possible at high
concentrations, by-products may exert non-specific effects. Despite
these findings, it is assumed that AH23848 is behaving as a
competitive antagonist at lower concentrations and so the relative
potency determined in the 3 species are still valid.
It would appear therefore that with regard to the antagonist
potencies, the rabbit platelet thromboxane receptor is the least
sensitive to the blocking action of all antagonists reflected by
lower pAio values, which reflects a lower affinity of the rabbit
thromboxane/endoperoxide receptor.
The possibility exists that the rabbit receptor in fact
represents an endoperoxide receptor. If this were the case
endoperoxide analogues would be more potent in their actions on
endoperoxide receptors than on thromboxane receptors, making it more
difficult to block, resulting in apparently lower affinities of the
rabbit receptor. With this consideration in mind, the blocking
potencies of both EP092 and ON011120 were compared against the
naturally occurring parent compound, PGH2 and STA2 (the latter
nominaly a thromboxane-like analogue) to determine whether there was
any difference found between the 3 species.
Table 4.7 lists the pA-|Q values for 0N011120 and EP092 against
STA2> PGH2 and 11,9-emPGH2 in the 3 species. With the exception of
STA2 in the presence of EP092 in human platelets this data is
124
comparable with the pA-jg values of the same antagonists determined
when 11,9-emPGH2 as the agonist. There is very little difference in
the potency of EP092 and 0N011120 against STAp and PGH2. From this
data there is no compelling evidence to suggest that the rabbit
receptor represents an endoperoxide receptor.
The finding that in human platelets EP092 exerts a much greater
blocking potency against STA2 may in fact be related to the
additional inhibitory activity of STA2. If this were the case, the
stimulatory activity of STA2 would be working against 2 opposing
inhibitory actions; (i) the specific antagonist effect of EP092 and
(ii) the non-selective inhibitory activity of STA2 at the higher
concentrations, therefore producing a larger shift to the right in
the log dose response curve, resulting in a larger pAig value which
may not be reflecting the true antagonist activity.
The antagonists studied fall into 3 clearly defined chemical
classes; (a) those which are basically modified
thromboxane/endoperoxide structures, (EP169, EP092, 0N011120, EP115
and PTA < > ZII (S)), (b) those derived from prostanoid structures
although bearing no resemblance to thromboxane/endoperoxides
(AH23848) and (c) those which bear no resemblance at all to
prostanoids (BM13177). Those in class A can be further divided into
two groups; EP169 and EP092 which are bicyclic semicarbazone
compounds with similar w chains. EP169 also has a modified a chain.
0N011120, EP115 and PTA < > ZII (S) possess indentical pinane-ring
structures and natural a chains, but differ in their w-chains.
0N011120 is an aza-pinane derivative developed from the combination
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of 2 classes of antagonists, the aza prostanoids (Le Breton, 1979)
and the pinane series (Nicolaou et al, 1979). PTA < > ZII(S)
differs from 0NO11120, where the NH-group at the carbon 13 position
is replaced by a double bond. EP115 on the other hand has a
semicarbazone group incorporated into the w chain, structurally
similar to the w chain of EP092 and EP169, but where the thiol group
is replaced by a carboxyl group. AH23848 which falls into class 2,
has nominally a PGD2 like structure, with a modified w chain and the
replacement of a diphenyl substituent at the C-9 hydroxyl group.
Finally, BM13177, the only non-prostanoid compound, is in fact an
achiral molecule and basically a sulphonamide derivative. Of these
antagonists, EP169, EP092 and AH23848 are the more potent reflected
by their higher pA-|Q values. The increased potency of EP169 may be
attributed to the difference in the ring structure. EP169 has
essentially a bicyclo-octane ring system whilst EP092 a bicyclo-
heptane ring.
Although a range of antagonist structures have been studied, the
limited number does not allow a meaningful structure-activity profile
to be drawn up.
The data presented here undoubtedly suggests that the rabbit
platelet thromboxane receptor is different with respect to its
affinity for several antagonists. At present, it is not possible to
conclude that these differences represent subtypes of the platelet
thromboxane receptor, but it is possible that if a wider range of
antagonists were studied one may be found which is actually more
potent at the rabbit platelet thromboxane receptor. From several
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line? of evidence it has been suggested that the thromboxane
receptors on platelets are in fact different from those on vascular
tissue (Lefer et al, 1980; Gorman, 1981; Mais et al, 1985A and B).
The platelet represents a complex situation whereby the autocatalytic
nature of the platelet creates the problem in that it is difficult to
determine whether equilibrium occupancy has been reached and, it is
therefore possible that complete aggregation occurs well before
equilibrium occupancy it attained. On the other hand, with smooth
muscle preparations cummulative dose response curves are obtained and
equilibrium is assumed to be reached once the contraction with a
given concentration of agonist has plateaued. The differences
observed in the activity of agonists or antagonists may in fact
reflect differences in the two experimental systems due to the
difficulties in establishing equilibrium. Furthermore, drug
distribution between the aqueous and lipid phase in the region of the
receptor may not be uniform in smooth muscle tissue preparations due
to the highly lipophilic nature of the many analogues.
The studies described above on the platelets were extended to
consider the effect of some of the antagonists on two smooth muscle
preparations: guinea-pig trachea and the rabbit aorta. PA10 values
for ON011120, AH23848 and BM13177 were determined for these
antagonists and Table 4.8 demonstrates that the blocking potency is
much lower on the rabbit aorta. In fact the pA-|Q values found for
guinea-pig trachea are very similar to those found on human and rat
platelets, whilst the pA-jg values for the rabbit aorta are comparable
to those on the rabbit platelet.
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Other groups have demonstrated that of several thromboxane-
sensitive smooth muscle preparations, the rabbit aorta is
consistently less susceptible to the blocking action of various
thromboxane antagonists; EP045 (Jones et al, 1982), EP092 (Jones et
al, 1984) and AH23848 (Brittain et al, 1985). Despite the
constraints of comparing data from different pharmacological systems
it is evident from the data presented here and that of other groups
that the affinities of thromboxane receptor antagonists on the smooth
muscle preparations; guinea-pig trachea and dog saphenous vein are
comparable to those found for human and rat platelets. The
affinities for thromboxane receptor antagonists for rabbit platelets
are indeed very similar to those found on the rabbit aorta, whereby
in both systems, a much lower affinity is observed. It would
therefore appear that the thromboxane receptor mediating aggregation
in human and rat platelets is similar to the corresponding receptors
mediating contractions in vascular and respiratory smooth muscle.
Perhaps the differences observed on the rabbit aorta and rabbit
platelets represent a subtype of thromboxane receptor confined to
that species. It is appreciated that direct binding ligands may
lead to the elucidation of thromboxane recptor subtypes fulfilling
the definitive receptor criteria.
The use of radioligands for characterisation of the receptors
has lagged behind the pharmacological approach mainly because of the
unavailability of a suitable radiolabelled ligand. Several ligands
have been synthesised and used for radioligand binding studies
including [3h]-13_azaprostonoic acid (13-APA) (Le Breton et al, 1979;
Hung et al, 1983), [3h]-9,11-epoxymethanoPGHp (Kattleman et al, 1986;
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Armstrong et al, 1983 and Pollock et al, 198^), j]—cis—13-APO, a
structural analogue of 13-APA (Halushka, et al, 1985) and [ "* ^5 j ]-p-rA-
OH (Mais et al, 1985C; Saussy et al, 198M). The use of these
ligands have clarified several important properties of the platelet
thromboxane receptor with regards to the specificity of binding and
its correlation with biological activities. However there are
discrepancies among the results on the studies carried out concerning
the number of binding components and density of binding sites. Some
of these discrepancies may possibly be merely attributed to
procedural differences, for example comparing data from PRP versus
washed platelet systems and also intact platelets versus platelet
membranes.
Radioligand binding studies using an appropriate radioligand may
therefore help to characterise the platelet thromboxane receptor
from different species and perhaps clarify whether the lower
antagonist affinity of the rabbit receptor demonstrated
pharmacologically is correlated with a lower binding-site affinity
determined from radioligand binding studies. Such studies may also
be of great value when comparing responses that are not only very
different in character (contraction versus aggregation) but also when
one system is protein-rich (PRP) and another a protein-free bathing
solution. Thus if binding studies were carried out on smooth muscle
tissue, studies of this kind may help to elucidate the differences
that exist between rabbit platelet/aorta thromboxane receptors, with
those on guinea-pig trachea and human/rat platelets. Using a
tritiated labelled ligand 9,11-emPGH2, preliminary studies on human
platelet membranes were carried out in this thesis. These studies
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yielded unsatisfactory results from which it was not possible to
extrapolate any meaningful data. Displacement curves were
associated with a large degree of error and at first this was
attributed to the lipophilic nature of 9,11-emPGH2 which could
account for the high degree of non-saturable binding. It has since
been considered that the low affinity of this ligand for the
receptor /binding site with a Kp possibly in the micromolar range
would contribute to the large degree of error. In these studies the
method of separation of bound from free ligand was by filtration and
it is possible that in this instance the time elapsing during this
separation period was much greater than the actual half-time for
dissociation of bound ligand. This would result in a loss of bound
ligand from the system. It has been reported that the time required
for separtion of bound from free should be less that one seventh of
the half-time of dissociation of bound ligand (Bennet, 1978). In
addition, the 9,11-epoxymethanoPGH2 ligand has been shown to interact
with the thromboxane synthetase enzyme which it inhibits (Moncada and
Vane, 1979). When using membrane preparations, error may arise from
binding of the ligand to the enzyme, rather than the receptor site
and so it may not be the suitable ligand.
The problems encountered in these preliminary studies would
possibly be overcome by using a more specific ligand with higher
affinity for the putative receptor, lacking in efficacy and
radiolabeled to a high specific activity (an advantage when receptor
density is low or if biological material was limited). Indeed the
[125j]-p7a-0H ligand meets these criteria and recent studies have
shown it to display saturable and specific binding to a putative
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thromboxane/endoperoxide receptor (Saussy et al, 1985). Their
radioligand binding data correlates with biological data. The use
of this ligand may in fact provide the necessary data to further
characterise the platelet thromboxane receptor in different species.
In, recent studies by Narumiya et al (1986) who have used this ligand
to compare the binding activity with the anti-aggregatory activity of
0N011120 in platelets from different species. They found specific
binding activity on washed human and dog platelets which correlated
well with the biological activity but failed to see specific binding
on rabbit platelets. Based on these findings they suggested that
there are differences in the ligand binding structures of the
platelet receptor in different species. Considering the data
reported in this chapter, micromolar concentrations of ON011120 were
necessary to produce thromboxane antagonism in washed platelet
suspensions. Since, Narumiya et al (1986) in fact used only
nanomolar concentrations of the antagonist in PRP system, it is
possible that specific binding would have been revealed if higher
concentrations of the ligand were used, especially with rabbit
platelet membranes.
In summary, this chapter describes the nature of the thromboxane
receptor with respect to its sensitivity to agonists, partial
agonists, and antagonists in human, rat and rabbit platelets
suspensions. The data presented here provides convincing evidence
that platelets from all three species are equisensitive to the
thromboxane-like action of several agonists and partial agonists.
These findings are in support with the data of thromboxane-
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agonist sensitivity on other tissue preparations (Fig.4.19). It is
evident that there is no significant difference in the agonist
potency. However, differences in antagonist potency are observed in
platelets from these three species, the rabbit platelet receptor of
lower affinity. Similarly, a marked difference in the affinity of
antagonists (EP092, EP045, AH23848) is found when comparing several
tissue preparations, the rabbit aorta having a lower affinity for
these antagonists (Jones et al, 1984; Humphrey & Lumley, 1986).
In light of these findings could this data suggest the
possibility of either more than one binding site at the
endoperoxide/thromboxane receptor or perhaps an interconvertable
site? The latter situation may occur if there was one binding site,
which could be of two interconvertible forms, an active and an
inactive state. Only when the agonist binds to the active state is
a response produced. Binding of either agonist or antagonist to the
inactive state, produces no effect. It is possible that the
antagonist only binds when the receptor is in the latter form and
perhaps, in the rabbit, this form has a lower affinity for the
antagonist.
Obviously, it would be necessary to investigate the nature of
the binding site at the molecular level before one could provide an






Diabetes is a condition which occurs either because of a lack of
insulin or because of the presence of factors that oppose the action
of insulin. The result of insufficient insulin is an increase in
blood glucose concentration (hyperglycaemia) as well as other
metabolic abnormalities, notably an increase in ketone bodies in the
blood. Although hyperglycaemia is a common factor in different
types of diabetes, the underlying causes vary, as does treatment and
long-term outlook. The majority of diabetics have 'primary'
diabetes which can be of two types (i) insulin-dependent and (ii)
non-insulin dependent diabetes.
Diabetes is a disease often associated with clinical
complications and patients with longstanding diabetes may develop
complications affecting the eyes or kidneys (microvascular
complications), nerves or major arteries. Coronary artery disease
is commoner in diabetics than in non-diabetics, especially younger
women with diabetes of long duration in whom the prevailence of this
disorder approaches that of men. This contrasts with the
differential prevailence in non-diabetics, where the complaint is
much commoner in men.
The cause of microvascular and macrovascular complications is
not understood, but diabetes mellitus is frequently found to be
associated with abnormal platelet and endothelial function.
Abnormal platelet deposition and thrombus formation may explain the
increased incidence of atherosclerosis and other microvascular
complications. However, other possible considerations concerning
the relation between altered platelet and endothelial function and
vascular disease must be taken into account; (i) diabetic vascular
disease could infact cause the platelet/endothelial defects; (ii)
the abnormalities could be both contributory to and result from the
vascular disease and (iii) the two may be totaly unrelated.
Despite other possibilities, most studies are carried out on the
basis that altered platelet/endothelial function as a consequence of
diabetes may contribute in some way to the diabetic vascular disease.
Indeed if this is the case, the following findings would be
expected:-
(i) Altered platelet function would be apparent in diabetics before
the manifestation of vascular disease. Platelet sensitivity to
aggregating agents, production of pro-aggregatory prostaglandins and
metabolites, activation of platelets 'in vivo' reflected by
thromboglobulin levels and perhaps 'in vivo' platelet survival are
some of the parameters which may be affected.
(ii) Impaired endothelial function may occur and could be reflected
by a decrease in production of prostacyclin (synthesised by
endothelial cells), an increase in the von Willebrand factor
(endothelial protein) and a decrease in fibrinolysis due to
diminished release of plasminogen activation by the endothelium.
(iii)An improvement in altered platelet and/or endothelial function
with insulin therapy implying that the defect(s) is related to the
insulin-deficient diabetic state.
(iv) A detection of platelet microthrombi at some stage in
experimental diabetes.
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(v) A diminished rate of progression of diabetic vascular disease
with anti-platelet drug therapy.
Hypersensitivity of platelets to aggregating agents is a
frequent phenomenon occurring in diabetics. Halushka et al (1977)
reported that platelets from diabetics produce more prostaglandin E
like material upon exposure to aggregating agents such as ADP,
adrenaline, and collagen. More recently it has been found that
platelets from diabetics synthesise more thromboxane from arachidonic
acid than do platelet from control subjects (Colwell et al, 1983;
McDonald et al, 1982). Similar results have been obtained in
spontaneously diabetic BB Wistar rats, whose platelets produce more
thromboxane in response to ADP collagen or thrombin (Subbiah and
Deitermeyer, 1980; Gerrard et al, 1980; Landgraf-Leurs et al, 1982
and McDonald et al, 1982). The origin of the increased
prostaglandins and thromboxanes is not clear. It has been suggested
that platelets from diabetics either free more arachidonate from
membrane phospholipids upon stimulation (Halushka et al, 1977;
Gerrard et al, 1980) or convert more arachidonate to metabolites
(Colwell et al, 1983). In fact, enhanced secondary phase
aggregation of diabetics was found to be corrected by the
administration of aspirin, (Sagel et al, 1975). In addition, Morita
et al (1983B) have postulated that platelets from diabetics have a
higher percentage of arachidonate in membrane phospholipids. These
findings were in fact demonstrated in diabetics who already had signs
of vascular disease, but increased prostaglandin and thromboxane
production (Stuart et al, 1979; Butkus et al, 1980) as well as
increased platelet sensitivity (Sagel et al, 1975; Halushka et al,
136
1981; Janka & Demel, 1981) have been reported in diabetics free from
microvascular complications (an absence of retinopathy by
opthalmologic examination in patients is usually a major indicator of
the microvascular status). In support of these findings similar
effects were demonstrated in the experimental animal model with
diabetes in the early state (Johnson, 1979A; Gerrard et al, 1980;
Rosenblum et al, 1981).
Blood vessels from patients with diabetes and from diabetic rats
have been found to synthesise less prostacyclin than vessels from
normal subjects (Colwell et al, 1983; Gerrard et al, 1980 and
Johnson et al, 1979B) reflecting an altered endothelial function in
diabetics. Since it has been suggested that prostacyclin may
protect the endothelium against platelet deposition, perhaps an
altered balance of prostacyclin/thromboxane in diabetics may in fact
promote the onset of vascular disease.
A number of circulatory substances relevant to coagulation
including lipids (Stuart et al, 1981), fibrinogen and the von
Williebrand factor (Lamberton et al, 198^4) have been found to be
abnormal in diabetic patients. An increased cholesterol
incorporation in the platelet membrane has been reported in
diabetics. This may promote increased release of arachidonate from
platelet phospholipids and hence increase thromboxane production.
If there is a direct relationship between high cholesterol and
increased thromboxane, the platelet hypersensitivity could well be a
consequence of abnormal plasma lipid concentrations.
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Non-enzymatic glycosylation of collagen in diabetics may be
another contributory factory in platelet hypersensitivity (Le Pape et
al, 1983). Glycosylated collagen from diabetics is a more potent
platelet aggregating agent than collagen from control subjects. It
is possible that overglycosylated collagen in the vessel walls of
diabetics could enhance platelet adhesion, aggregation and the
release of platelet granule contents at the site of vessel injury.
Although the effect of overglycosylated collagen on platelets may
play a part in the development of vascular disease in diabetics, it
will not be related to platelet hypersensitivity to other aggregating
agents.
Shortened platelet survival and platelet hypersensitivity have
been reported in diabetes and other conditions (angina pectoris,
hypertension and myocardial infarction) that are associated vessel
injury and atherosclerosis (Mustard & Packham, 1977). The precise
relationship is not clear. Perhaps an increased rate of platelet
clearance could result from increased platelet adherence at the site
of vessel injury and lead to increased platelet turnover.
Beta-thromboglobulin (£TG), a specific platelet protein which is
stored in platelet a granules is released to the surrounding plasma
during platelet aggregation. Its presence in the circulation
reflects 'in vivo' platelet activation. Elevated g-thromboglobulin
levels have been found in diabetic blood, including newly diagnosed
diabetics free from angiopathy (Preston et al, 1978; Betteridge et
al, 1981; Burrows et al, 1978).
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These findings are indeed in favour of a role of apparent
altered platelet/endothelial function in the genesis of vascular
complications and added support is gained from reports that platelet
microthrombi are evident in retinal microvessels very early on in the
diabetic state (Ishibashi et al, 1981).
If there is a direct causal relationship between abnormal
platelet/endothelium function and vascular disease, it would be hoped
that pharmacological intervention to reduce platelet and endothelial
abnormalities, would delay or prevent the occurrence of diabetic
vascular disease.
In choosing suitable therapy for the prevention or delaying of
vascular disease, the underlying mechanism of enhanced platelet
aggregation must be established. The most consistent finding has
been the increased production of aggregation-induced thromboxane A2
(Halushka et al, 1981; Silberbauer et al, 1981). Most studies to
date have employed arachidonate or collagen (which releases
endogenous arachidonate) to demonstrate enhanced platelet aggregation
(Petersen and Gormsen, 1978; Davis et al, 1978). However, it
cannot be determined from these studies whether improved thromboxane
receptor coupling or an increase in the number of thromboxane
receptors may also contribute to this increased sensitivity.
The first study (Study I) in this chapter was therefore aimed at
investigating the changes at the receptor level in platelets from
diabetics with established micro-angiopathy. Using a stable
thromboxane mimetic, 11,9-epoxymethanoPGH2 which directly stimulates
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the thromboxane receptor, it was possible to compare the sensitivity
of the platelets at the receptor level from diabetic patients to
those of control subjects. Platelet sensitivity to collagen was
also investigated to confirm platelet hypersensitivity to this agent.
Although the intervention at the platelet/endothelial level is
one possible approach to control vascular complications, it is
possible that careful metabolic control may restore platelet function
to normal in diabetic patients. Beneficial effects of insulin
therapy on platelet function include a fall in ft-thromboglobulin
levels (Preston et al, 1978) and a decrease in whole blood
aggreg ability (Juhan et al, 1982). However several observers have
reported an increase in sensitivity of platelets to aggregating
agents 'in vitro' after insulin (Janka and Demmel, 1981; Hilsted et
al, 1980). Due to the inconsistent findings it is therefore still
not clear whether metabolic control does restore platelet function to
normal. Inconsistencies may arise because of the diverse methods
employed in studying platelet function and the difficulty in
maintaining a close control over diabetic groups. The aim of the
second study (Study II) was therefore to investigate whether there
were any changes in certain aspects of platelet function (platelet
sensitivity to the aggregating agent, ADP, the anti-aggregatory
agent, Iloprost, thromboxane production and adenylate cyclase
activity reflected by cyclic AMP levels) in two groups of young
insulin-dependent diabetics in which glycaemic control was
significantly improved in one group.
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RESULTS
Study I - Platelet Thromboxane Receptor Sensitivity in Healthy
Volunteers and Diabetic Patients with Background and Proliferative
Retinopathy
Patients
The patients studied were type I (insulin-dependent) diabetic
patients, 12 with background and 12 with proliferative retinopathy.
These patients were compared with 12 non-diabetic healthy volunteers.
The three groups were comparable for age and sex, and the diabetic
groups were matched for duration of diabetes. Blood glucose levels,
percentage haemoglobin A (HbA), and platelet counts were measured at
the time of study and no significant difference was found between the
two diabetic groups. These parameters are summarised in Table 5.1.
Persistent hyperglycaemia modifies (glycosylates) haemoglobin A and
these levels reflect blood glucose concentrations. Unlike blood
glucose levels .glycosylated haemoglobin concentration (HbA-|) do not
fluctuate from hour to hour and give an indication of blood glucose
levels up to four weeks before the sample was taken. They are
therefore useful in a long-term assessment of control.
Classification of retinopathy was based upon opthalmoscopic and
fluorescein angiographic appearances in all patients. In the
background retinopathy group, three patients had scattered
microaneurysms and haemorrhages, seven patients had hard exudative
changes and two patients had ischaemic preproliferative changes.
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None of the diabetic subjects were taking any medication other than
insulin, all were clinically free of nephropathy (urine Albustix
negative and plasma creatinine less than 150ymol/l) and all had
easily palpable peripheral pulses. Blood was collected between 0800
and 0900 hours from fasted diabetics and control subjects.
Results I
A comparison of dose-response curves for aggregation induced by
11,9emPGH2 in the presence and absence of froben (10yM) and EP092
(0.25yM) in control and platelets from diabetic donors was carried
out. The nature of the aggregatory waves in control and diabetic
subjects was similar.
11,9emPGH2 acts directly at the platelet thromboxane receptors
to induce platelet aggregation. Secondary aggregation partly
results from the stimulation of granule release by 11,9-emPGH2 itself
and partly from a small contribution by an endogenous thromboxane
component. In the presence of Froben the latter component is
eliminated (Fig.5.1). In the presence of EP092, the dose-response
curve for aggregation induced by 11,9-emPGH2 was shifted to the right
giving an indication of the affinity of EP092 for the receptor.
Similar dose response curves were established using collagen as
the agonist. Shifts in the dose response curves were established in
the presence of EP092 and Froben. In these studies collagen was
left in the platelet suspension for 4 minutes, since the onset of




11,9-emPGH2 (0.33^ljM) Collagen (2^ig/ml)
i drug addition
Figure 5.1 Typical aggregation curves observed in human PRP
(control donors). Aggregation is induced by 11,9-
epoxymethanoPGHp and collagen in the presence of EP092
(0.25pM) and Froben (10pM). Collagen was incubated for
1 minutes.
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11,9-emPGH2 induced aggregation, Froben blocks AA metabolism and
totally abolished aggregation induced by the supramaximal dose of
collagen (2yg/ml). EP092, the TX receptor blocker, also produces
complete inhibition of the response indicating a marked effect of the
endogenous TX-endoperoxide component (Fig.5.1).
From the log dose response curves for collagen and 11,9_emPGH2,
the concentration of each agonist required to produce 50^ of the
maximal response was determined for the control and diabetic groups.
There was no significant difference in the concentration of collagen
required to give 50% of the maximum aggregation wave (EC50) between
the two diabetic groups and the control group. In the presence of
the thromboxane receptor antagonist EP092 (0.25pM), log dose response
curves for collagen were shifted to the same extent in the three
groups, as shown by the new EC50 values. No significant differences
in the dose ratios were evident. The cyclo-oxygenase inhibitor
Froben (10pM) produced a greater shift EP092 of the control
aggregation curves than EP092. However, there was no significant
difference in the shifts with EP092 in the 3 groups and although
Froben appeared to be slightly less effective in the proliferative
retinopathy group, the difference did not reach statistical
significance (Table 5.2).
There was a significant difference between the 3 groups in the
concentration of 11,9-emPGH2 required to induce a 50% aggregation
response. The proliferative retinopathy group were most sensitive
to 11,9-emPGH2 and as a result the EC50 value was less than in either
the control or background retinopathy groups (p < 0.005).
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Furthermore EP092 produced a significantly larger shift in the
aggregation curve in the proliferative retinopathy group as judged by
the dose ratio when compared with the other 2 groups (p < 0.005).
It may be of interest that in the presence of Froben, no difference
was found between the 3 groups in either the EC50 or dose ratio.
Release of 5HT was simultaneously measured during these
aggregation experiments (Table 5.3). No difference was observed in
the release of 5HT in response to both collagen and 11,9emPGH2
between the three groups. Basal cyclic AMP levels and the elevation
in cyclic AMP induced by PGE-) (0.2pM) were also measured. No
significant difference was observed in the basal levels or the rise
in the 3 groups (Fig.5.2).
Statistical analysis of the dose ratios was by Kruskal-Wallis
one-way analysis of variance by ranks. Comparison of cyclic AMP
levels between the groups was carried out using the independent
Student's t-test.
Study II - Improvement of Glycaemic Control
Patients
Nine moderately-well controlled male insulin-dependent diabetics
underwent platelet function tests at time 0 (To) and again after six
months (T-|). Five of these patients (tight control group) improved
their glycaemic control as indicated by changes in their glycosylated
haemoglobin over the six month period, while four ("usual" control
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group) were unable to improve their glycaemic control (Table 5.4).
Opthalmoscopy following mydriasis showed three patients in the 'tight
control' group and two patients in the 'usual control' groups to have
mild background retinopathy. All were clinically free of
nephropathy (urine Albustix negative and plasma creatinine less than
150mol and all had easily palpable peripheral pulses. None were
taking medication except insulin and none had experienced a
hypoglycaemic reaction within 24 hours of venesection. Blood was
withdrawn from fasting diabetic subjects between 0800 and 0900 hours.
Results II
Log dose response curves were established for ADP induced
aggregation using platelets from nine subjects before and 6 months
after a period of glycaemic control. The concentration of ADP
required to produce 50$ of the maximum aggregation wave response
(EC50) waP esentially unchanged following 6 months of glycaemic
control (Table 5.5). In the presence of the prostacyclin mimetic,
Iloprost (InM) the log dose response curves for ADP were shifted to
the right. Before improvement of glycaemic control (T0) the shift
of the curves to the right was similar in both groups. However,
after 6 months (T-]) there was a significant increase in the
responsiveness of the platelets to Iloprost in the 'tight' control
group, reflected by a much greater shift to the right of the log dose
response curve for ADP (Table 5.5).
Thromboxane B2 production in response to exogenous collagen
(2yg/ml) was measured. There was no significant difference in TXB2
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level? before glycaemie control in the two groups. However, a
significant increase (p < 0.05) was apparent at T-| , in the group
whose glycaemic control had improved (Fig.5.3).
Cyclic AMP levels both basal and after exposure to Iloprost were
measured in the two groups at T0 and T-] (Table 5.5). No significant
difference was apparent in these values.
























Figure 5.2 Basal platelet cyclic AMP levels and cyclic AMP levels
after exposure to prostaglandin E-j in control in
diabetic retinopathy groups. Results are given as the
mean ± s.e.m. n = 12 in all groups.
ES3 = basal cyclic AMP level


















Figure 5.3 Ratio of platelet TXB2 production at 6 month? (T-j) with
platelet TXB2 production at start of the study (Tq) in
the "usual control" and "tight control" groups.
* p < 0.05 (mean ± s.e.m.).
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DISCUSSION
The results from study 1 demonstrate that platelets from Type I
diabetics with proliferative retinopathy are slightly more sensitive
to the thromboxane mimetic 11,9~emPGH2 than platelets from Type I
diabetic patients with background retinopathy and control subjects.
In the presence of Froben the increased sensitivity to 11,9-emPGH2
was reduced. In non-diabetics subjects the major mechanism of the
action of the mimetic does not involve activation of the thromboxane
generating system (Hamberg et al, 1975; Moncada and Vane, 1978).
It would appear therefore that since Froben eliminates the endogenous
thromboxane component and reduces the sensitivity to 11,9~emPGH2»
then the increased sensitivity in the proliferative group is not a
direct effect of the 11,9~emPGH2 at the receptor. The demonstration
that in the presence of the thromboxane receptor blocker, EP092 the
shift of the dose response curves to the right were similar in the
three groups, indicates that the affinity of EP092 for the receptor
is similar in the 3 groups.
The mechanism of increased sensitivity in the proliferative
retinopathy group remains undefined; the possibility that enhanced
release of dense granule constituents namely 5HT, may be responsible
for increased sensitivity due to the direct action of 11,9-emPGH2
endogenous thromboxane on the granules can be ruled out, since it is
apparent from Table 5.3 that there is no significant different in the
release of 5HT induced by either collagen or 11,9~emPGH2 in each of
the 3 groups. The increased sensitivity, therefore may be due to an
increased endogenous thromboxane production ocurring during secondary
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aggregation.
In contrast to previous studies with diabetic patients
(Silberbauer et al, 1981; Sagel et al, 1975; Jones et al, 1985A and
Janka and Demmel, 1981) enhanced platelet sensitivity to collagen was
not apparent in this study whether measured as platelet aggregation
or as 5HT release. In non-diabetic subjects endogenous PGH2 and
thromboxane A2 production are the major mediators of collagen-induced
aggregation (Vargaftig et al, 1981). The aggregation EC50 values
for collagen were similar in the 3 groups. The thromboxane receptor
antagonist EP092 produced a similar shift of the aggregation curve in
each group. The cyclo-oxygenase inhibitor, Froben appeared to be
slightly less effective in inhibiting collagen induced aggregation in
the proliferative group indicated by smaller shift of the dose
response curves. Although this effect did not reach statistical
significance, the decreased activity of Froben in this group may be
expected if there was an increased endogenous thromboxane synthesis,
although in this instance it is not apparent in the aggregation EC50
values. It is clear from Table 5.3 that collagen is a more
effective stimulator of the release reaction and since a marked
reduction in release is evident in the presence of Froben, endogenous
TXA2 and the endoperoxides must play a major part in collagen induced
release of 5HT. Since no statistically significant differences were
demonstrated either in EC50 values or 5HT release values in response
to collagen, it would seem likely that the mechanism underlying
collagen-induced aggregation is similar in platelets from diabetics
to those of control groups.
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The apparent similarity in platelet sensitivity to collagen
between the 3 groups in this study contrasts with other studies
(Silberbauer et al, 1981; Sagel et al, 1975; Jones et al, 1985A;
Janka and Demrael, 1981). These discrepancies may be accounted for by
the careful age restriction and comparability of subjects during
recruitment to the study. Age is an important determinant of
platelet function in both non-diabetic and diabetic patients
(Leccrubier et al, 1980).
In addition no difference was observed between either the basal
level of platelet cyclic AMP or the elevated level of cylcic AMP
following exposure to prostaglandin E-| in both the diabetic and
control groups. This finding is in agreement with a recent study of
prostacyclin binding to platelets and activation of adenylate cyclase
(Shepherd et al, 1983) which showed similar PGI2 binding and
adenylate cyclase activity of human platelets from proliferative
diabetics and control subjects. These reports are in sharp contrast
to a report by Lagarde and co-workers (1981 A) who found that
diabetics had lower resting levels of cyclic AMP and a diminished
response to inhibitory prostaglandins when compared to controls.
One possible explanation for these discrepancies is that in this
study and the one by Shepherd (1983) the subjects were young and age
matched (25-28 years and 31-35 years respectively), whereas in the
report by Lagarde et al (1981), the duration of diabetes vascular,
complications and age range (17-61 years) were very wide.
In summary, this study shows that platelets from young Type I
diabetic patients with microvascular disease in the form of
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background and proliferative retinopathy are similar to platelets
from normal subjects in their response to collagen-induced
aggregation. However, diabetics with proliferative retinopathy were
found to have platelets with a slightly enhanced sensitivity to the
thromboxane mimetic 11,9-emPGH2. Since the increased sensitivity
does not appear to be mediated by a direct effect at the receptor
level, it is unlikely that thromboxane receptor antagonists would
prove to be useful therapeutic drugs to reduce an enhanced
sensitivity of platelets to thromboxane in diabetics with
proliferative retinopathy. Owing to the absence of differences in
platelet sensitivity to collagen in the 3 groups studied, and the
slight increase in platelet sensitivity to 11,9-emPGH2 in the
proliferative group, it is unlikely that an alteration in platelet
function is a major causative factor in the genesis of retinopathy,
and may in fact be secondary to the microvascular complication.
The second study deals with two groups of diabetic patients;
those that did not improve their glycaemic control over six months
('usual' control group) and those that did improve their glycaemic
control ('tight' control group). Although significant improvement
of the glycosylated haemoglobin (HbA-| ) was obtained, HbAi levels in
the 'tight' control group did not reach normal levels.
The sensitivity of platelets from nine diabetic subjects was
assessed by measuring the aggregation response to ADP and the effect
of the anti-aggregating agent, Iloprost. There was a trend of
increasing sensitivity to ADP in the group whose glycaemic control
was improved, but this change did not achieve statistical
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significance. Since platelet sensitivity of the individual
fluctuates from day to day, perhaps if the numbers in each group were
larger, a significant difference might have been demonstrated. It
has been reported (Janka and Demmel, 1981) that during poor metabolic
control platelet functions are depressed as reflected by decreased
platelet aggregation responses and it has been suggested that during
prolonged hyperglycaemia, depletion of platelet glycogen stores and
decreased ATP generation could account for depressed platelet
function. In addition erythrocytes and leukocytes have been found
to exhibit subnormal functions in a state of poor metabolic control
(Peterson et al, 1977).
Platelets from the 'tight' control group were found to be
significantly more sensitive to the inhibitory agent, Iloprost after
improvement of glycaemic control. The dose response curves for
diabetics in the tight control group were shifted much further to the
right in the presence of Iloprost. At first instance, this would
suggest that the increased sensitivity is mediated through raised
cyclic AMP levels possibly due to enhanced adenylate cyclase activity
or improved receptor coupling. However, no significant difference
was found in the cyclic AMP levels measured in plasma after exposure
to Iloprost or in the basal levels with the improvement of glycaemic
control. It is possible that the increase in Iloprost sensitivity
in the 'tight' control group, reflected by a more marked inhibition
of aggregation occurs at some site other than the prostacyclin
receptor adenyl-cyclase complex; perhaps a more efficient
sequestration of cytosolic free calcium.
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Platelets from diabetics have been demonstrated to have
decreased sensitivity to inhibiting prostaglandins (Betteridge et al,
1982; Davi et al, 1982). Furthermore, 'in vivo' reduced vascular
PGI2 levels have been found at particularly high blood glucose levels
(Johnson et al, 1979B, Silberbauer et al, 1979; Aanderud et al,
1985; Wilson and Tan, 1985). It may not be surprising that in this
study, subsequent lowering of blood glucose results in an increased
sensitivity to inhibiting prostaglandins. Furthermore, Janka and
Demmel (1981) also found an increase in adenylate cyclase activity
with improvement of glycaemic control in a heterogeneous group of
non-insulin and insulin dependent diabetics.
In addition, platelets from diabetics in the tight control group
were found to produce more TXB2 in response to exogenous collagen,
following improvement of glycaemic control. Reduced prostaglandin
production from endogenous platelet arachidonic acid (Janka and
Demmel, 1981) and reduced serum thromboxane levels in diabetics
(Tindall et al, 1981; Ylikorkala et al, 1981) have been reported.
Jones et al, (1983) have demonstrated reduced arachidonate acid
levels in the platelet membrane phospholipids of diabetics which
correlated negatively with glycosylated haemoglobin. Thus lowering
of glycosylated haemoglobin with improvement of glycaemic control may
in fact increase the availability of arachidonic acid from membrane
phospholipids (Jackson et al, 1984) and may explain the increased
TXB2 production observed in this study.
The overall picture from this study, shows an increase in
sensitivity to Iloprost and an increased production of thromboxane
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Bp. Normally enhanced aggregation response? may be expected with an
increase in thromboxane production. In this instance perhaps the
action of increased thromboxane is opposed by the increased
sensitivity of the inhibitory system and this may offer an
alternative explanation for the lack of a significant change in the
ADP aggregation response accompanying improved glycaemic control.
It has been reported that platelets from mature rats are more
sensitive to prostacyclin as well as showing increased sensitivity to
collagen when compared to young rats (Giani et al, 1985). It is
possible that a similar situation operates in diabetics undergoing
improvement of glycaemic control whereby an enhanced inhibitory
system exists to counteract the effects of increased thromboxane in
order to maintain a haemostatic balance.
Results in this study, indicate that short term glycaemic
control in a heterogeneous group of insulin dependent diabetics does
not markedly change all aspects of platelet function in favour of
reducing the prothrombotic state, i.e. increased platelet thromboxane
production. It may also be of interest that in the first year at
least, improved glycaemic control does not necessarily slow the
evolution of mild microangiopathic complications in the form of non¬
proliferative diabetic retinopathy (Lauritzen et al, 1983; Kroc
Study Group, 1983). Indeed in some instances a significant
deterioration in retinopathy has been reported (Dahl-Jorgensen et al,
1985; Tamborlane et al, 1982). The present study demonstrates that
with improved glycaemic control over six months towards, but short of
physiological there is an increased production in the proaggregatory
agent, thromboxane A2 which may be a contributory factor in the
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deterioration of microvascular disease, particularly in the form of
retinopathy. However, the increased sensitivity to prostacyclin may
in fact reflect a compensatory mechanism in the body to counteract
the increased proaggregatory factors.
At present, it would be wise not to expect short-term control to
eliminate the risk of thrombosis. However, it remains to be
investigated whether treatment achieving long term control may prove
to be the desirable way to lessen the risk of developing further
vascular disease and related thrombotic complications. One must
bear in mind that in addition to the evidence which suggests that
platelet/endothelial functions contribute to thrombo-embolic
complications, perhaps the mode of therapy (i.e. improving glycaemic
control) employed to reduce the hyperglycaemic state may also be a
causative factor in these conditions.
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In this clinical study the control subjects were healthy
volunteers working within our university department. It should be
emphasised however that control subjects are not a random
representation of the population. The use of such control groups
from a narrow cross-section of the population may be of importance in
this study since there are likely to be marked differences in the
dietary and social habits of these individuals to those in diabetic
groups. The individuals diet, alcohol consumption, smoking habits,
etc. were not considered when choosing controls in this study.
Since all of these factors as well as others can affect platelet
function there are limitations in comparing these control groups with
diabetics. If a random cross-section of subjects were chosen as
controls perhaps a truer representation of the population would be
achieved. Furthermore if daily fluctuations in individuals'
platelet function were measured, perhaps one could assess the
validity of comparing control groups to diabetics over a period of
time.
During the studies in this thesis because time was a limiting
factor it was not possible to choose a control group representing a
true cross-section of the population.
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Chapter 6
Hypothyroidism and platelet function
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INTRODUCTION
Hypothyroidism and thyrotoxicosis, like diabetes mellitus are
associated with coronary heart disease and other complications.
Hypothyroid patients have been shown to have twice the incidence of
severe coronary atherosclerosis compared to controls matched for age,
sex and blood pressure (Vanhaelst et al, 1967). There has been much
discussion as to whether hypercholesterolemia that accompanies
primary hypothyroidism accelerates the development of coronary
atherosclerosis. Necropsy data suggests that hypercholesterolemia
in hypothyroid patients predisposes coronary atherosclerosis but only
in the presence of hypertension. In normotensive patients the
degree of atherosclerosis is no greater than in age-and sex-matched
normotensive controls (Steinberg, 1968). Despite
hypercholesterolemia and increased atherosclerosis the incidence of
myocardial infarction in untreated hypothyroids is not increased.
However, it has been demonstrated that when patients are given
thyroxine, the incidence of angina pectoris and the risk of
myocardial infarction increases (Wayne, 1960). In addition to these
problems, haematological abnormalities have also been observed in
association with hypothyroidism, including easy bruising, menorrhagia
and bleeding tendancies. It is possible that thyroid function
disorders, in particular hypothyroidism, may be associated with a
haemostatic imbalance. In response to diminished oxygen
requirements and decreased erythropoietin, red cell mass is
decreased. Furthermore, the intrinsic clotting mechanism has been
found to be defective in the hypothyroid state (Egeberg, 1963. 1964)
and a decrease in the plasma concentration of factors VIII and IX
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together with an increase in capillary fragility may be responsible
for the bleeding tendancies reported in hypothyroids (Simone et al,
1965). Furthermore changes in both plasma constituents and
erythrocyte deformability have been found which may be responsible
for increasing blood viscosity (Larsson et al, 1985) and altering red
cell shape (Wardrop and Hutchison, 1970).
Several groups have shown fibrinolytic activity to be increased
when thyroxin levels are below normal (Bennet et al, 1967; Hume,
1965; Jacobsen, 1968) and it has been suggested that a depression of
the fibrinolytic activity following administration of thyroxin may
facilitate the formation of an occluding thrombus in coronary
arteries.
The close association of haematological disorders and
hypothyroidism may indicate a possible role for platelets in these
abnormalities. Since platelet counts are normal in hypothyroidism
(Egeberg, 1963), platelet disfunction is likely to be of a
qualitative nature. In fact, it has been demonstrated that platelet
adhesivensss is reduced in hypothyroidism and only increases to
normal after thyroid hormone replacement therapy (Hellem et al,
1975). Although, clear haematological disorders, including some
aspects of platelet function are associated with hypothyroidism, very
few platelet studies have been carried out on hypothyroid patients.
One study has shown that platelets from hypothyroids responded very
weakly to various aggregating agents including ADP, adrenaline and
collagen, measured by the turbidometric aggregation method of Born
(1962). Replacement therapy with thyroxine (T3) rendered these
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platelet? hyper-responsive to the aggregating agent? above (Gardikas
et al, 1972).
Contrasting effects are observed in thyrotoxic patients whose
thyroid glands have become overactive. In such conditions, the
plasma cholesterol levels are low, the intrinsic coagulation systems
overactive and the fibrinolytic system are depressed. In addition,
platelet abnormalities have been demonstrated; including increased
platelet adhesiveness (Hellem et al, 1975), a decreased platelet
count and a reduced platelet life span (Lamberg et al, 1971). In
view of these abnormalities, an enhanced risk of platelet thrombus
formation may be expected. However, the incidence of
atherosclerosis in hyperthyroid patients is very low and this has
been attributed to the anti-atherogenic effct of the thyroid hormone
(Myasnikov et al, 1963). This group demonstrated that in
cholesterol-fed rabbits treatment with thyroid hormones lowered serum
cholesterol levels and increased the coronary blood flow consequently
reducing local thrombus formation. Thus the anti-atherogenic effect
of the thyroid hormone and low cholesterol levels associated with
thyrotoxicosis are in favour of preventing thrombotic tendancies.
Thyrotoxicosis may be treated in a number of ways; by surgical
removal of part of the gland, carbimazole treatment (which involves
inactivation of thyroid stimulating hormone) and the use of radio¬
active iodine. The use of radio-active iodine is the most common
method employed especially in the early stages of thyrotoxicosis.
However, it is often difficult to predict the dose of radioactive
iodine to administer. In these circumstances the emergence of
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clinical hypothyroidism often results and thyroxin replacement
therapy is necessary to increase thyroid levels to the euthyroid
state. When undergoing replacement therapy the patient is at risk
of developing angina pectoris or a myocardial infarction (Wayne,
1960). In fact, the institution of thyroxine replacement therapy
once clinical hypothyroidism has emerged has been suggested to be
associated with significant morbidity, especially in older patients
who constitute a large percentage of the hypothyroid population
(Rosenbaum and Barzel, 1981; Bahemuka and Hodkinson, 1975).
Enhanced platelet sensitivity accompanying treatment could also
contribute to the risk of coronary arteriosclerosis, angina pectoris
and myocardial infarction.
This study was designed to investigate platelet function in a
group of clinically hypothyroid patients before and after replacement
therapy. Platelet sensitivity was measured using two differently
acting aggregating agents, ADP and the thromboxane mimetic, 11,9-
epoxymethanoPGH2- It is thought that platelet reactivity Is
controlled to some extent by a thromboxane-prostacyclin balance and
an imbalance of these two arachidonate metabolites may lead to
abnormal platelet function. For these reasons, both TXBp production
and cyclic AMP levels (which reflect prostacyclin activity) were
determined before and after treatment with the thyroid hormone.
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RESULTS
Blood (100ml) was collected from patients on the morning of the
experiment and platelets (as PRP) were prepared as described in the
methods chapter. Five patients were studied, two of whom had
Grave's disease and three who were diagnosed with multinodular
goitre. All the patients were thyrotoxic and became hypothyroid
after radioactive iodine. The clinical details of each of the
patients are shown in Table 6.1.
Platelet aggregation studies were carried out before (0 mths)
and after (6 mths) thyroxine replacement therapy. Log concentration
response curves were established for ADP and the thromboxane mimetic,
11 ,9-epoxymethanoPGH2. From these curves the concentration of each
agonist to produce a 50$ maximal response (EC50 value) were
determined (Fig.6.1).
It is apparent from Fig.6.1 A that there is an increase in
platelet sensitivity to ADP after treatment at the 6 month period
reflected by a decrease in the EC50 values. This increased platelet
sensitivity is statistically significant (0.05 > p > 0.02).
Although there is also a reduction in the EC50 values for 11,9-emPGH2
induced aggregation at 6 months, the difference did not reach
statistical significance.
Thromboxane B2 production in response to exogenous collagen
(2pg/ml) was measured before and after treatment. PRP was incubated
with collagen for 60 seconds at 37°C. The reaction was terminated
1 60
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a. ADP b. 11,9-emPGH
i 2
Figure 6.1 The EC50 value? (pM) for platelet aggregation induced by
(A) ADP and (B) 11,9~epoxymethanoPGH2 before and after
thyroxine treatment. * 0.05 > p > 0.02.
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and TXB2 was extracted as described in the methods chapter. There
was no statisticlly significant difference in the thromboxane levels
before and after 6 months of thyroxine treatment (Fig.6.3).
Elevations in cyclic AMP levels in response to Iloprost (0.03yM)
were measured at 0 months and 6 months (Fig.6.2). There is a marked
fall in elevated cyclic AMP levels after thyroxine treatment which
reached statistical significance (0.05 > p > 0.02). There was no
significant difference in basal levels of cyclic AMP before (12.25 ±
1.02) and after (16.00 ± 2.92) thyroxine treatment. Statistical
tests were carried out using the Wilcoxon rank sum test.
161
Cyclic AMP (pmol)
Figure 6.2 Cyclic AMP production (pmol/ml of PRP) after exposure to
Iloprost (0.03pM) before and after thyroxine treatment.

































Figure 6.3 TXB2 (pg/ml of PRP) production in response to collagen
(2yg/ml) (incubated for 60 seconds) before and after
treatment with thyroxine.
Values are the mean ± s.e.m. from 5 patients.
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DISCUSSION
It appear? from this study that thyroxine treatment in
hypothyroidism is associated with enhanced platelet aggregation.
The increased sensitivity after six months of replacement therapy is
more marked with ADP than 11 ,9-epoxymethanoPGH2 and only the former
aggregating agent induces a change which is statistically
significant.
There is a much greater scatter in the ADP EC50 values (0.7 -
3.0pM) before treatment when compared with those of 11,9-
epoxymethanoPGH2 (0.5 - 0.9pM). The number of patients studied was
small and individual or daily fluctuations may contribute to the
scatter observed in ADP EC50 values. However, the scatter was
markedly reduced following treatment. The two extreme ADP EC50
values before treatment correlate with the 2 extreme values of T3
levels before treatment. It is possible that platelet sensitivity
to ADP is more susceptible than 11,9-emPGH2 to metabolic changes
(such as T3 levels) and the scatter of ADP EC50 values may be related
to T3 levels and the degree of hypothyroidism in the patient. There
does not appear to be any correlation between the ADP EC50 values and
those of 11,9-emPGH2 (i.e. the individuals most and least sensitive
to ADP do not correspond to those most and least sensitive to 11,9-
emPGH2). This may suggest that the metabolic changes associated
with hypothyroidism affect platelet sensitivity to ADP and 11,9—
emPGH2 in different ways.
Indeed the mechanisms underlying the aggregatory response
1 62
induced by these agents differ; ADP has a large direct component at
an ADP receptor and a contribution from the release reaction. 11,9-
EpoxymethanoPGH2 acts directly at an endoperoxide/thromboxane
receptor as well as inducing the release of granule constituents
either directly or indirectly through endogenous TXAp.
Since the EC50 values presumably reflect mainly primary wave
aggregation, the increased ADP sensitivity may be a consequence of
improved stimulus-response coupling at the platelet ADP receptor.
The finding that thromboxane B2 production in response to collagen
was not significantly altered after thyroxine treatment, may indicate
that there is not an enhanced metabolic conversion of arachidonate or
increased arachidonate availability. Whether there is a more
efficient triggering of the release reaction would not be apparent
from comparing EC50 values but it is possibile that second phase
aggregation may also be enhanced due to an improved release reaction.
Measurement of products of 'in vitro' release would show whether this
was the case or not.
Although a significant decrease in the elevated cyclic AMP
levels following thyroxine treatment is evident, this fall is
unlikely to be a factor contributing to the decreased ADP EC50 values
in the 'in vitro' system. Since ADP has a tendancy to inhibit the
adenylate cyclase enzyme (Haslam et al, 1979) and prostacyclin
enhances it, a reduction in the activity of this enzyme system may
cause the basal levels of cyclic nucleotides to be depressed, which
could account for enhanced aggregatability 'in vitro'. In this
instance, the basal levels of cyclic AMP before and after treatment
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are not significantly different. It would seem therefore that 'in
vitro* cyclic AMP levels are not contributing to the enhanced 'in
vitro' platelet sensitivity to ADP.
Although the marked reduction in the prostacyclin-stimulated
cyclic AMP levels would not be of any consequence in the 'in vitro'
platelet system a similar reduction 'in vivo' may have considerable
implications. The thromboxane/prostacyclin balance is one of a
number of factors governing platelet reactivity (Gorman et al, 1977).
If platelet reactivity 'in vivo' is controlled by a prostacyclin
feedback mechanism, depressed activity of the prostacyclin
receptor/adenylate cyclase complex with subsequent reductions in
cyclic AMP levels would perhaps be reflected by enhanced thromboxane
activity.
The enhanced sensitivity to ADP, observed 'in vitro' following
thyroxine treatment may be of relevance 'in vivo'. It has been
reported that thyroxine promotes various metabolic actions of
adrenaline (Gardikas et al, 1972). In vivo a synergy between the
increased sensitivity to ADP and enhanced activity of adrenaline may
contribute to hypersensitivity of platelets. These factors as well
as a supressed receptor-adenylate cyclase complex may be major
contributory parameters in the development of vascular complications
following thyroxine treatment.
In summary, the results of this study demonstrate that depressed
platelet function selectivity gains sensitivity to the aggregating
agent, ADP following thyroxine replacement therapy. Although basal
1 6H
cyclic AMP levels were not affected by thyroxine treatment, a marked
reduction in the prostacyclin inhibitory system was observed.
Depressed platelet sensitivity in the hypothyroid state may
contribute to the easy bruising and bleeding tendancies and may
explain the low incidence of myocardial infarction in these patients.
The reports that thyroxine replacement therapy promotes undesirable
vascular complications may in part be due to an overall improvement
in metabolic rate and heart function. However, an improvement of
platelet function and a reduced activity of the inhibitory feedback
mechanism may be important contributory factors in the development of
vascular complications. In addition, a concommitant decrease in
fibrinolytic activity following thyroxine therapy (Bennet et al,
1967) may facilitate the formation of an occluding thrombus in the
coronary arteries and may also have a pathogenic role in the genesis
of vascular disorders.
It is likely that several factors may contribute to the various
complications associated with thyroxine replacement therapy, but in
light of these studies, it may be valuable to consider the addition





The experiments described in this thesis have been concerned
with the actions of stable analogues of several arachidonic acid
metabolites. The synthetic endoperoxide and thromboxane mimetics
have the same intrinsic biological activity as the parent compound
and investigation of their biological actions has led to a better
understanding of vascular haemostasis, including platelet function,
in addition to stimulating new ideas in the development of future
anti-thrombotic therapy.
Thromboxane A2 has been implicated as the mediator of a variety
of circulatory and cardiopulmonary disease states, including
myocardial ischaemia (Lefer, 1982), some types of angina (Lewy et al,
1979, 1980), circulatory shock including traumatic and endotoxic
shock (Lefer, 1983) and atherosclerosis (Mehta and Mehta, 1981). In
addition platelets from diabetics display an increased release of
thromboxane and their blood vessels have been found to have a
decreased production of prostacyclin (Harrison et al, 1978; Johnson
et al, 1978).
A group of drugs which have been widely used to reduce the
deleterious effects of thromboxane A2 are the non-steroidal anti¬
inflammatory drugs (NSAIDs, e.g. aspirin). They may do so by
interfering with prostaglandin and thromboxane biosynthesis and hence
reducing the tendency for platelets to aggregate.
However, it has been demonstrated that aspirin, whilst
inhibiting thromboxane in platelets, also inhibited the synthesis
prostacyclin to a similar degree in vascular tissue (Weskler et al,
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1983; Preston et al, 1981). The "aspirin dilemma" emerged as a
consequence (Moncada & Vane, 1979, Marcus, 1977) and the simultaneous
inhibition of prostacyclin and thromboxane synthesis was considered a
possible reason for the disappointing results of clinical trials of
high dose aspirin therapy (de Gaetano et al, 1982). It was proposed
that if certain aspirin dose regimens were devised it may be possible
to inhibit platelet thromboxane synthesis without interfering with
prostacyclin synthesis in vascular tissue (platelet cyclo-oxygenase
was believed to be more sensitive than vascular cyclo-oxygenase to
aspirin inhibition). Unfortunately, studies with cultured
endothelial cells, laboratory animals and man have not completely
dissociated the two effects (de Gaetano et al, 1982). Perhaps it
should be considered, that the effects of these drugs may vary in
different pathological conditions in which platelet and/or
endothelial behaviour may be affected. Enhanced platelet turnover
and/or endothelial damage may decrease the effectiveness and/or
selectivity of aspirin.
Another approach considered in the design of anti-thrombotic
therapy was the development of thromboxane synthetase inhibitors.
Theoretically a selective inhibitor of thromboxane synthetase should
prove to be a superior anti-thrombotic agent to aspirin and other
NSAIDs, since it would allow continued prostacyclin formation by the
vessel walls and other cells. Endoperoxides released from these
tissues or those released from platelets may be utilized.
Imidazole, one of the first such agents was found to inhibit the
thromboxane synthetase enzyme at doses that had no effect on the
cyclo-oxygenase enzyme (Moncada et al, 1 977 A). Thromboxane
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synthetase inhibitors have indeed been widely studied in a variety of
disease states with some degree of success (Lewis and Tyler, 1983).
However, one drawback of thromboxane synthetase inhibitors is that
they do not block the effects of the endoperoxides, PGG2 and PGH2
which have the same intrinsic activity as thromboxane. This is an
important consideration since redirection of prostaglandin
endoperoxides metabolism to prostacyclin which has been reported
(Blackwell et al, 1978) will only occur at the site of the platelet
vessel wall interaction if the prostacyclin synthesizing capacity is
intact (Davies & Menys, 1983). If the vessel wall is damaged or
obstructed by an atheromatous plaque, the prostacyclin synthetase
enzyme may not utilize the platelet endoperoxides under these
conditions. Furthermore, other redirected metabolites, particularly
PGD2 and PGF2a may contribute to vasoconstrictor or cardiopessent
effects. The future of thromboxane synthetase inhibitors as
therapeutically useful drugs is dependent upon the maintenance of
prostacyclin formation and a role for it in the preservation of
endothelial thromboresistance.
The problems encountered with the thromboxane synthetase
inhibitors may be overcome by the use of thromboxane receptor
antagonists, which specifically act at the receptor level on the
platelet or vascular tissue. Thromboxane receptor antagonists
differ from thromboxane synthetase inhibitors in several ways and may
be of importance 'in vivo' to combat the deleterious effects of
thromboxane. The primary advantage of thromboxane receptor
antagonists is that they antagonise the endoperoxides and thromboxane
A2 directly at the receptor level. The use of thromboxane receptor
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antagonists does not lead to an increase in the synthesis of the
classical prostaglandins (e.g. PGF2a) which may not be beneficial
since they could constrict blood vessels. Furthermore, thromboxane
receptor antagonists would protect the receptors from the effects of
continually produced thromboxane and possibly be of greater
therapeutic value once the disease process has started.
Furthermore, antagonists are not likely to alter the bleeding time
which is significantly increased with enzyme inhibitors.
Thromboxane receptor antagonists therefore have some theoretical
advantages over other drugs and may be of value in circulatory
disease states (i.e. circulatory shock, myocardial ischaemia, and
other heamostatic disorders). Indeed preliminary data has indicated
that thromboxane receptor antagonism may be an effective mode of
therapy in circulatory shock, whereby thromboxane A2 i? thought to
mediate the pathogenesis of the shock state by contributing to
splanchnic ischaemia (Lefer et al, 1979, 1980).
A definitive characterisation of thromboxane receptor subtypes
on platelets and the vasculature would perhaps allow the development
of drugs exhibiting selectivity in their action, either at the
platelet or on the vasculature and may improve the therapeutic
usefulness of such thromboxane antagonists.
The first suggestion that platelets and vascular thromboxane
receptors were different was based on early studies using the 'first
generation thromboxane antagonists', PTA2 and CTA£ (Nicolaou et al,
1979). As mentioned previously in chapter A, these compounds have
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since been found to exert functional antagonism possibly through
elevation in cyclic AMP (Jones et al, 1984). These additional
effects may contribute to the intra-species differences reported in
thromboxane sensitivity and the differences between tissues and
platelets. If indeed these compounds are also acting at
prostacyclin receptors, these receptors may also exhibit differential
sensitivity between tissues, platelets and species. The differences
observed with these compounds, may therefore not be solely due to
thromboxane receptor differences.
In this instance, the use of prostacyclin receptor antagonists
would have the potential to eliminate any prostacyclin-like effects
and therefore allow the nature of these differences to be elucidated.
Although prostacyclin would have no therapeutic value, they would
have potential as pharmacological tools.
It would appear from studies in this thesis, that there are
species differences in the sensitivity of some thromboxane sensitive-
systems with respect to antagonist activity, yet similar in
sensitivity to agonists. The differences in antagonist sensitivity
between many vascular and platelet systems are small in comparison to
the intra-species differences; the affinity of antagonists for the
rabbit thromboxane receptor on platelets and the vasculature are very
similar, but somewhat different from the affinities found on human
and rat platelets. Similarly there are little differences in the
antagonist affinities found on tissues such as guinea-pig trachea,
dog saphenous vein and platelets from human and rat blood.
Presumably the agonist binding site is similar in rat, rabbit and
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human platelet? and possibly to those on the vasculature. The
difference in antagonist binding affinity may be a product of
evolution, found only in certain species. Its significance however
from an evolutionary (survival) point of view is not clear.
Owing to conflicting evidence put forward in other studies
(Saussy et al, 1985, Mais et al, 1985B), there is a need for further
definitive studies to characterise the nature of these underlying
differences. It may be possible to decide whether there is a clear
cut separation of these receptors based on cell types or whether
there are different mixtures of receptors in differing ratios within
each cell type.
Although the pharmacological approach to the characterisation of
receptors from differing tissues or organs has its limitations in the
interpretation of results, it has proven useful and provided enough
information for the initial characterisation of receptors in many
cases (e.g. B-j & B2 adrenergic and H-| and H2~histaminergic
receptors). Subsequent 'in vitro' radioligand binding assays may in
fact provide a more definitive conclusion as to whether thromboxane
receptor hetereogeneity exists. Radioligand binding studies may
provide the answers as to whether there are differences in affinity,
receptor number or perhaps distribution of receptors. As already
discussed, the rabbit platelet receptor and possibly the rabbit
vascular thromboxane receptor have a somewhat lower affinity for
thromboxane antagonists. In order to achieve sufficient binding of
a labelled ligand to attain a displacement curve, ligand
concentrations of 10-100pM would be necessary. Unless the
172
radioligand solution could be diluted with cold labelled ligand,
excess quantities of radioligand would need to be used in ligand
binding studies on rabbit platelets or vascular tissue and such
exercises would prove to be extremely costly.
If the thromboxane/endoperoxide receptor represents a protein
complex embedded in a lipid domain in the membrane, perhaps a subtle
conformational alteration of the protein structure may be reflected
by the differences in affinities observed between the receptors. If
the antagonist action is dependent upon the conformational size
and/or lipophilicity/hydrophilicity of the molecule, perhaps only a
subtle conformational alteration at the rabbit thromboxane receptor
may decrease the accessibility of the antagonists.
The recent solubilization of an endoperoxide/thromboxane A2
binding site (Saussy et al, 1985) has demonstrated such a site in an
active form. Antagonists were readily displayed by other agents.
The dissociation constant values for a series of analogues were
similar to those determined from binding studies and pharmacological
experiments on platelets. The binding site was of protein nature
with a molecular mass of about 200 kDaltons. Purification of this
binding unit and analysis of the structure may in fact open up
another approach whereby the nature of thromboxane receptor
differences may be examined at the molecular level.
Other alternatives for anti-platelet and anti-thrombotic drugs
may be sought, particularly in conditions where thromboxane may not
be the sole mediator of the deleterious effects. The development of
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orally active prostacyclin analogues with a long duration of action
may provide the answer for drugs to control 'in vivo' platelet
aggregation and thromboembolic disorders and which would be superior
to enzyme inhibitors which are generally less selective. However,
since prostacyclin and its derivatives exert potent vasodilator
effects as well as anti-platelet action, long-term vasodepressor
actions may not be without other side effects, possibly on the
cardiovascular system. The definitive separation of platelet and
vascular actions in an active synthetic prostacyclin analogue both
for use as a research tool and as a clinically useful agent would be
the ultimate objective in the development of prostacyclin mimetics.
However, until the pharmacokinetic parameters of these analogues
are fully elucidated and some mechanism of controlling the
distribution of the analogues from the blood to the various tissue
compartments is developed, metabolically stable prostacyclin
analogues with long duration of action 'in vivo' will remain to be
identified. Although there is some evidence from experimental
studies of selectivity on platelets distinct from the vasodepressor
action of prostacyclin, there is as yet no stable analogue that has a
highly selective action on platelets 'in vivo' (Karlm et al, 1981).
Recently the development of compounds which act both as
prostacyclin mimetics and thromboxane antagonists (EP035, EP057,
Armstrong et al, 1986) offers another promising approach for
therapeutic measures against thromboxane action. These types of
compounds may prove to be therapeutically useful since in addition to
specifically antagonising TXA2, they would eliminate any
1 m
vasoconstriction or residual platelet aggregation induced by the
prostaglandin endoperoxides and also have direct PGl2~like anti¬
aggregatory activity.
Prostacyclin by increasing cyclic AMP prevents platelet
aggregation induced by all known agonists as well as disaggregating
platelets 'in vitro' (Gryglewski et al, 1976). 'In vivo' multiple
agonists are likely to act in concert. In a syndrome of platelet
mediated vascular occlusion, inhibition of thromboxane action alone
may not be completely effective. Thus compounds such as EP035 and
EP057 may have greater therapeutic potential in situations where
there is an increased thromboxane production as well as an increase
in mediators of aggregation and vasoconstriction which are non-
thromboxane.
Before the discovery of prostacyclin, it was suggested that
dietary dihomo-)f-linolenic acid, the precursor of prostaglandins of
the '1' series (e.g. PGGi , PGE-] and TXA-j ) could be employed as a
measure in the prevention of thrombosis. PGG-] and thromboxane A-|
have no pro-aggregatory effects and in fact PGE-) has an anti¬
aggregatory activity. However, the use of dihomo-^-linoleic acid is
possibly not the most rational approach for the prevention of
thrombosis since the endoperoxides PGG-| and PGHi are not substrates
for prostacyclin synthesis. An accumulation of these substances or
diW»fflo-&'-l'noJen/taci'Jlcould adversely affect the prostacyclin protective
mechanism (Willis et al, 197*0. An alternative means of dietary
manipulation in favour of decreasing aggregatory/vasoconstrictor
compounds without affecting antiaggregatory measures to any great
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extent could be achieved by incorporating the polyunsaturated fatty
acid, eicosapentanoic acid (E.P.A.) into the diet. Eicosapentanoic
acid has a higher degree ofi/nsaturation and metabolism of this fatty
acid gives rise to prostaglandins of the '3' series. When vascular
tissue is incubated with eicosapentajioic acid, an anti-aggregatory
substance is released namely prostacyclin 13 (Gryglewski et al,
1979). Synthetic prostacyclin I3 is as potent in anti-aggregatory
activity as prostacyclin. In contrast, thromboxane A3 has weaker
pro-aggregatory activity than thromboxane A2 (Raz et al, 1979).
Furthermore, it was found in studies in this thesis, that
eicosapentanoic acid itself has an anti-platelet action. Gryglewski
and co-workers (1979) have also shown that it inhibits 'in vitro'
platelet aggregation induced by ADP, collagen and arachidonic acid.
'In vivo' eicosapenta^noic acid is incorporated into the platelet
phospholipids replacing some of the arachidonic acid. It may exert
an anti-platelet effect by either competing with arachidonic acid for
the cyclo-oxygenase and lipoxygenase enzymes (Culp et al, 1980) or by
being converted to the less pro-aggregatory compounds, PGH3 and TXA3
(Gryglewski et al, 1979).
e
Fish and fish oils are rich in eicosapentanoic acid and studies
have shown that diets high in eicosapentanoic acid sources alters the
<2.
ratio of arachidonic/eicosapenta^ioic acid present in membrane
phospholipids (Dyerberg and Bang, 1979; Black et al, 1979; Seiss et
al, 1980). In fact, the incidence of thrombosis and subsequent
infarct size was found to be reduced in dogs fed on a fish oil diet
(Culp et al, 1980). The high fish diet of Eskimos may explain why
this group have a low incidence of acute myocardial infarction, low
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blood cholesterol levels and an Increased tendancy to bleed (Dyerberg
and Bang, 1979).
Thus with regards to dietary manipulation either by
supplementation or by dietary change another possible therapeutic
approach in the treatment of thrombotic disorders or as a
prophylactic measure is made available. Perhaps over the next few
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Increased platelet thromboxane receptor sensitivity in diabetic patients
with proliferative retinopathy
A.Collier1, P.Tymkewycz2, R.Armstrong2, R.J.Young1, R.L.Jones2 and B.F.Clarke1
1 Diabetic and Dietetic Department, Royal Infirmary and 2 Department of Pharmacology, University of Edinburgh, Edinburgh, UK
Summary. Platelet aggregation to collagen in 12 Type 1 (insu¬
lin-dependent) diabetic patients with background retinopathy
and 12 Type 1 diabetic patients with proliferative retinopathy
was compared with an age- and sex-matched control group.
An analogue of prostaglandin H2, 11,9 epoxymethano-pros-
taglandin H2, which directly stimulates thromboxane recep¬
tors, and EP 092, which is a competitive thromboxane A2 re¬
ceptor antagonist, were used to investigate changes at platelet
thromboxane receptor level in these groups. The concentra¬
tion of collagen (EC50) required to give 50% of maximum
aggregation did not differ between the two diabetic groups
and the control group. However, platelets from the prolifera¬
tive retinopathy group were significantly more sensitive to the
thromboxane mimetic (11,9 epoxymethano-prostaglandin H2)
(p< 0.005) than the background retinopathy and control
groups. This change may be a factor in the development of
proliferative retinopathy.
Key words. Platelets, thromboxane sensitivity, cAMP, prolifer¬
ative retinopathy.
Previous studies in diabetes mellitus have demonstrated
abnormalities of platelet function such as exaggerated
response to aggregating agents [1] and refractoriness to
inhibiting prostaglandins (PG) [2, 3]. Hyperaggregation
is reported to be associated with poor glycaemic control
[4], increasing age [5], and the presence of micro- and
macrovascular changes [6, 7], A number of circulatory
substances relevant to coagulation, including lipids [8],
fibrinogen [9] and von Willebrand factor [10] have also
been reported as abnormal in diabetic patients. How¬
ever, particularly in the presence of vascular complica¬
tions [11,12,13], the results have been inconsistent, per¬
haps because of the diverse methods used and the
failure to obtain homogenous patient groups.
Where a possible mechanism for enhanced platelet
aggregation has been investigated, the most consistent
finding has been the increased production of aggrega¬
tion-induced thromboxane A2 (TXA2) [14, 15]. TXA2,
which is the predominant metabolite of platelet arachi-
donic acid (AA), is a powerful platelet aggregator and
vasoconstrictor [16, 17]. Most studies have employed
AA itself or an agent such as collagen, which releases
endogenous platelet AA, to demonstrate enhanced
platelet aggregation. Since the production of TXA2 is
known to be increased, it cannot be determined from
these studies [11, 12] whether improved receptor cou¬
pling or an increase in the number of thromboxane re¬
ceptors may also contribute to this increased sensitivity.
The aims of this study were to confirm platelet hy-
peraggregability to collagen and to investigate the
changes at receptor level in platelets from diabetic pat¬
ients with established microangiopathy using an ana¬
logue of PGH2, 11,9 epoxymethano PGH2 (11,9-em
PGH2), which directly stimulates thromboxane recep¬
tors [18, 19], plus a competitive thromboxane receptor
antagonist (EP 092) [20], Young insulin-dependent dia¬
betic patients who had background and proliferative
retinopathy as well as a non-diabetic control group
were selected in order to investigate the possible rela¬
tionship between platelet function and susceptibility to
proliferative retinopathy.
Subjects and methods
The patients studied were 24 Type 1 (insulin-dependent) diabetic pat¬
ients, 12 with background and 12 with proliferative retinopathy. The
patients were compared with 12 non-diabetic healthy volunteers. The
three groups were comparable for age and sex, and the diabetic
groups were matched for duration of diabetes. There was no signifi¬
cant difference between the two diabetic groups in blood glucose,
HbA, or platelet counts at the time of the study. (Table 1). Classifica¬
tion of retinopathy was based on ophthalmoscopic and fluorescein
angiographic appearances in all patients. In the background retinopa¬
thy group three patients had scattered microaneurysms and haemor¬
rhages, seven patients had hard exudative changes and two patients
had ischaemic preproliferative changes. None of the diabetic subjects
were taking any medication other than insulin, all of the patients were
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Table i. Average age, duration of diabetes, plasma glucose, HbA, and platelet counts in control and diabetic retinopathy groups
Group Number of Average age Duration of Plasma glucose HbA, (%) Platelet
Subjects (yrs) diabetes (yrs) (mmol/1) count (x 109/l)
Control 12 (6F, 6M) 26.7 ±1.3 - 4.6 ±0.3 7.6 ±0.3 274 ±11
Background 12 (6F, 6M) 27.6 ±0.9 15.2 ±1.1 10.5 ±1.0 11.8 ±0.7 257 ±16
Retinopathy NS NS NS NS
Proliferative 12 (6F, 6M)a 27.0 ± 1.5" 14.6± 1.4b 11.6 ± 1.7b 12.6±0.7b 245 ± 12b
Retinopathy
Results expressed as mean±SEM. a NS between the three groups; b NS between the diabetic groups
Table 2. Results of aggregation EC50 and dose ratio for collagen and 11,9 emPGH2 alone and in the presence of EP 092 (0.25 pmol/1) and Froben
(10 pmol/1). Results expressed as mean±SEM
Group Collagen Collagen Dose Collagen Dose 11,9 emPGH2 11,9 emPGH2 Dose 11,9 emPGH2 Dose
ec5° + EP 092 Ratio +Froben Ratio EC50 + EP 092 Ratio + Froben Ratio
EC5o ec50 EC50 EC50
(pg/ml) (pg/ml) (pg/ml) (ng/ml) (ng/ml) (ng/ml)
Control 0.8 ±0.1 1.9 ±0.3 2.4 ±0.2 8.3 ±1.9 9.8 ±2.0 99.4 ±10.0 115.3 ±5.2 1.7 ±0.1 124.7 ± 9.4 1.31 ±0.1
Background 0.74 ±0.1 1.8 ±0.3 2.7 ±0.5 6.6 ±1.6 10.8 ±3.4 85.4 ±11.5 193.8 ±28.4 2.6 ±0.6 120 ±12.9 1.51 ±0.4
retinopathy
Proliferative 1.1 ±0.2 1.9 ±0.4 1.9 ±0.2 4.9 ±0.7 5.0 ±0.5 63.5 ±6.6 176.0 ±20.2 3.15 ±0.6 100.4± 8.8 1.62 ±0.1
retinopathy
Significance NS NS NS NS NS p< 0.005 NS p < 0.005 NS NS
p < 0.005, significant difference between proliferative retinopathy group and background retinopathy group
clinically free of nephropathy (urine Albustix negative and plasma
creatinine less than 150 (imol/1) and all had easily palpable peripheral
pulses.
Blood (100 ml) was collected between 08.00 and 09.00 hours from
fasted diabetic patients and control subjects into plastic centrifuge
tubes containing acid-citrate dextrose (ACD) anticoagulant and cen-
trifuged at 120 g for 20min. The platelet-rich plasma (PRP) was then
pre-incubated with [14C] 5-hydroxytryptamine (final concentration
1 pg/ml) for 30 min at 37 °C. Platelet aggregation was studied using
the photometric method of Born [21, 22]. Dose response curves for
aggregation induced by collagen and 11,9-em PGH2 were determined
both in the presence and absence of a cyclooxygenase inhibitor, Fro¬
ben (10 pmol/1), which eliminated the production of endogenous
TXA2 and allowed assessment of aggregation in the absence of the
secondary aggregation wave. In addition, we measured the shift in
dose-response curve for aggregation using a fixed concentration of a
competitive TXA2 receptor antagonist EP 092 (0.25 pmol/1). Each ali¬
quot was warmed to 37 °C for 2 min prior to the addition of the aggre¬
gating agents. If used, Froben or EP 092 were added at time zero,
2 min before the addition of the aggregating agent.
Release of platelet dense granule constituents (5HT, ADP) were
measured using the radiolabeled isotope [l4C] 5-hydroxytryptamine
prelabelling technique [22]. Basal platelet cAMP and the rise in cAMP
induced by PGE, (0.2 pmol/1) were measured by a protein binding as¬
say [22, 23].
The glycosylated haemoglobin assay was carried out by electro¬
phoresis using commercially available agar plates (Corning Medical,
Halstead, UK) as described by Read et al. [24], the normal range being
6-8%.
11,9-em PGH2 and PGE, were purchased from Upjohn, Kalama¬
zoo, Mi, USA. Collagen was obtained from Diamed Diagnostics Ltd,
Liverpool, England. EP 092 was synthesised in the laboratory of the
Department of Pharmacology, University of Edinburgh. Flurbiprofen
(Froben) was a gift from Boots Pharmaceuticals Ltd, Nottingham,
England. [14C] 5-hydroxytryptamine was purchased from Amersham,
UK. All of the solutions were free of ethanol and all subsequent dilu¬
tions were made up in 0.9% saline.
Statistical analysis
Statistical analysis of the dose ratios was by Kruskal-Wallis one-way
analysis of variance by ranks. Comparison between the groups for the
cAMP results was by independent Student's t-test.
Results
There was no difference in the concentration of collag¬
en (EC5o) required to give 50% of the maximum aggre¬
gation wave between the two diabetic groups and the
control group (Table 2). Similarly, the thromboxane re¬
ceptor antagonist EP092 shifted all three curves to a
similar extent, as shown by the new EC50 values in the
presence of EP 092, and by the dose ratios (DR)
(DR = EC50 in the presence of EP 092/EC50 collagen
alone). The cyclooxygenase inhibitor Froben produced
a more marked shift of the control aggregation curves
than observed with EP 092. Froben appeared to be
slightly less effective in the proliferative retinopathy
group, but this was not statistically significant.
There was, however, a significant difference be¬
tween the three groups in the concentration of 11,9-em
PGH2 required to induce a 50% aggregation response.
Less 11,9-em PGH2 was required for the proliferative
retinopathy group than for either the control or retinop¬
athy groups (p <0.005). Furthermore, EP 092 produced
a significantly larger shift in the aggregation curve in the
proliferative retinopathy group as judged by the dose
A.Collier et al.: Platelet thromboxane sensitivity 473
Table 3. Results of platelet release reaction in control and diabetic retinopathy groups due to collagen (2 pg/ml) and (250 ng/ml) 11,9 emPGHi
alone and in the presence of EP 092 (0.25 p.mol/1) and Froben (10 pmol/1)
Group Collagen Collagen Collagen ll,9emPGH2 11,9 emPGH2 ll,9emPGH2
+ EP 092 + Froben + EP 092 + Froben
Control 58.8 ±2.2 41.1 ±3.6 19.8 ±1.1 34.9 ±1.0 30.9 ±1.4 32.7 ± 1.3
Background 51.8 ±4.5 39.3±3.9 21.6±1.4 30.8±2.9 26.7±2.9 29.3±2.3
retinopathy
Proliferative 55.3 ± 5.7 30.7 ±4.1 18.4±2.4 32.8±2.4 28.7±3.4 30.1 ±1.7
retinopathy




Fig. 1. Basal platelet cAMP levels and cAMP levels after exposure to
prostaglandin Ei (PGE,) in control and diabetic retinopathy groups.
Results given as mean ± SEM. n = 12 in all groups. HH Basal level
of cAMP; | |cAMP level after exposure to prostaglandin E-|.
PRP = platelet rich plasma
ratio when compared with the other two groups (p <
0.005). In the presence of Froben no difference was
found between the three groups. (Table 2)
5-Hydroxytryptamine release in response to both
collagen and 11,9-em PGH2 showed no difference be¬
tween the three groups (Table 3).
There was no difference in the basal levels of cAMP
found in platelets from the three groups or in the rise in
cAMP induced by PGE| (Fig. 1).
Discussion
This study demonstrated that platelets from Type 1 dia¬
betic patients with proliferative retinopathy are more
sensitive to 11,9-em PGH2 than platelets from Type 1
diabetic patients with background retinopathy and con¬
trol subjects. However, unlike previous studies in dia¬
betic patients [15, 26-28], we did not Find increased
platelet sensitivity to collagen, whether sensitivity was
measured as platelet aggregation or as 5-hydroxytrypt-
amine release. In non-diabetic subjects endogenous
PGH2 and TXA2 production are the major components
of collagen-induced aggregation [29], The aggregation
EC50 for collagen was similar for the two diabetic and
control groups, with the reversible thromboxane antag¬
onist EP 092 producing a similar shift of the aggrega¬
tion wave in each group. The cyclooxygenase inhibitor
Froben appeared to be slightly less effective in the pro¬
liferative group than in the background retinopathy and
control groups, but this did not achieve statistical signif¬
icance. The slight decrease in the efficacy of Froben in
this group is consistent with increased thromboxane
synthesis in response to collagen without alteration in
the aggregation EC50 level. From these observations it
would appear that the mechanism for collagen-induced
aggregation is similar in both diabetic patients and con¬
trol subjects.
Age is an important determinant of platelet function
in both non-diabetic subjects and diabetic patients [5].
During recruitment to our study we paid particular at¬
tention to careful age restriction and comparability.
This may account for the apparent discrepancy in plate¬
let collagen sensitivity in diabetic patients in this study
compared with other studies [15, 26-28],
In contrast, platelets from the diabetic group with
proliferative retinopathy were more responsive to the
thromboxane mimetic 11,9-em PGH2. This increase in
sensitivity was reduced in the presence of the cyclo¬
oxygenase inhibitor, Froben. In non-diabetic subjects
the major mechanism of the action of the mimetic does
not involve activation of the thromboxane generating
system [16, 17]. It would appear, therefore, that the in¬
creased sensitivity is not a direct effect of the 11,9-em
PGH2 on the receptor. The mechanism of increased sen¬
sitivity in the proliferative retinopathy group remains
undefined; however, it may be due to increased endoge¬
nous thromboxane production during secondary aggre¬
gation.
There was no difference between either the basal
level of platelet cAMP levels or the increased cAMP
level after exposure to PGE] between diabetic patients
and control subjects. This is in agreement with a recent
study of PGI] binding to platelets [31] and activation of
adenylate cyclase, but in sharp contrast to that of La-
garde et al. [32], where lower resting levels of cAMP and
a diminished response to inhibiting prostaglandins were
474 ' A.Collier et al.: Platelet thromboxane sensitivity
reported. The likely explanation is that in our study and
that by Shepherd et al. [31] the subjects were young and
age-matched, whereas in the report by Lagarde et al.
[32] the ranges of age, duration of diabetes and vascular
complications were very wide.
In conclusion, platelets from young Type 1 diabetic
patients with microvascular disease in the form of back¬
ground and proliferative retinopathy are similar to
platelets from normal subjects in their response to col¬
lagen-induced aggregation. In contrast, platelets from
diabetic patients with proliferative retinopathy demon¬
strate increased sensitivity to a thromboxane mimetic;
this may be a factor in the development of proliferative
retinopathy.
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